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Abstract 
Plaguing humans for more than two millennia, manifest on every continent studied, and with 
more than one billion patients having at attack in any year, migraine stands as the sixth most 
common cause of disability on the planet. The pathophysiology of migraine has emerged from a 
historical consideration of the “humors” through mid-twentieth century distraction of the now 
defunct Vascular Theory to a clear place as a neurologic disorder. It could be said there are 
three questions: why, how and when? Why: migraine is largely accepted to be an inherited 
tendency for the brain to lose control of its inputs. How: the now classical afferent trigeminal 
durovascular afferent pathway has been explored in laboratory and clinic; interrogated with 
immunohistochemistry to functional brain imaging to offer a roadmap of the attack. When: 
migraine attacks emerge due to a disorder of brain sensory processing that itself likely cycles, 
influenced by genetics and the environment. In the first, premonitory, phase that precedes 
headache; brainstem and diencephalic systems modulating afferent signals, light- photophobia 
or sound- phonophobia; begin to dysfunction and eventually to evolve to the pain phase and 
with time the resolution or postdromal phase. Understanding the biology of migraine through 
careful bench-based research has led to major classes of therapeutics being identified: triptans- 
serotonin 5-HT1B/1D receptor agonists, gepants- calcitonin gene-related peptide- CGRP receptor 
antagonists, ditans, 5-HT1F receptor agonists, CGRP mechanisms monoclonal antibodies and 
glurants- mGlu5 modulators; with the promise of more to come. Investment in understanding 
migraine has been very successful and leaves us at a new dawn, able to transform its impact on 
a global scale, as well as understand fundamental aspects of human biology. 
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I. Introduction 
Migraine is a severe and disabling brain condition (340), listed as the 6th most disabling disorder 
globally by the World Health Organization; and the most disabling of all neurological disorders 
(303). Unfortunately its ranking is increasing with time (620, 827). It has a one year prevalence 
of 15-18% worldwide (536, 539), if both episodic and chronic migraine are included, and has a 
huge financial burden on global economies; costing the US $US19.6 (757) and the European 
Union €27 billion (43) annually. It is likely that the true socio-economic cost of migraine is 
currently significantly higher given a recent study highlighting nearly £6 billion in service use 
and lost employment in the UK alone (591). Migraine predominantly affects females, 3:1, and 
significantly affects quality of life (137), in many cases during peak years of productivity. It is 
characterized by attacks of unilateral, throbbing head pain, with sensitivity to movement, 
visual, auditory and other afferents inputs (386). Other symptoms such as tiredness, irritability, 
reduced concentration and yawning can precede the headache by up to 48 hours (300): the 
premonitory phase. Most attacks are followed by hours or a day of feeling unwell, usually with 
tiredness called the postdrome (299, 465). Additionally in approximately one-third of migraine 
patients their attacks are associated by neurological deficits associated which include cortical 
perturbations, collectively termed migraine aura (678).  
 
A. Historical Aspects 
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Headache has been known for probably 6000 years ago, although it is not clear what type of 
headache (232). Migraine, indeed the more modern construct of chronic migraine, can be 
readily recognized in the work of Willis in the Seventeenth Century (855). The debate over the 
pathophysiology of migraine has largely centered on neural or vascular mechanisms that may 
be involved in triggering and driving attacks. The arguments have existed for several centuries 
and have cycled somewhat. Historically, nearly 150 years ago both seemed to be prevalent, 
migraine was thought of as a disorder of the brain by Edward Liveing. In his famous text ‘On 
Megrim, Sick Headache, and some allied disorders: a contribution to the pathology of nerve-
storms’, he describes migraine as the result of ‘nerve-storm, an inherited tendency for the 
discharge of nerve force, a ‘neurosal seizure’’ (544). At the same time Peter Wallwork Latham 
lectured (509, 510) and published ‘On Nervous or Sick-Headache’ (511), describing the likely 
origin of migraine through vasodilation, triggered, interestingly, by aura; both theories have 
been reviewed in historical context (840). Latham used experimental observations in his 
laboratory, and migraine triggers, to demonstrate his theory, and he could be considered a 
trailblazer in some ways. 
 
The studies of Wolff and colleagues in the 1940s on cranial blood vessels in conscious patients 
revisited the idea of migraine perhaps most likely being a vascular disorder (358, 679, 861). The 
concept persisted for nearly five decades until the development of sumatriptan both supported 
it (266), and yet led to its further questioning (435). As it emerged sumatriptan had both 
vascular and neural effects, so the role of the cranial vasculature was questioned. The theory of 
migraine pain being due to a sterile inflammation of the dural meninges caused by antidromic 
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activation of the trigeminal nerve evolved (566). However, the spectacular failure of as many as 
ten compounds that were active in the preclinical dural neurogenic inflammation model has 
caste consider doubt on the concept (660). The description of purely neural effects of 
sumatriptan, such as those on nociceptive durovascular neurons in the trigeminocervical 
complex (419, 462) began a renaissance of thinking of migraine and its treatment as primarily a 
neural construct.  
 
B. Where we do stand now? 
 
Migraine certainly involves the brain: in some respects the controversy remains rather similar 
and pivots around two issues: initiation and the origin of the pain. While the initiation of a 
migraine attack is frequently associated with reported internal and external triggers, even this 
concept is being revisited by a more central interpretation that arises when considering the 
premonitory phase. The origin of the neuronal mechanisms that underlie the primary condition 
in susceptible people are still not known, and that must be a primary goal of research in this 
area. It is certainly widely accepted that migraine involves activation and sensitization of 
trigeminovascular pathways, as well as brainstem and diencephalic nuclei (21, 91). Furthermore 
a primary dysregulation of sensory processing is likely to result in the constellation of 
neurological symptoms that affect our senses. It has been suggested that migraine may be 
considered as a brain state of altered excitability (158, 182, 183, 206, 750). Certainly migrainous 
premonitory symptoms can occur many days before the headache (300, 466, 712); they are 
neurological symptoms that are non-nociceptive in their nature, which points to an origin in the 
brain. Furthermore the identification of multiple genes responsible for familial hemiplegic 
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migraine (FHM) (268), which increases the likelihood of severe aura symptoms, and the 
identification of a genetic predisposition in family studies (795), provides strong support for the 
view that migraineurs may be genetically susceptible or predisposed. While the term 
excitability is often used to characterize these responses, a state of hypersynchrony (49, 627) 
would explain the clinical symptoms of migraine very well. 
 
C. Objectives of the review 
 
The objective of this review is to describe the clinical manifestations of migraine in a context of 
the clinical and preclinical data that illustrate the anatomy, physiology and pharmacology 
relevant to these symptoms. The reviewed data will support the theory that migraine, at its 
core, is a disorder of the brain, caused by a dysfunction in areas of the brainstem and 
diencephalon that alter the perception of sensory inputs, and cause other neurological deficits. 
We will show how brain function is broadly affected when these systems changes take place in 
migraine. 
 
II. Clinical Manifestations 
Migraine is a complex and multifaceted disorder of the brain which in its entirety may last over 
several days. Migraine has been classically dissected into four phases: the premonitory, aura, 
headache and the postdrome phase. These may occur in a linear sequential order but in most 
cases migraine phases show a significant overlap, such that the linear ordering is both attractive 
and deceptive in its simplicity. While we will try to dissect the pathophysiology of the 
symptomatology in stages, it is important to recognize that some symptoms, such as tiredness 
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or concentration impairment, may well attend all phases. In reality, only head pain, by its 
absence or presence, marks itself out. 
 
A.  International Classification of Headache Disorders (ICHD) 
 
The International Classification of Headache Disorders (ICHD), a valuable tool for the 
standardized diagnosis of primary and secondary headache disorders, which is now available in 
its third edition (ICHD-3, summarized in Table 1) (386). From its first (384) through second (385) 
editions, it led to a significant improvement in diagnostic accuracy, and to improved and 
focused preclinical and clinical research, in particular clinical trials, in an unprecedented way. 
However, given its aim to define the clinical picture for the use in a clinical setting, it focuses on 
the headache and aura phases as they are characterized by disabling symptoms that commonly 
require medical intervention. Its weakness is the over-reliance on a polythetic approach where 
there are a broad set of criteria without one or other being necessary or sufficient. This 
contrasts to a monothetic approach where some or all parts are necessary and sufficient. The 
conflict comes with face validity for clinicians; it remains an unresolved issue. The impact on 
physiology is where migraine symptoms, such as osmophobia (464, 714, 878), are not 
mentioned because they are not usually “needed” by a polythetic approach, which may leave 
them less studied. In the review, we aim to capture as much of the pathophysiology as possible, 
and will be inclusive where possible, symptom-wise, and use the concept of phases, as limited 
as they be in a disorder that often is marked by a continuum. 
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B. Premonitory Symptoms 
 
The majority of migraineurs experience a range of premonitory symptoms well before the 
typical migraine headache initiates. Despite being described in the literature for decades (228) 
their pathophysiological relevance and their clinical implications have been largely neglected. 
Premonitory symptoms of a migraine attack, which may precede the headache phase by up to 
72 hours (300), include changes in mood and activity, irritability, fatigue, food cravings, 
repetitive yawning, stiff neck, and phonophobia. These symptoms may endure well into the 
aura, headache (373) and even postdrome phases (105, 299, 465). The current ICHD-3beta 
precludes the existence of premonitory symptoms within two hours of headache onset (386); 
this clearly has no logical basis and needs attention. We adopted above the definition of the 
symptoms starting anytime prior to headache. The consistency of these symptoms allows some 
migraineurs to reliably predict their migraine attacks (300). The fact that these symptoms are to 
a large extent of hypothalamic origin and imaging studies using H2O PET show an increase in 
hypothalamic blood flow during the presence of premonitory symptoms (559), suggests a 
prominent role of the hypothalamus in the early stages of the attack.  
 
Interestingly many of the trigger factors described by migraineurs, such as for example sleep 
deprivation, hunger or bright light may in fact represent premonitory symptoms of an already 
ongoing attack. This relationship explains why observations in clinical studies that aimed at 
prospectively identifying and validating trigger factors of migraine commonly differ from 
findings obtained from questionnaire-based studies in which patients merely describe their 
own perception of factors triggering their migraine attacks (401).  
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Understanding the pathophysiological mechanisms underlying the premonitory symptoms may 
offer insights in the structures of the central nervous system involved in the early phases of a 
migraine attack and ultimately contribute to identifying a novel therapeutic approach that 
would exert its action before the headache begins.  
 
C. Aura phase 
 
About a third of migraineurs experience transient neurological deficits, the migraine aura, in 
the context of their migraine attacks (678). The ICHD-3 defines the migraine aura as one or 
more transient, fully reversible neurological deficits, of which at least one has to have a 
unilateral localization, that develop over five or more minutes and of which each deficit lasts 
between 5 and 60 minutes. Detailed prospective diary study work has shown that 26 % of 
patients have at least one of three auras that lasts longer than an hour (825). This draws 
attention to the polythetic problem, since investigation of aura lasting over an hour would be a 
large waste of resources. Five per cent of auras are over four hours (825); so perhaps that is a 
useful cut-off. While a visual aura, which may show positive (fortification spectra), negative 
(scotoma) or both phenomena is found in over 90 % of the cases, and the most common deficit, 
sensory, motor, speech, brainstem and retinal aura symptoms may also occur. Aura symptoms 
may precede the headache phase but may last well into the headache phase or even initiate 
during the headache phase. In contrast to the common belief that the aura and headache 
phases follow a sequential order, recent studies have demonstrated that the overlap of these 
phases is very common rather than being the exception (373). In migraineurs suffering from 
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motor aura symptoms such as in hemiplegic migraine, aura symptoms usually show a longer 
duration and may last up to 72 hours. In these severe cases of migraine aura, the deficits 
usually coexist with migraine headache. Remarkably, positive phenomena in hemiplegic aura 
are very unusual; one would predict jerks prior to weakness if there was invariably an initial 
depolarization. Since that is not the rule, the clinical phenomenology insists that one keeps an 
open mind about migraine aura pathophysiology going forward. 
 
A transient wave of neuronal depolarization of the cortex, the cortical spreading depression 
(CSD), is believed to be the pathophysiological brain mechanism underlying the clinical 
phenomenon of migraine aura. While in humans the electrophysiological correlate of a CSD has 
not been demonstrated during a migraine aura, the correlation between the neurophysiological 
characteristics of a CSD, its retinotopic propagation on the visual cortex and the characteristics 
and dynamics of the visual deficits suggest CSD as its pathophysiological correlate (158, 513). 
Indirect observations derived from imaging studies further support this concept (192, 366, 640). 
Whether CSD is causally linked to the initiation of headache is still extensively debated and 
discussed in greater detail in below, nevertheless, based on the current understanding of 
migraine, it is unlikely that CSD is involved in the initiation of the complete syndrome of 
migraine (307).  
 
D. Headache Phase 
 
In the latest edition of the ICHD-3, migraine is defined as headache attacks lasting 4-72 hours 
that are accompanied by nausea, photophobia and phonophobia, or both. The headache is 
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characterized as unilateral, pulsating, of moderate or severe intensity and aggravated by 
physical activity; two of these characteristics suffice to fulfill the diagnostic criteria. In 
comparison to previous editions, ICHD-3 distinguishes chronic migraine, which occurs on 15 or 
more days per month, from episodic migraine in a more practical fashion, building on the 
appendix definition (637). Whether the distinction has utility as it stands, ie whether the fifteen 
day cut-off is appropriate, remains unclear. As yet the distinction has not offered ground-
breaking physiological insights. 
 
E. Postdrome 
 
The postdrome phase has been largely neglected and is not even defined in the glossary of 
terms in ICHD-3beta (386). The findings from the few studies that have focused on this last 
phase of a migraine attack indicate that its characteristic symptoms reflect those observed 
during the premonitory phase (105, 299, 465). A prospective, systematic electronic diary study, 
typical postdrome symptoms include tiredness, difficulties in concentrating and neck stiffness. 
It remains unclear whether these symptoms initiate in the premonitory phase and persist 
throughout the headache phase into the postdrome phase, if they may also initiate during the 
headache phase, or even appear after the headache phase has ended. Migraineurs commonly 
relate symptoms of the postdrome phase to the medication that successfully abolished their 
headache indicating that these symptoms appear or re-appear after the headache phase has 
ended while they seem to play a negligible role during the headache phase. However, a meta-
analysis of a clinical trial program revealed that postdrome symptoms are seen in the placebo 
arm most prominently when pain is relieved (318).  
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III. Imaging migraine pathophysiology 
The phases of migraine, including the inter-attack phase, which are described above clinically 
present a useful way to consider brain imaging results. Given the basic concept that migraine is 
inherited- a trait, which is well illustrated in electrophysiological studies (206, 709), we shall 
cover those studies in brief as a backdrop before discussing imaging findings. All these methods 
suffer to some extent from the principle issue of trait and state. This is true of functional inter-
ictal studies as there is no external validation that nothing has started or that the attack has 
ended. It can be argued that triggered studies have the advantaged of homogeneity relative to 
when the migraine attack process commenced. Another overall issue that applies to all 
physiological studies in migraine; indeed all studies where controls are used is how one factors 
in false negative history in controls. The cumulative lifetime incidence of episodic migraine in 
North American females is 43% (759). If one considers probable migraine and chronic migraine, 
and the vigorous debate around over-lap with tension-type headache, being sure a control does 
not harbor migraine biology is very challenging. The authors find in any study they have done 
finding “vanilla” controls is the most difficult part of the work. These caveats apply across all 
these modalities. 
 
A. Neurophysiology of migraine as a backdrop to imaging 
 
The application of neurophysiological methods in migraine patients has offered important 
insights into the condition. These approaches offer temporal over spatial discrimination and 
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prior to MRI, and still to some extent, better opportunities for repetition. What has emerged 
very clearly from studies in visual, somatosensory, auditory and nociceptive domains is 
activation that differs from controls reliably. A prevailing synthesis of the data is to consider 
thalamocortical dysrhythmia (185, 819) to be key to migraine pathophysiology (206). It has 
been observed for some time that migraine patients fail to habituate normally between attacks, 
for example the intensity dependence auditory evoked potentials is augmented between 
attacks in migraine patients (37, 834). Remarkably this normalizes in the days before an attack 
(452). Interestingly this measure has a serotonin dependence that can be altered by triptans, 
serotonin 5-HT1B/1D receptor agonists (See Section IX) (671). Potentiation of the passive 
“oddball” auditory event-related potential similarly suggests migraineur’s brains do not 
habituate in non-migraineurs do (833), as does an interical habituation deficit as measured by 
the nociceptive blink reflex in migraineurs (213). This has led to the concept that the migraine 
brain over-responds, as distinct from being hyperexcitable (38, 181, 182, 709) 
 
B. Inter-attack imaging studies 
 
1. Structural studies 
 
Several studies have identified differences between migraineurs and control subjects in respect 
of brain structure. Structural studies are typically cross-sectional, and have to be interpreted in 
view of functional interactions of pain processing areas with the trigeminal system. Voxel-based 
morphometry has demonstrated reduced gray matter in pain processing areas, such as the 
anterior cingulate cortex, amygdala, insula, operculum, and the frontal, temporal and 
precentral gyri. Interestingly, gray matter reduction in the anterior cingulate cortex was 
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correlated with the frequency of migraine attacks (812). In contrast, gray matter volume was 
increased in the caudate nuclei bilaterally in migraineurs with high frequency attacks if 
compared to patients with low frequency (555). The somatosensory cortex, and especially the 
somatotopical representation of head and face further depicted increased thickness in 
comparison to controls (199). The same group used diffusion tensor imaging to evaluate white 
matter integrity. They demonstrated reduced fractional anisotropy in migraineurs along the 
thalamocortical tract, in migraineurs with aura also in the ventral trigeminothalamic tract, and 
in migraineurs without aura in the ventrolateral periaqueductal gray (PAG) (199). In another 
study, diffusion tensor imaging was applied to 16 patients and 15 controls to measure the 
extent of tissue damage in the brain. Only minor diffusivity changes were identified in the gray 
matter whereas the normal-appearing white matter and changes in brain volume were equally 
distributed in both groups (689). In a larger study with 22 patients and 20 controls, T1 
relaxation time was shorter in the thalamus of migraine with aura patients compared with 
migraine without aura and healthy controls. (359). In an international collaboration 3T scans 
from 131 migraineurs were obtained and pooled and showed volume loss in patients compared 
to controls in the central nuclear complex, anterior nucleus and lateral dorsal nucleus, as well 
as reduced striatal volume (553). Overall, the studies demonstrate that the ability of developing 
migraine attacks is reflected by structural alterations in pain processing areas such as the 
anterior cingulate cortex and the trigeminal somatosensory system. From the nature of the 
method, it remains unclear if these changes are the consequence of repetitive migraine attacks 
or if they are involved in migraine pathophysiology.  Using diffusion tensor MRI it was shown 
that fractional anisotropy was higher and mean diffusivity lower in migraine without aura 
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patients compared to controls in their thalami between attacks. This change normalized in 
migraineurs during attacks (184). Importantly, there was correlation between changes in the 
right thalamus and the days from the last attack (184). Building on these observations using 
voxel-based morphometry with T1-eeighted 3T MRI it was shown that migraine without aura 
patients have lower gray matter density in the right inferior parietal lobule, right temporal 
inferior gyrus, right superior temporal gyrus, and left temporal pole interictally, with no 
reductions ictally (180). Taken together the data suggest plastic changes attendant the migraine 
attack that may underlie disorder progression. 
 
2. Functional studies 
 
Functional studies complement structural brain imaging. They are typically divided into those 
looking at the function of the migrainous brain at rest, i.e. the true inter-ictal state, and in those 
investigating its response to external stimuli. 
 
i. Metabolism and Receptor Pharmacology 
 
The classic way of analyzing functional differences between two groups at rest is to assess 
regional brain metabolism with 18F-FDG PET. This identifies functional differences in 
migraineurs independently from specific external stimuli, as with BOLD-fMRI, or from pre-
defined brain areas, as with seed-based ’resting state’ analysis. Therefore, studies using 18F-FDG 
PET can be regarded as very close to the biology of the disease, although exposure to radiation 
and poor spatio-temporal resolution are clearly limiting factors. Kim and colleagues (467) 
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compared twenty interictal episodic migraineurs with control subjects. Migraine was associated 
with hypometabolism of central pain processing areas including bilateral insula, bilateral 
anterior and posterior cingulate cortex, left premotor and prefrontal cortex, and left primary 
somatosensory cortex. This suggests a dysfunction of central pain processing in the interictal 
state possibly reflecting the readiness of the brain to develop migraine attacks. Interestingly, 
there was no area of hypermetabolism. 
 
ii. Stimulated blood flow changes 
 
Photophobia is one of the key non-head pain symptoms defining migraine (386). Patients 
typically describe light being too bright (abnormal sensitivity to light) or even painful by causing 
or worsening head or eye pain (phototic allodynia). Even interictally migraineurs tolerate less 
luminence than healthy controls (817). Similarly, migraineurs but not controls activate the 
visual cortex (cuneus and lingual gyrus) when exposed to different luminous intensities as 
shown in seven interictal migraineurs with H215O-PET (116). Interestingly, the application of 
trigeminal pain also led to an activation in the same areas in control subjects. This indicates that 
activation of the trigeminal system, as might happen during migraine attacks, could result in a 
facilitation of the retino-geniculate-cortical pathway of visual processing and/or a dysfunction 
of visual association areas causing photophobia. 
 
Using fMRI, Moulton and colleagues (614) measured the brainstem response to heat stimuli 
and identified a reduced response in the nucleus cuneiformis, which is known to be a 
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component of brainstem pain modulating circuits. During migraine attacks, this dysfunction 
might lead to hyperexcitability of trigeminovascular neurons and thus to the perception of 
headache. The same group further found the anterior temporal pole of migraineurs being more 
active after painful heat stimulation when compared to control subjects (613). The temporal 
pole further depicted increased functional connectivity to various brain regions that might be 
involved in migrainous symptoms, such as the anterior cingulate cortex, the somatosensory 
cortex, amygdala, and others. Similarly, it can be shown by investigating the response to painful 
heat stimulation to the dorsum of the hand that migraineurs with high frequency attacks had 
reduced BOLD-response in the basal ganglia, putamen, caudate and pallidum, compared to 
controls (555). 
 
Demarquay and colleagues (207) evaluated olfactory processing in migraineurs with habitual 
olfactory hypersensitivity. They assessed regional cerebral blood flow (rCBF) in 11 migraineurs 
and 12 controls. During odor-stimulation migraineurs had increased rCBF in the left temporal 
pole and lower values in the frontal and temporo-parietal regions, posterior cingulate gyrus and 
right locus coeruleus. Subjects with olfactory hypersensitivity differed from those without in the 
left piriform cortex and antero-superior temporal gyrus. Some specific symptoms in 
migraineurs, such as olfactory hypersensitivity, are therefore associated with a unique cortical 
response even outside of attacks. Taken together, these data suggest that various cortical and 
subcortical areas in the brain of migraineurs respond differently to external stimuli when 
compared to healthy controls. This might imply that a migraineur’s brain is ‘dys-excitable’ (750) 
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with pre-conditioned functional abnormalities that concertedly exacerbate during migraine 
attacks.  
 
iii. Resting-State Studies 
 
While structural brain imaging identifies differences between grey or white matter and 
stimulus-driven fMRI locates individual dysfunctional areas, the ‘resting state’ approach 
assesses the cross-talk between different areas (functional connections) by measuring the 
correlation of low-frequency spontaneous fluctuations between remote brain areas (280, 281). 
 
Mainero and colleagues demonstrated that migraineurs have stronger connectivity between 
the PAG and several brain areas that are relevant for nociceptive and somatosensory 
processing. They further showed an association between this connectivity and frequency of 
migraine suggesting some pathophysiological relevance of this correlation for pain modulation 
in migraine (554). Cutaneous allodynia is thought to be the manifestation of central 
sensitization during migraine attacks. Comparing the ‘resting state’ connectivity of migraineurs 
with and without cutaneous allodynia, differences in the connectivity of the PAG/nucleus 
cuneiformis to various discriminative pain processing centers (brainstem, thalamus, insula, 
cerebellum) and higher order pain modulating areas (frontal and temporal regions) were 
identified (719). This implies that individual symptoms during migraine attacks are reflected by 
interictal abnormal communication between pain-modulating areas. Further, although both 
groups were migraineurs (386) with normal routine investigations, the presence of ictal 
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allodynia seems to determine different sub-syndromes of migraine indicating that migraine 
itself might also be pathophysiologically diverse. Linking studies in the headache phase, seed-
based resting state fMRI has demonstrated increased connectivity between primary visual and 
auditory cortices and the right dorsal anterior insula, and between the dorsal pons and the 
bilateral anterior insulae; neither correlated with migraine frequency (801), suggesting the 
changes were a trait of migraine pathophysiology. Another intriguing possibility if fMRI for 
classification. Using a seed-based approach, resting functional connectivity of the right middle 
temporal, posterior insula, middle cingulate, left ventromedial prefrontal and bilateral 
amygdala regions best discriminates migraine and control brains (166). While have a circularity 
because the gold-standard remains clinical, it can be seen such approaches may yield both 
insights into biology and NextGen approaches to treatment trial outcomes as a biomarker of 
change, for example in preventive studies. 
 
In contrast to the seed-based resting-state networks, i.e. those identified by looking for the 
connectivity of one or other ‘seed’ area (e.g. PAG or nucleus cuneiformis), task-free resting 
state studies using independent component analysis without a priori hypothesis have been 
conducted. Tessidore and colleagues (788) compared this default mode network of 20 patients 
with migraine without aura to 20 age- and gender matched controls. Migraineurs had 
decreased connectivity in prefrontal and temporal regions of the default mode network. The 
authors speculate that such dysfunction of the default mode network might be related to 
maladaptive reactions to stress or environment putatively being characteristic for migraine.  
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In summary, being a migraineur means having subtle differences in brain structure and function 
even outside of attacks. Importantly, most areas are part of the unspecific pain processing 
areas or of the trigeminal system. A major challenge is to understand how these differences 
predispose to migraine attacks, or in other words, which structures drive the ‘migraine cycle’ 
from interictal via premonitory phase to the headache phase and, finally, the postdrome period 
that then runs over back to the interictal phase.  
 
iv. Mitochondrial Energy Metabolism 
The recognition of migraine as a component of mitochondrial cytopathies (221) offers an 
avenue to explore how that biology may produce migraine. An initial study of mitochondrial 
DNA did not find any of the typical MELAS or MERRF mutations (470). The successful 
completion of a randomized controlled trial of riboflavin (vitamin B2) as a preventive treatment 
of migraine (710), further lends an argument to pursue metabolic dysfunction as a possible 
susceptibility in some patients. Using 31P-NMR spectroscopy Welch and colleagues (843) 
showed a change in phosphate metabolism in patients with migraine with aura during an 
attack. Again with 31P-NMR spectroscopy a later study in patients with migraine without aura 
showed changes in phosphate metabolism (607). Similar results were seen in children (545). 
Using a 3T MRI and 31P-NMR spectroscopy it has been shown in the occipital cortex of patients 
with migraine without aura that there are changes in energy metabolism (683). There is, as 
could be expected some distribution of the energy changes across the patients studied, so it 
seems likely that these findings could explain some, and not all, of the biology of migraine 
expression.  
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C. Premonitory phase 
 
From a clinical perspective, the premonitory phase that connects the asymptomatic interictal 
phase with the headache attack has to be crucial for understanding the mechanism of migraine 
ignition. One of the most important fMRI studies in this respect assessed the (de-)activation 
pattern elicited by trigemino-nociceptive stimulation of the nasal mucosa as the headache day 
approached (749). When compared to control subjects, interictal migraineurs have reduced 
activation of the spinal trigeminal nuclei. This deactivation had a cyclic behavior over the course 
of a migraine interval: there was normalization prior to the next attack and a significant 
reduction of deactivation during the attack (Figure 1). This cyclic behavior might thus reflect the 
increased susceptibility of the brain to generate the next attack, and the identification of its 
pacemaker would be crucial for our understanding of the start of a migraine attack.  
 
The earliest clinical signs of a migraine attack are so-called premonitory symptoms, which occur 
prior to head pain but already tell the patient that a headache is on its way. Based on their 
manifestation, they are likely related to the hypothalamus (56, 482) and include concentration 
problems, tiredness, irritability or depression. When compared to the headache phase, they 
typically resemble some of the non-headache symptoms of a migraine attack and thus might 
persist during the headache phase. Recently Maniyar and colleagues (559) triggered migraine 
attacks in eight patients with migraine without aura in patient who could predict the 
occurrence of headache by a pronounced premonitory phase. During the premonitory phase, 
i.e. still in the absence of head pain, H215O-PET demonstrated activation of the hypothalamus, 
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the midbrain ventral tegmental area, and the PAG (Figure 2). This functional correlate of 
premonitory symptoms suggests a possible role of the hypothalamus in generating migraine 
attacks. Of great interest in this regard are data from a single patient whose responses to 
trigeminal nociceptive stimuli were tracked with BOLD-fMRI over a 30 day period. Hypothalamic 
responses were increased as the attack neared, and there was coupling of the effects with the 
dorsolateral pons (715).  In addition, the hypothalamus might be important for the non-
headache symptoms during the pain phase since when studied in seven spontaneous migraine 
attacks with H215O- PET activation of the hypothalamus was seen (209) – although the location 
of both activations were distinct. It is noteworthy that activations seen in the trigeminal-
autonomic cephalalgias (575, 576, 581, 582, 748 ) are more posterior than reported in migraine. 
 
D. Aura phase 
  
The typical visual aura usually begins prior to the headache phase, but can also occur at the 
same time or even independently from any headaches (373, 825). It often starts with a blind or 
scintillating spot in the center of the visual field (15). Lashley (506) reported some observations 
of his own visual aura: in his case, the scotoma increased in size over about one hour drifting in 
a C-shape toward the temporal field of one side. The velocity of the corresponding spread over 
the visual cortex was calculated to about 3 mm/min. A hypothetical underlying mechanism was 
established only a few years later by Leão (517-519), who stimulated rabbit cortex electrically 
and found an EEG depression spreading at a similar rate of 3 mm/min centrifugally from the site 
of stimulation, and suggested it might be the basis for migraine aura (520). Over decades it was 
suggested that typical visual aura could be attributed to such a ‘cortical spreading depression’ 
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(CSD, see below) (513). The occurrence of CSD in humans remained hypothetical until Olesen 
and colleagues (640) injected 133Xe into the carotid artery during human migraine aura and 
demonstrated a spreading alteration of rCBF. Two decades later, patients who could trigger 
their visual aura or who were able to get access to the study center in the early phase of a 
visual aura were scanned with fMRI using checkerboard stimulation (366). The change of blood 
oxygenation level-dependent (BOLD) signal in the visual cortex in response to this checkerboard 
stimulation during the course of a visual aura behaved in various aspects similarly to the CSD 
from the animal model (518, 519). This included a signal spread with a velocity of about 3.5 
mm/min, which corresponded to the clinical prediction (506) and the CSD elicited in rabbit 
cortex (518, 519). This suggests that visual aura in migraine might indeed be a consequence of a 
CSD-like event. Hadjikhani and colleagues (366) further identified the origin of this peculiar 
response to checkerboard stimulation being in the visual association cortex V3A.  
 
E. Headache phase 
 
As described earlier perhaps the most striking symptom of a migraine attack for most patients 
is headache, although additional symptoms have to be present to make the diagnosis, such as 
nausea, photophobia, phonophobia and movement sensitivity (386). Accordingly, the imaging 
pattern obtained during migraine attacks always represents a combination of these symptoms 
with some possibly reflecting individual symptoms, such as head pain, photophobia or 
allodynia, and others giving evidence of the underlying mechanisms.  
 
28 
 
 
 
1. Head pain 
 
The phenotype of primary headache disorders is far more complex than head pain alone that is 
for instance elicited by noxious stimulation of the skin. However, the experience of pain is 
present in noxious head pain and spontaneous migraine attacks, and the signature identified in 
functional brain imaging of experimental head pain should also be found in migraine headache. 
In other words, the demonstration of additional areas in primary headache disorders might be 
regarded more specific for migraine and thus might reflect symptoms other than head pain or 
even mechanisms driving migraine attacks. Functional brain imaging of noxious pain in the head 
will be discussed at this place since it greatly simplifies our understanding of functional brain 
imaging of migraine. Using H215O-PET in seven healthy subjects, May and colleagues (585) 
measured rCBF after the injection of a small amount of capsaicin into the forehead. They found 
an increase of rCBF in the pain state in several brain areas including the bilateral insula, the 
anterior cingulate cortex, the cavernous sinus and the cerebellum. Importantly, there was no 
activation of the brainstem. 
 
2. Migraine attacks 
 
One of the most influential migraine studies of the last two decades measured rCBF using PET 
with 15C-labeled O2 integral inhalation in nine migraineurs during spontaneous right-sided 
migraine attacks. When compared to the pain-free interval, there was an increase of rCBF 
during migraine in the cingulate cortex, the auditory association cortex, and the parieto-
occipital junction near the visual association cortex. In addition, the migraine state showed 
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increased rCBF in the midbrain, the dorsal rostral pons close to the PAG and raphe nuclei (842). 
In comparison to the non-specific pain-signature of the capsaicin experiment above (585), this 
study located various migraine symptoms to different areas of the brain with the experience of 
head pain to the cingulate cortex, photophobia to the visual association cortex, and 
phonophobia to the auditory association cortex. These signals disappeared after successful 
termination of the attack. However, the increased rCBF in the brainstem persisted in the early 
pain-free phase. This structure might thus not just reflect a migraine symptom but it indicates a 
dysfunction of importance for the generation or in sustaining of the migraine attack itself 
(Figure 3). The relevance of the brainstem for the pathophysiology of migraine is further 
supported by clinical studies and basic research. For instance, the new onset of migraine in 
previously non-migraineurs who have been treated with deep brain stimulation of the PAG for 
other pain conditions (677, 822) and the accumulation of iron in the PAG over the duration of 
illness (844) point to the PAG being crucial for the development of migraine. As described here 
in several sections, several animal studies support this view by demonstrating that brainstem 
nuclei, such as PAG and raphe nuclei have great influence on trigeminovascular processing in 
experimental migraine models (21).  
 
More refined techniques with higher spatial and temporal resolution have led to functional 
brain imaging studies supporting the importance of the brainstem for migraine 
pathophysiology. Bahra and colleagues (66) compared migraine to another primary headache 
(cluster headache) and demonstrated that the brainstem activation is specific for migraine. 
Afridi and colleagues (13) assessed the laterality of this activation in unilateral migraine attacks. 
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They found it being ipsilateral to the headache side and concluded that unilateral pain might be 
a consequence of unilateral brainstem dysfunction. Importantly, as described above, Maniyar 
and colleagues (559) also found the dorsal rostral pons and the PAG, but also the hypothalamus 
being activated in the early premonitory phase supporting the view of a ‘migraine mediator’ in 
these areas. When combining the clinical picture of migraine being a dysmodulation of sensory: 
nociceptive, light, sound, and olfactory, input and the findings from functional brain imaging, 
brainstem or hypothalamic structures, or both, seem to be crucial for the pathophysiology of 
migraine and might reflect the anatomical location of brain dysfunction leading to the complex 
pattern of migraine attacks.  
 
3. Photophobia 
 
Denuelle and colleagues (208) studied eight migraineurs during headache attacks, after relief by 
sumatriptan and in the migraine-free interval. By applying continuous light stimulation, they 
found that low luminance stimulation resulted in an increase of rCBF as measured by H215O- 
PET: there was hyperperfusion of the visual cortex during the headache attack (cuneus), after 
headache relief (cuneus and lingual gyrus), but not in the inter-itcal state. This might reflect 
hyperexcitability of the visual cortex during migraine attacks. By definition, the persistence 
after headache relief was independent of the presence of head pain. This might point to the 
structural correlate of photophobia being located in the primary and supplementary visual 
cortex. Interestingly, the areas activated during migraine attacks by low luminance were the 
same as the areas activated interictally by increasing luminous intensities supporting the view 
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that migraine and even its associated symptoms are continuously subject to a cycling 
mechanism.  
 
Although conducted in the premonitory phase studies of non-headache symptoms without pain 
have been valuable in showing the independence of these phenomena from pain yet their 
important biology in migraine. It has been shown comparing patients with triggered 
premonitory attacks that those with photophobia, photic hypersensitivity given the lack of pain, 
had activation of extrastriate visual cortex (Brodman area 18) (559). In addition, interictal 
connectivity in the visual system is seen using resting state methods in the lingual gyrus (785). 
Similarly to the premonitory visual findings, when comparing patients with or without nausea in 
the same experimental design, those with nausea had activation in the rostral dorsal medulla in 
an area that included the nucleus tractus solitarius, dorsal motor nucleus of the vagus nerve 
and the nucleus ambiguous, as well as activation in the periaqueductal gray (PAG) (560). These 
studies build a picture of the brain regions involved in migraine and clearly show mechanisms 
that are not simply pain-dependent. 
 
Different visual migrainous phenomenona are associated with a dysfunction of different areas 
of the visual association cortex. For instance, the cuneus and lingual gyrus are involved in 
photophobia (208), whereas V3A might be the origin of typical visual aura (366). When further 
comparing the imaging results during migraine premonitory phase, i.e. hypothalamic and 
brainstem activation with those of cortical activation during typical migraine aura, it seems 
likely that aura and migraine are different phenomena. 
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4. Blood-brain barrier 
 
The integrity of the blood-brain barrier (BBB) in migraine is a crucial question particularly for 
therapeutics (see section X).  It has been speculated for some time that the BBB may be 
disrupted in migraine (378). Schankin and colleagues (708) used a bespoke PET ligand 11C-
dihydroergotamine, measuring the influx rate constant Ki, average dynamic image and time 
activity curve using arterial blood sampling. At rest, there was binding of 11C-dihydroergotamine 
in the choroid plexus, pituitary gland, and venous sinuses as expected from the pharmacology 
of dihydroergotamine (367). This was not altered in controls or migraine patients with a 
nitroglycerin-triggered attacks; and is broadly consistent with the known data suggesting the 
BBB is intact in migraine (243, 328). However, whether medicines access the brain is an entirely 
different question. Sumatriptan, classically considered peripherally acting, has a concentration 
of 10-20% the venous levels in the CSF of dog (433). After oral administration of sumatriptan 
100mg in volunteers not having migraine, it could be measured in the CSF (626) in amounts 
sufficient for pharmacological actions. Similar discussions are had concerning gepants, 
calcitonin gene-related peptide receptor (CGRP) antagonists. Using 11C-MK-4232, a CGRP 
receptor antagonist and PET ligand, it has been shown that telcagepant, a clinically proven 
CGRP receptor antagonist (Table 4) has low receptor occupancy (425). Lastly, it is often said, in 
a careless manner that monoclonal antibodies do not cross the BBB. It is clear from very careful, 
older studies that about 0.1% of the intravenous concentration can be found in the CSF (262). 
These data have recently been corroborated with 125I-LY2951742 ligand study, again a clinically 
proven IgG4 CGRP peptide monoclonal antibody (Table 4) found again at about 0.1% 
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concentration in CSF versus plasma (447). There are two themes from these data: first, from a 
macro perspective the BBB is normal in migraine; secondly, BBB and CSF access is not an all-or-
nothing principle. The real question is how much of any treatment is needed for a clinical effect 
in the brain. This is certainly an unresolved but important question. 
 
F. Postdromal phase 
 
The postdromal phase follows the end of head pain for hours or days when the patient is pain-
free but still does not feel back to normal. In contrast to the headache phase and the 
premonitory phase, the postdrome has not been studied specifically with brain imaging. This 
remains a substantial opportunity and a real challenge. 
 
IV. Anatomy of trigeminovascular pain pathways  
The previous section has described what we have learned from imaging the brain in 
migraineurs. Distinct areas of the brain are activated suggesting a role for them in migraine 
pathophysiology; whether this is triggering the attack, generating the pain, or an involvement in 
some of the associated neurological symptoms that occur in the duration of an attack. Much 
has been learned from preclinical anatomical and physiological studies about the association of 
these different brain regions to each other, defining the involvement of specific brainstem and 
diencephalic nuclei and cortical areas in this network. These studies have also been able to 
determine how nociceptive information from craniovascular structures is processed resulting in 
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the perception of headache during migraine, as well as associated neurological sensory 
symptoms.  
 
A. Peripheral afferent projections 
 
The pain associated with the head in a migraine attack, including the frontal, temporal, parietal, 
occipital and high cervical region, is thought to be the consequence of activation of the 
trigeminovascular system (Figure 4). The anatomy of the trigeminovascular system has been 
well described over the last 70 years and this has helped to understand the pathophysiology of 
migraine and the distribution of its pain. The brain is known to be largely insensate, but a rich 
plexus of nociceptive nerve fibers that originate in the trigeminal ganglion innervate the pial, 
arachnoid and dural blood vessels, including the superior sagittal sinus and middle meningeal 
artery, as well as large cerebral arteries (594, 658, 679). Activation of these structures, 
particularly the dura mater, with mechanical, chemical or electrical stimulation results in 
headache pain very similar to the pain in migraine, as well as other symptoms associated with 
migraine, including nausea and photophobia (594, 658, 679). Interestingly, stimulation of sites 
away from these blood vessels is much less nociceptive, with correspondingly lower symptoms 
of headache. The nociceptive innervation of the intracranial vasculature and meninges includes 
non-myelinated (C-fibers) and thinly myelinated (Aδ-fibers) axonal projections, mainly through 
the ophthalmic (V1) division of the trigeminal nerve, but also to a lesser extent, through the 
maxillary (V2) and mandibular divisions (V3). There is also a neuronal innervation of the dura 
mater from the cervical dorsal root ganglia (563). The axon terminals of nociceptive nerve fibers 
that innervate the dura mater contain vasoactive neuropeptides including calcitonin gene-
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related peptide (CGRP), substance P, neurokinin A and pituitary adenylate cyclase-activating 
peptide (PACAP) (237, 804-806) (Table 1), which are thought to be released upon stimulation 
causing vasodilation of dural and pial vessels (234, 662, 852).  
 
B. Central afferent projection  
 
There is also a central afferent projection from the trigeminal ganglion that enters the caudal 
medulla of the brainstem, via the trigeminal tract, which terminates in the spinal trigeminal 
nucleus caudalis (Sp5C; TNC), as well as the upper cervical spinal cord (C1-C2). Nociceptive Aδ- 
and C-fibers predominantly terminate in the superficial laminae, I and IIo, as well as deeper 
laminae V-VI (22, 135, 408, 541, 542, 601) of the TNC and cervical extension. Stimulation of the 
dural vasculature in animal models, including the superior sagittal and transverse sinuses, and 
middle meningeal artery, results in activation of neurons in the TNC, C1 and C2 regions of the 
cervical spinal cord – together known as the trigeminocervical complex (TCC) (135, 329, 334, 
461). Furthermore stimulation of the greater occipital nerve also causes neuronal activation in 
the same regions and enhances convergent inputs from the dural vasculature (75, 76). These 
data suggest that the trigeminal nucleus extends beyond its caudalis boundary to the dorsal 
horn of the higher cervical region in a functional continuum that includes the cervical extension. 
This convergence of neuronal inputs into the TCC (330, 422, 463) and the convergence of inputs 
from intracranial and extracranial structures probably accounts for the distribution of pain 
perception in migraine over the frontal and temporal regions, plus the involvement of parietal, 
occipital, and higher cervical regions (74). Therefore the severe and throbbing nature of pain in 
migraine is thought to result from activation, or the perception of activation, of these 
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nociceptive inputs from intracranial and extracranial structures, that converge and are relayed 
through the TCC. Activation of these neural pathways in animal models of migraine has become 
a reliable way to further understand migraine pathophysiology, as well as being used to screen 
for potential therapeutic targets. 
  
C. Ascending projections from the trigeminocervical complex (TCC) 
 
All nociceptive information from craniovascular structures is relayed through the TCC, and via 
ascending connections to other areas of the brainstem and diencephalon, involved in the 
processing of pain and other sensory information. Functional physiological and tracing studies 
have allowed mapping of these ascending connections. Activation of these structures is thought 
to contribute to the perception of pain during migraine, and also to autonomic, endocrine, 
cognitive and affective symptoms that last throughout the entire migrainous episode.  
 
There is a reflex connection from the trigeminal nucleus to the parasympathetic outflow to the 
cranial vasculature via the superior salivatory nucleus (SuS) (584). The SuS is activated by dural 
electrical stimulation (473), or directly from the brainstem (336), and this traverses back to the 
TCC via the parasympathetic outflow to the craniovasculature (25, 312). There are also direct 
ascending connections with other medullary pontine nuclei including the rostral ventromedial 
medulla (RVM), nucleus raphe magnus (NRM), parabrachial nucleus and locus coeruleus (543, 
688), and midbrain nuclei, the ventrolateral periaqueductal gray (vlPAG) and cuneiform nucleus 
(543), with demonstrated functional nociceptive inputs from the dura mater (133, 135, 236, 
330, 418, 422). Somatosensory and visceral nociceptive information from the head and 
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orofacial structures, via the TCC, is also conveyed directly to hypothalamic nuclei, along the 
trigeminohypothalamic tract, including the anterior, lateral, posterior, ventromedial, 
perifornical and supra-optic hypothalamic nuclei (126, 129, 556-558), and activated by dural 
nociceptive stimulation (85, 556). Likewise, functional dural inputs are relayed through the 
caudal medullary TCC, via the quintothalamic (trigeminothalamic) tract, to the thalamus (543, 
579, 731, 820, 851). Specifically dural nociceptive inputs are processed in the 
ventropostermedial (VPM) thalamus and its ventral periphery, the medial nucleus of the 
posterior complex, including posterior thalamic nucleus and the intralaminar thalamus (132, 
135, 346, 347). 
 
D. Brainstem and thalamic projections to subcortical and cortical structures 
 
The processing of pain is complex and mediated by a network of neuronal structures which 
include the cingulate cortex, insulae and thalamus (211, 799). The thalamus is believed to be at 
the heart of the central processing and integration of nociceptive information, and is regarded 
as a relay center for handling the incoming sensory information, and even modulating it. A so 
called ‘Pain Matrix’, which includes the thalamus, as well as primary (S1) and secondary (S2) 
somatosensory areas, anterior cingulate cortex (ACC) and prefrontal cortex, is believed to be 
involved in integrating all sensory, affective and cognitive responses to pain, and becomes 
active during nociceptive processing (211, 799). The extent to which parts of this matrix is 
attentional as much as a pain-related is debated (615). Other subcortical structures, which have 
anatomical connections to brainstem and thalamic nuclei, are known to be involved in this fluid 
network depending on the context of the pain, and likely contribute to the complexity of 
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neurological symptoms experienced by migraineurs, additional to their headache. The 
amygdala and hippocampus are structures likely to be crucial in processing affective and 
cognitive responses to pain, respectively. Retrograde tracing from the amygdala reveals 
projections from the parabrachial nucleus and specifically lamina I and II of the TNC (445), 
which may contribute to an altered emotional state during migraine, and its comorbidity with 
anxiety disorders and depression (130). Furthermore, indirect projections from the trigeminal 
nucleus, through the amygdala to the hippocampus (484), confirmed in rodents, may 
contribute to altered cognition. It is likely that in time, continued research will reveal the 
importance of these and other subcortical structures to the pathophysiology of associated 
neurological symptoms in migraine. 
 
Craniovascular projections, via trigeminovascular neurons, to VPM thalamic nuclei (876, 877), 
have been identified and are believed to be the principal thalamic relay conveying nociceptive 
information to higher cortical pain processing regions (659). Other thalamic nuclei, which may 
also be involved in processing nociceptive craniovascular inputs includes the posterior (Po) and 
lateral posterior/dorsal (LP/LD) thalamic nuclei (132, 202, 632). Two recent studies have been 
able to trace the connections of these nuclei to the regions of the cortex that ultimately process 
this information (illustrated in figure 4). In rat (631) and cat (501), dural nociceptive VPM 
neurons projected to mainly primary (S1) and secondary (S2) somatosensory cortices, as well as 
the insula. These data suggest that the processing of craniovascular sensory and discriminatory 
information, particularly in the ophthalmic (V1) trigeminal division, is somatotopically organized 
to cortical regions, which may account for the ability of migraineurs to localize their intracranial 
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pain to specific head regions, as well as the intensity and quality of their pain. On the other 
hand, dural nociceptive PO, LP and LD thalamic neurons project to many functionally distinct 
and anatomically remote cortical regions, including S1 and S2, but also to motor, parietal 
association, retrosplenial, auditory, visual and olfactory cortices (631). These data suggest that 
the processing of craniovascular nociceptive information in PO, LP and LD thalamic neurons 
relay directly to cortical areas, suggesting a role in cognitive and motor deficits during migraine, 
as well as allodynia, photophobia, phonophobia and osmophobia. 
 
E. Interpretation of human imaging in context 
 
In the section on imaging studies the specific regions of the brain activated during spontaneous 
and experimentally-induced migraine, and their contribution to other symptoms is explored. 
The anatomical and physiological preclinical studies described in this section plot the pathway 
of nociceptive craniovascular inputs through the trigeminovascular system that project and are 
processed in higher pain processing centers, and parallel the findings from the imaging studies 
in migraineurs. Thus, there is clear translation between preclinical studies and clinical findings, 
with evidence of dorsal pontine and midbrain activation occurring during a migraine attack (9, 
842), even during premonitory symptoms, triggered by an experimental mediator (559). Also 
PET imaging studies demonstrate evidence of activation of hypothalamic nuclei (209), and 
activation in the ACC, frontal cortex, visual and auditory cortices, as well as the thalamic nuclei 
contralateral to the side in which the pain is experienced (9, 66, 842). Therefore, similar 
processing centers to those utilized after nociceptive activation are involved, with recent work 
using functional connectivity approaches that describes statistical dependencies between 
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spatially segregated neurons (748, 755, 801). The anatomy and physiology of the pain pathways 
involved in migraine are well described and help us to understand their role in the 
pathophysiology of the generation of pain in migraine and the associated neurological 
symptoms.  
 
V. Modulation of trigeminovascular pain pathways  
 
Ascending connections from the TCC to many areas of the brain are involved in processing 
nociceptive somatosensory information from the head and face, and determine how it is 
perceived. However there are also many endogenous mechanisms that modulate 
trigeminovascular nociceptive traffic, which can further determine the perception of this 
information. As indicated in section III there is clear evidence of activation in areas of the 
brainstem and diencephalic nuclei before, during and after the cessation of migraine with 
treatment (9, 13, 66, 209, 842) that cannot be explained as solely a consequence of the pain 
response. Certainly descending modulation of somatosensory processing is not unique to 
migraine and has previously been described with respect to spinal responses. Brainstem 
modulation can have both a facilitatory effect, contributing to chronic pain (270) and an 
inhibitory influence, through supraspinal and spinal stimulation, on spinal nociceptive 
processing (271, 666, 703). There is still much debate surrounding the role of brainstem and 
diencephalic activation during migraine. Does this activation signal an area of the brain where 
migraine may be triggered, or is it a consequence of activation of the trigeminovascular system, 
which drives other symptoms in migraine? 
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Human imaging studies have helped us learn a great deal about the central mechanisms likely 
responsible for symptoms in migraine, and those involved in its pathophysiology but a 
limitation of human imaging studies is that they cannot dissect specific nuclei, only general 
regions. This often poses more questions than providing answers. However preclinical studies 
have been able to dissect specific nuclei that provide endogenous modulation of 
trigeminovascular nociceptive traffic, which may or may not also be involved in the more 
general modulation of pain (descending projections are summarized in figure 5). These studies 
may provide us with more of the answers that are necessary to determine the role of these 
brain areas in migraine.  
 
A. Brainstem modulation 
 
1. Superior salivatory nucleus (SuS) 
 
The SuS, located in the pons, is part of the trigeminal autonomic reflex, receiving a reflex 
connection from the trigeminal nucleus (584). It contains the cell bodies of neurons that are 
part of the cranial parasympathetic autonomic vasodilator pathway (745). These neurons 
project predominantly through the greater petrosal branch of the facial (VIIth) nerve, via the 
sphenopalatine (pterygopalatine) ganglion (360) to the cranial vasculature, including the dura 
mater and lacrimal gland. Activation of the SuS and its parasympathetic projection to the 
cranial vasculature is thought to contribute to the autonomic symptoms sometimes found in 
migraine (26, 494), but particularly in trigeminal autonomic cephalalgias, such as cluster 
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headache and paroxysmal hemicranias (309). The SuS also has bidirectional connections with 
areas of the hypothalamus, including lateral (423, 745) and paraventricular hypothalamic nuclei 
(424, 688, 745) as well as the A5 and the parabrachial nucleus, and limbic and cortical  areas 
(745). These are regions involved in feeding, sleep and stress, which may contribute to 
triggering mechanisms in migraine, as well as to associated neurological symptoms (131). 
 
Studies in rodents have demonstrated that direct stimulation of the SuS activates two 
populations of neurons in the TCC (25, 26). First, via retrograde activation of the trigeminal 
autonomic reflex, within the brainstem, there are responses that are not blocked by inhaled 
oxygen. The second population of neurons causes activation of the parasympathetic outflow to 
the cranial vasculature, which indirectly activates trigeminal afferents from the dura mater to 
the TCC, also resulting in autonomic symptoms. Autonomic symptoms are demonstrated by 
increased flow in the lacrimal duct/gland. Both neuronal and autonomic responses are 
attenuated by inhaled oxygen and blockade of the autonomic pterygopalatine ganglion (26) 
(Figure 6). Furthermore, chemical manipulation of the SuS with either lidocaine or an excitant 
differentially modulates light-responsive TCC activity (635). Activation of the parasympathetic 
outflow to the cranial vasculature, through stimulation of the sphenopalatine ganglion (311, 
338) and the facial nerve (304, 305) also causes increases in cerebral blood flow at the cortical 
level. Neurons that project from the SuS to the extracranial vasculature are believed to release 
vasoactive intestinal peptide (VIP) as their primary transmitter (341, 344), which is known to be 
released during cluster headache (320) and paroxysmal hemicrania (321), and during migraine 
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attacks that present with cranial autonomic symptoms (325). VIP may, in part, be the mediator 
of autonomic symptoms associated with these primary headaches.   
 
There is also evidence of 5-HT1D receptors and CGRP in the sphenopalatine ganglion on neurons 
that innervate the lacrimal gland and trigeminal ganglion (438). Therefore they are in a position 
to modulate trigeminovascular nociceptive activation and autonomic symptoms, which may 
explain why triptans can relieve symptoms in migraine, and why naratriptan is able to attenuate 
neuronal responses in the TCC and increases in lacrimal flow after SuS stimulation (26). These 
data imply that the SuS can activate neurons of the trigeminovascular system, but also 
modulate the responses of nociceptive inputs, as well as make changes at the level of the 
cortex, implying an ascending effect. Activation of these neurons is likely to contribute many of 
the symptoms experienced by migraineurs, including pain, cranial autonomic symptoms, and 
symptoms related to hypothalamic activation that are characteristic of migraine.  
 
2. Locus coeruleus (LC) 
 
The LC is also located in the pons and is the principle site of noradrenaline synthesis in the brain 
(36) and receives projections from the paraventricular hypothalamic nucleus (688). Imaging 
studies have indicated that dorsal pontine regions may be activated before and during 
migraine, which might include the LC (559). Its stimulation causes a frequency-dependent 
reduction in intracranial blood flow, indicating vasoconstriction, measured as an increase in 
internal carotid resistance (335, 336). This response is predominantly mediated by a α2-
adrenceptor mechanism (337). Furthermore, the maximal level of reduced cerebral blood flow 
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after LC stimulation was in the occipital cortex (319), an area where blood flow changes 
occurring during migraine aura are thought to begin (192, 640). Accompanying this intracranial 
vasoconstriction is a frequency-dependent increase in extracranial blood flow, indicative of 
vasodilation, measured by a drop in the vascular resistance in the external carotid (335). These 
responses demonstrate that brainstem nuclei can generate vascular changes in the intra and 
extracerebral vasculature that have been demonstrated during migraine (502), and particularly 
cause cortical blood flow changes similar to those found in migraine aura, which therefore may 
be triggered by brainstem activation. 
 
3. Rostral ventromedial medulla (RVM)  
 
The RVM is a cluster of neurons in the medulla. It is predominantly identified as receiving 
bidirectional projections from the ventrolateral PAG (vlPAG), as well as the spinal dorsal horn 
(80, 273, 412). This pathway is thought to provide descending control of pain processing to the 
spinal dorsal horn because of the high concentration of endogenous opioid signaling and has 
been described as the ‘endogenous pain modulatory pathway’ (272, 275, 573). ‘ON’, ‘OFF’ and 
‘Neutral’ cells in the RVM, all of which are non-serotonergic (291, 292, 572), have been 
hypothesized to provide descending control of spinal nociceptive neurons (272, 274). ‘ON’ cells 
facilitate firing of neurons that receive nociceptive inputs, and are inhibited by opioids, whereas 
‘OFF’ cells are tonically active and their firing inhibits nociceptive inputs, and they are activated 
by opioids (273). The role of ‘Neutral’ cells is not clear; they do not respond to noxious heat to 
the tail in rodents, hence their description. However they have been shown to respond to other 
forms of noxious stimulation to other regions of the body, including the face, in either an ‘ON’ 
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or ‘OFF’ fashion, which might indicate they are subtypes of these cells (253). The role of the 
RVM in the descending control of nociceptive spinal neurons may also be applied to the 
trigeminovascular system as well, controlling dural nociceptive inputs to the TCC. Studies have 
shown that RVM neurons identified as either ‘ON’, ‘OFF’ or ‘Neutral’ cells, by their response to 
paw withdrawal, in a lightly anesthetized state, also responded to an inflammatory soup 
applied to the dura mater (236). ‘ON’ cells were potently activated by the inflammatory soup 
with firing maintained for 105 minutes. ‘OFF’ cells were transiently inhibited during initial 
application of inflammatory soup with recovery after 10 minutes, and ‘Neutral’ cells were 
unaffected. Furthermore, in conscious animals, the dural inflammatory soup also causes 
hypersensitivity to cutaneous facial and hind-paw innocuous stimulation (236), caused by 
central sensitization of trigeminovascular neurons (132, 135) (see section VI). These responses 
are inhibited by application of bupivacaine directly into the RVM, locally anesthetizing 
descending projections to the TCC (236). These data demonstrate that dural nociceptive 
trigeminovascular activation activates specific neurons in the RVM, involved in the modulation 
of pain processing, and local changes within this region can modulate the perception of sensory 
stimulation and neuronal activation in response to dural or cutaneous facial nociceptive 
activation.  
 
4. Nucleus raphe magnus 
 
The nucleus raphe magnus (NRM) is at the level of the RVM and makes up part of the 
endogenous pain modulatory pathway described above (271), sending specifically serotonergic 
projections to the TCC and spinal cord in rats and cats (546, 547). It is a region that is activated 
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by dural nociceptive stimulation (473) and ‘ON’ and ‘OFF’ cells respond to meningeal, corneal 
and facial cutaneous stimulation, alongside other extracephalic inputs including tail, hind- and 
fore-paw (254). In the same study, intravenous treatment with naratriptan increased the 
spontaneous activity of ‘OFF’ cells after 10 and 30 minutes, while mean ‘ON’ cell firing activity is 
significantly decreased. Therefore facial cutaneous and dural meningeal stimulation, which 
activates ‘ON’ or ‘OFF’ cells in the NRM, as well as being activated by stimulation in other 
regions, may be modulated by anti-migraine treatment. Furthermore, conditioning electrical 
stimuli applied to the NRM inhibits dural and periorbital-evoked nociceptive neuronal 
responses in the TCC (498). Interestingly, cortical spreading depression (CSD), believed to be 
the experimental correlate of migraine aura (see Section VII), causes a significant reduction in 
the discharge firing in the NRM, which subsequently antagonizes the inhibitory effects of NRM 
stimulation on dural-evoked neuronal firing in the TCC (498). It is widely established that the 
NRM represents the predominant serotonergic projection to the trigeminal nucleus in the 
brain, which indicates that this is the pharmacology of these responses, but manipulation of 
GABAergic and orexinergic receptor systems in this region also differentially modulates dural-
nociceptive trigeminovascular inputs. Micro-injection of lidocaine and GABA causes facilitation 
of dural-nociceptive trigeminovascular neuronal responses, which is mediated by GABAA-
receptor activation (773), as a GABAA-receptor agonist causes similar facilitation, and a GABAA-
receptor antagonist causes inhibition of dural nociceptive responses (773). Likewise, micro-
injection of orexin A and orexin B into the NRM, which is mainly an inhibitory structure, 
facilitates neuronal activity in the TCC, an effect that was predominantly driven by OX2 
receptors (772). It is clear from these data that manipulation of the NRM is specifically involved 
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in the tonic descending modulation of neuronal firing in the TCC in response to peripheral intra- 
and extracranial nociceptive inputs. 
 
5. Periaqueductal grey (PAG) 
 
The ventrolateral periaqueductal grey (vlPAG) has become identified with migraine 
pathophysiology since Weiller’s (842) imaging study demonstrated dorsal midbrain activation 
during a migraine attack, in a region that could include the PAG. Subsequent imaging studies 
conducted in spontaneous or experimentally-triggered migraine have repeatedly demonstrated 
midbrain activation before, during and after the cessation of pain with sumatriptan treatment, 
in migraine (9, 13, 66, 209, 559). These studies indicate that the PAG may be involved in the 
pathophysiology of migraine, particularly in the modulation of trigeminovascular nociceptive 
responses, although the exact role of the PAG in migraine pathophysiology is hotly debated and 
discussed later in this section.  
 
The PAG is a midbrain structure, within the brainstem, which makes direct projections to the 
medullary and spinal dorsal horn, but predominantly indirectly via the RVM, where it is believed 
to contribute to the descending endogenous pain processing pathway. It also makes 
connections with hypothalamic, thalamic and cortical neurons, which associate it with higher 
pain processing and potentially other associated neurological symptoms in migraine.  The 
dorsal raphe nucleus that sits within the PAG can influence brain mechanisms in terms of blood 
flow (342, 343) and sleep (278). The clearest indication of the PAG’s role in pain mechanisms is 
from studies that showed that electrical stimulation of the PAG produces analgesia in conscious 
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rats (685), a response which has been replicated to some extent in humans (588, 872). 
Therefore there is clear evidence of the PAG’s role in endogenous pain modulation to spinal 
nociceptive processing, predominantly via the RVM. There is also clear evidence that the PAG is 
involved in modulating trigeminovascular nociceptive processing, particularly with dural inputs. 
Electrical stimulation of the vlPAG in cats causes a transient inhibition of dural nociceptive 
trigeminovascular neurons (474). Similarly in rats, when bicuculline, a GABAA receptor 
antagonist, is micro-injected local into the vlPAG, dural-evoked trigeminovascular nociceptive 
neurons are inhibited, as well as basal trigeminal tone (471, 472). These descending inhibitory 
mechanisms appear to be mediated to some extent by the P/Q-type voltage-gated calcium 
channel. Trigeminovascular nociceptive responses are facilitated by local micro-injection of 
agatoxin, a P/Q-type voltage-gated calcium channel blocker, although this response seems to 
be modulated by non-GABAergic neurons, as the facilitation does not block the GABAA-
mediated response (471, 472). As described in the ‘Migraine Genetics’ section, P/Q-type 
voltage-gated calcium channels are implicated in familial hemiplegic migraine (FHM), where a 
missense mutation in the CACNA1A gene that encodes the α1 subunit of the neuronal CaV2.1 
P/Q-type voltage-gated calcium channel is present in the majority of patients (645). This 
mutation leads to multiple gain-of-function effects, including enhanced neurotransmission and 
reduced susceptibility to CSD (813). These data combined provide a suggestion of a specific 
genetic mutation that may cause dysfunction in the descending brainstem modulation of 
trigeminovascular nociceptive traffic involved in migraine.  
 
6. Neurotransmitter systems modulating the trigeminovascular system 
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Descending brainstem modulation of spinal and trigeminovascular nociceptive traffic may also 
be modulated by different neurotransmitter systems implicated in migraine. Triptans, specific 
5-HT1B/1D receptor agonists (310), were the first dedicated anti-migraine therapeutics, believed 
to act either at the cranial vasculature, or more likely, in the authors’ view, at the level of the 
TCC (433, 435). It is worth noting that glutamatergic transmission is well established in the 
trigeminocervical complex with NMDA (171, 317, 516, 764) and GluK1 involvement (46), as is 
opioidergic transmission (761), although neither have provided clinically useful to date (Table 4, 
345). 
 
i. Endocannabinoids 
 
Endocannabinoid (22, 24, 27, 28, 361) mechanisms have been implicated in migraine 
pathophysiology and may represent a potential novel therapeutic approach. When either 
naratriptan or CB1-mediated endocannabinoids (Figure 7A and B) are locally micro-injected into 
the vlPAG they cause transient inhibition of dural nociceptive neurons in the TCC, as well as 
inhibiting basal trigeminal tone (24, 77). There is no effect on noxious or innocuous cutaneous 
facial inputs in the ophthalmic dermatome of the trigeminal nerve. Interestingly, the CB1-
mediated effects are inhibited by co-application with a 5-HT1B/1D receptor antagonist. These 
data may imply that the endocannabinoid responses are mediated by neurons, or at least 
within the same synapse, that may also contain 5-HT1B/1D receptors, and that part of the 
therapeutic effects of triptans, may also be mediated in the vlPAG.  
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Endocannabinoids are described as ‘synaptic circuit-breakers’ (459) acting as retrograde 
neurotransmitters in the PAG and RVM. They are released from post-synaptic sites acting on 
pre-synaptic CB1 receptors to prevent the release of GABA and glutamate. The mechanism 
through which these neurotransmitter systems in the brainstem provide descending 
modulatory control of trigeminovascular nociceptive processing is not clear and we propose a 
mechanism through activation of ‘ON’ and ‘OFF’ cells (Figure 7C and D). In the PAG local 
injection or endogenous release of serotonin (or triptan) and endocannabinoids inhibit the 
release of GABA from presynaptic terminals, causing the disinhibition of output neurons (703), 
which activate monosynaptic glutamatergic projections to ‘OFF’ cells in the RVM to modulate 
nociception (609). It is also known that activation of post-synaptic orexin 1 receptors in the PAG 
stimulate the synthesis and release of endocannabinoids, resulting in retrograde inhibition of 
GABA release (398), which may be involved in this mechanism. At the same time we 
hypothesize that this descending glutamatergic projection also synapses with an inhibitory 
interneuron in the RVM, which inhibits activity of ‘ON’ cells, thus switching off activity at the 
level of the TCC second order neuron. Within the RVM endocannabinoids inhibit GABAergic 
projections to ‘OFF’ cells, increasing ‘OFF’ cell activity by disinhibition (597, 598). Also 
endocannabinoids inhibit glutamate release from glutamatergic projections to ‘ON’ cells, thus 
reducing ‘ON’ cell activity at the level of the TCC. There is also thought to be state-dependent 
and bidirectional control of pain modulation through serotonergic projections from the RVM to 
the TCC that is distinct to ‘ON’ and ‘OFF’ cells (269). 
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ii. Functional consequences of brainstem modulatory dysfunction 
 
It is often argued that if a dysfunction of brainstem nuclei, that includes the descending pain 
modulatory system, is involved in the pathophysiology of migraine, which alters the perception 
of nociceptive activation of the trigeminovascular system, it would also affect the way that pain 
is processed at the spinal level. However, it has been shown repeatedly that the descending 
modulation of trigeminovascular nociceptive traffic seems to be different from that of spinal 
nociceptive processing. In the vlPAG descending modulatory effects tend to only alter dural-
evoked Aδ-fiber trigeminovascular nociceptive responses, as well as basal trigeminal tone, but 
it does not alter either noxious or innocuous cutaneous facial responses, particularly C-fiber 
responses (24, 77, 410, 471, 472). However; previous studies clearly indicate that the PAG-RVM 
pathway provides descending control of only noxious cutaneous pinch-evoked C-fiber 
responses at the spinal level (836, 837), with innocuous inputs and spinal tone unaffected. In 
preclinical studies stimulation of cranial structures predominantly causes activation of neurons 
with A-fiber latencies in both the TCC and VPM thalamic neurons (501, 631, 729), which 
project to the somatosensory cortex, and even when C-fiber intensity stimulation is used, only 
A-fiber latency responses are identified. It is not clear why there are so few C-fiber latency 
responses in this trigeminovascular pain pathway that project to the cortex. It may indicate that 
the nociceptive trigeminovascular projections that are thought to be activated primarily during 
migraine are mediated predominantly by A-fibers, and hence the descending modulation from 
the brainstem is mediated by a separate population of neurons to those that project to the 
spinal cord and modulate spinal nociceptive processing. 
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Spinal nociceptive responses appear to differ from trigeminovascular nociceptive responses, 
which may explain why spinal pain perception is not altered during migraine and treatment. 
Triptans are the classic example, they are extremely effective in the acute treatment of 
migraine, but carry little (823) or no analgesic properties with respect to other pain types, such 
as facial pain (379). In preclinical studies noxious, mechanical trigeminal neuronal responses are 
inhibited by naratriptan, whereas similar noxious mechanical spinal responses are unaffected 
(187). Furthermore ‘ON’ and ‘OFF’ cells in the NRM, that respond to noxious stimulation 
throughout the body, including cephalic and extracephalic regions, respond to naratriptan 
treatment, but as described above, we know they only relieve migraine related head-pain. It is 
often thought that this difference is related to the location of 5-HT1B/1D receptors on cranial 
blood vessels and at the level of the TCC. However, it is clear triptans have effects in the vlPAG 
(77), and indeed on trigeminothalamic neurons (730), and clearly alter neuronal responses in 
the NRM, which would imply they would affect pain processing in general, but they do not. It is 
possible that the population of neurons that project to the trigeminovascular system behave 
differently and respond differentially to noxious inputs, and hence the clear definition of 
migraine as a separate and unique pain disorder.  
 
B. Hypothalamic modulation  
 
Imaging studies in migraine have predominantly located activation in the midbrain, with 
increased activation in the hypothalamus before (559) and during (209) also demonstrated. 
Activation in the hypothalamus more posteriorly in trigeminal autonomic cephalalgias (339) is 
well described (575, 576, 580, 581). The hypothalamus is involved in a number of crucial 
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physiological functions including controlling the sleep-wake cycle, feeding, thirst, arousal and 
urination, as well as autonomic and endocrine regulation (650, 727). These mechanisms 
implicate it in the early origins and premonitory symptoms of migraine, where sleep 
disturbance (348), changes in arousal (197) and mood, food craving, thirst and urination (300) 
are known to occur and can increase the likelihood of an attack, as well as early symptoms.  
 
The hypothalamus is also thought to be involved in pain processing. It has reciprocal 
connections with the TCC, including the trigeminal nucleus caudalis (556, 558, 688), as well as 
many structures involved in the processing of nociceptive inputs, including the nucleus tractis 
solitaris, RVM, PAG and NRM (727). Nociceptive stimulation of the dura mater activates 
neurons in the anterior, posterior, ventromedial, and supra-optic hypothalamic nuclei, and 
potentially paraventricular hypothalamic nuclei (85, 557). Hypothalamic nuclei also have 
descending projections to the SuS (423, 424, 688, 745), where they are thought to be in 
involved in autonomic regulation, and its activation may contribute to autonomic symptoms in 
migraine (494), and especially trigeminal autonomic cephalalgias (315), as well as contributing 
to further activation of trigeminal afferents from the cranial vasculature (25, 26, 635). 
Hypothalamic descending projections are known to be involved in the descending modulation 
of nociceptive inputs at the spinal level (277), and several of these descending projections have 
been shown to modulate trigeminovascular nociceptive processing.  
 
1. Posterior hypothalamic nucleus 
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The posterior hypothalamic region is activated as a consequence of dural electrical stimulation 
in cat (85), and is implicated in imaging studies from both migraine and trigeminal autonomic 
cephalalgias. Orexins A and B are hypothalamic neuropeptides that are made solely in 
hypothalamic nuclei, including the posterior hypothalamic region (356) and are involved the 
hypothalamic regulation of sleep, feeding and arousal and the autonomic system (405, 700, 
802). Intravenous orexin A is able to inhibit dural-evoked trigeminovascular transmission, but 
locally injected into the posterior hypothalamus, orexin A and B differentially modulate dural 
and cutaneous evoked nociceptive trigeminovascular responses (78). Orexin A inhibits dural 
electrical and thermal facial cutaneous evoked neuronal responses in the TCC, while orexin B 
facilitates these same responses. Given the role that both the hypothalamus and orexinergic 
system play in pain modulation, feeding, arousal and sleep regulation, these data provide a 
causal link between the possible origin for the triggering of migraine and premonitory 
symptoms (hypothalamus), a neurotransmitter system (orexinergic) known to be involved in 
the homeostasis of these triggers and symptoms, and a role of both in the descending control 
of trigeminovascular nociception, thought to contribute to the pain in migraine.  
 
Another hypothalamic neuropeptide that has similarly been implicated in hypothalamic 
mechanisms in migraine is somatostatin that has five recognized receptor subtypes (429). It is 
involved in the regulation of food intake (754) and glucose metabolism by acting as a tonic 
inhibitor of glucagon release during by low glucose concentrations (162). Injection of a non-
specific somatostatin antagonist, cyclosomatostatin, into the posterior hypothalamus, inhibits 
dural and facial cutaneous nociceptive neuronal inputs in the TCC (79), demonstrating a 
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potential role in the descending modulation of trigeminovascular nociceptive traffic. 
Interestingly, systemic octreotide, a somatostatin analogue agonist, was effective in the 
treatment of cluster headache, but not migraine (527, 577), indicating that these hypothalamic 
neurotransmitters may not be universally involved in all primary headaches, but certain types, 
demonstrating the importance of these specific descending mechanisms to their 
pathophysiology.  
 
2. Paraventricular hypothalamic nucleus 
 
The paraventricular hypothalamic nucleus (PVN) is a region that shows increased neuronal 
activation after both electrical dural stimulation in cats (85) and dural inflammatory soup in rats 
(557), but in both cases the data are increased without showing significance, or not increased in 
all animals. However clear descending projections to the TNC, particularly nociceptive laminae I 
and IIo, and the SuS have recently been demonstrated (688). In the same study a host of local 
chemical manipulations in the PVN were shown to alter dural nociceptive and basal neuronal 
activity in the TNC (688). Micro-injection of muscimol, the GABAA receptor agonist, into the 
PVN, inhibited basal and dural-evoked trigeminovascular neuronal activity. The level of 
inhibition was attenuated when rats had been previously exposed to a ‘stress’ protocol. 
Gabazine, a GABAA receptor antagonist, was able to facilitate dural-evoked responses. Similarly, 
microinjection of the autonomic and sensory neuropeptide, PACAP-38 facilitates basal 
trigeminal neuronal activity and after-discharges (responses greater than C-fiber latency), and 
the PACAP antagonist, PACAP6-38 inhibited basal and all nociceptive dural-evoked 
trigeminovascular neuronal responses. Finally micro-injection of naratriptan, a 5-HT1B/1D 
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receptor agonist, used in the acute treatment of migraine attenuated both basal and dural-
evoked trigeminovascular responses. These findings demonstrate the powerful modulatory role 
the PVN has on trigeminovascular nociceptive traffic, and with descending projections to the 
SuS, it clearly has a role in modulating, or even triggering, nociceptive, autonomic and stress-
related processes in migraine, and likely, trigeminal autonomic cephalalgias. 
 
3. A11 Hypothalamic nucleus 
 
The A11 hypothalamic nucleus is located along the rostrocaudal axis of the periventricular grey 
of the caudal hypothalamus (193), providing direct dopaminergic inhibitory projections to the 
spinal cord dorsal horn (193, 740), believed to be the sole source of dopamine in the spinal cord 
(413). Dopamine activation is known to alter dural trigeminovascular nociceptive responses, at 
the level of the peripheral dural vasculature, through dopamine D1 receptor mechanisms (18, 
156) and centrally at the level of the TCC through dopamine D2 receptor mechanisms (89, 156). 
Electrical stimulation of the dopaminergic A11 projection causes a significant inhibition of 
noxious dural and cutaneous facial-evoked inputs in the TCC, mediated through D2 dopamine 
receptors (156). However, lesioning the A11 nucleus facilitates both noxious and innocuous 
dural and cutaneous facial-evoked inputs (155, 156). The facilitation in neuronal firing to 
noxious stimuli is reversed by both 5-HT1B/1D and dopamine D2 receptor agonists, but only the 
D2 receptor agonist was able to reverse the facilitatory effects in neuronal firing of innocuous 
stimulation to the cutaneous facial region (155). In normal conditions, it is likely that the A11 
nucleus provides descending tonic inhibitory control of incoming trigeminovascular nociceptive 
traffic through the release of dopamine, acting on dopamine D2 receptors. During migraine it is 
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possible that a dysfunction of the A11’s inhibitory projection to the TCC removes the tonic 
inhibition through dopamine release, causing a facilitation of neuronal responses and 
hyperalgesia and allodynia to somatosensory inputs in the trigeminal distribution. The use of 
dopamine antagonists is often cited as not consistent with A11 involvement, although clinically 
employed medicines with randomized controlled trial evidence (294), have more complex 
pharmacology then simple dopamine receptor interactions. Interestingly restless leg syndrome, 
which is believe to be caused by a dysfunction in the A11 nucleus (172), is treated with D2 
receptor agonists (644), and there is certainly a suggestion that migraine is co-morbid with 
restless leg syndrome (72, 686).  
 
The data regarding the hypothalamic modulation of trigeminovascular pathways clearly 
demonstrate that several regions are involved in modulating basal and incoming nociceptive 
inputs to trigeminovascular neurons. It is possible that a dysfunction in any one of these regions 
may result in altered processing of nociceptive inputs that is processed and generates 
migrainous pain, or indeed this dysfunction could actually result in triggering activation of 
previously quiescent trigeminovascular neurons that is perceived as noxious activation, if these 
neurons receive projections from dural afferents, and is processed as migraine. Furthermore, 
nuclei in the hypothalamus are uniquely placed and involved in the regulation of many other 
homeostatic processes, such as feeding, sleep/wake, arousal, stress, that potential triggers of 
migraine may alter the way nociceptive information is processed, but also the triggering of 
migraine through the hypothalamus also results in many of the associated neurological 
symptoms (411). Future studies into the role of the hypothalamus in migraine are likely to 
58 
 
 
 
dissect further significant revelations that help us to elucidate its pathophysiological 
mechanisms.   
 
VI. Thalamic processing of trigeminovascular pain 
 
The thalamus is the major center for processing sensory nociceptive information in the brain, 
and relaying this information for processing in cortical structures where it is perceived by 
individuals. Ventroposteromedial (VPM), posterior, lateral posterior/dorsal thalamic nuclei have 
all been demonstrated to receive functional nociceptive inputs from the dura mater (132, 202, 
632, 876, 877), and this can modulate how this painful experience is perceived. Several of the 
most effective acute and preventive treatment strategies are able to modulate dural 
nociceptive trigeminothalamic inputs, when locally applied to the VPM. Acute treatments such 
as ‘triptans’ (5-HT1B/1D receptor agonists) (730) and CGRP receptor antagonists (769) are able to 
inhibit acute dural nociceptive inputs. Likewise, the migraine preventives propranolol (729), 
sodium valproate (47) and topiramate (44) are also able to inhibit dural nociceptive 
trigeminothalamic inputs in the VPM. Targeting specifically the thalamus alters the perception 
of the nociceptive input coming from the periphery without the peripheral effects of drugs, 
which results in a reduced pain response. Additionally targeting the thalamus allows one to 
dissect novel effective therapeutic targets without peripheral effects, which are suitable for 
those patients with cardiovascular and cerebrovascular disorders. Indeed, in the topiramate 
study it was possible to dissect out that the major pharmacological mechanism in the VPM was 
via glutamatergic kainate (iGluR5) receptors, an effect that was also found at the TCC (44). 
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iGluR5 receptor targets have been proven to be effective in the acute treatment of migraine  
(448, 704), demonstrating a purely centrally mediated approach can treat migraine, with effects 
mediated by the VPM. Targeting the processing of trigeminovascular nociceptive information in 
the thalamus may represent a step forward in the development of therapeutics.  
 
Evidence of thalamic activation during migraine is clear (9, 66), but the role it plays is thought to 
go beyond that of merely a relay in processing sensory nociceptive information to the 
somatosensory cortices. It has also been demonstrated that activation in thalamic nuclei can 
also contribute to the modulation of trigeminovascular and other spinal nociceptive inputs. 
Below we describe in detail how cutaneous allodynia; the perception of pain in response to 
normally innocuous stimuli, in the cephalic and extracephalic regions, is likely the consequence 
of sensitization of central trigeminal and thalamic neurons (132, 135). The particular 
contribution of the thalamus is the spread of cutaneous allodynia beyond the site of pain to 
contralateral cephalic and extracephalic regions via sensitization of thalamic neurons, 
particularly in the posterior, VPM and lateral regions. Hence the perception of somatosensory 
trigeminovascular and spinal inputs are altered as a result of sensitization of thalamic neurons. 
The authors of these studies propose that the mechanism of sensitization may be the result of a 
sequential sensitization of first, second and third-order trigeminovascular neurons through 
incoming signals coming from the peripheral dural trigeminal innervations (132, 135, 766). 
Although activation and sensitization of thalamic neurons via mechanisms directly through 
medullary, midbrain and hypothalamic nuclei, as described above, could potentially also drive 
this response (Section– Theories of Migraine).  
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VII. Cortical processing of trigeminovascular pain 
In recent years evidence has been growing that migraineurs suffer an alteration in cortical 
excitability that may act as a susceptibility factor for migraine attacks (60, 61, 182, 505, 749). 
While the mechanism of how this might contribute to migraine is not known, it is certainly 
undeniable that there is endogenous corticofugal modulation of trigeminovascular nociceptive 
inputs via medullary and midbrain structures. In a recent study in rats descending projections 
from the cerebral cortex, specifically from contralateral insular and primary somatosensory (S1) 
cortices, to laminae I-II and III-IV, respectively, of the TNC were demonstrated (630), although 
ipsilateral functional connections have also been demonstrated (771). These descending 
connections have been previously shown in humans (490). Functionally it has been 
demonstrated that CSD, the experimental paradigm believed to represent the neural 
mechanism of migraine aura (Section VII), is able to inhibit neuronal activity in the NRM. 
Further, repetitive CSDs were able to reverse the descending inhibitory effects that the NRM 
has on dural nociceptive trigeminovascular responses (498), demonstrating a cortico-NRM 
modulation of trigeminovascular nociceptive inputs.  
 
Cortical spreading depression is known to cause neuronal activation in the TNC, an effect that 
has been hypothesized to be mediated by activation of peripheral dural nociceptive 
trigeminovascular mechanisms (879, 880). However, CSD evoked increases in basal 
trigeminovascular discharge firing has been shown to be at least partly independent of a 
peripheral trigeminovascular action, indicating a mechanism driven within the central nervous 
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system (500). Further studies show that different regions of the cortex differentially effect 
peripheral trigeminovascular nociceptive inputs. CSD initiated in the contralateral insular cortex 
induced facilitation of dural-evoked neuronal responses in the TNC, whereas CSD initiated in 
the contralateral S1 somatosensory cortex inhibited the same responses (630). CSD initiated in 
the primary visual cortex enhances or inhibits dural-evoked responses, but does not affect 
noxious facial cutaneous-evoked responses (630). Of note, CSD initiated in the ipsilateral 
parietal region, an area which conveys the somatosensory and visual cortices, also causes a 
significant inhibition of dural-evoked nociceptive neuronal firing in the TCC in 9/30 neurons; a 
response that is mediated by the 5-HT1B/1D ‘triptan’ receptor (771). The remaining 21 neurons 
were unaltered by parietal CSD. These cortico-brainstem-trigeminal networks are positioned to 
influence dural and cutaneous nociception, and altered cortical excitability, believed to affect 
susceptibility in migraineurs, would clearly change how intra and extra-cranial somatosensory 
information is processed, and ultimately perceived by the migraineur.  
 
VIII. Neural Basis for Headache Pain Quality and Associated Symptoms  
As indicated by the ICHD-IIIβ (386) and outlined in section 2 specific criteria are laid out for the 
headache quality in migraine, and migrainous symptoms are not just restricted to headache 
pain but it is also accompanied by many other symptoms of the sensory system and 
homeostatic function that occur throughout the duration of the migraine attack. These can 
include hypersensitivity to sensory inputs such as light (photophobia), sound (phonophobia) 
and touch (cutaneous allodynia), but also symptoms caused by disruption to normal 
homeostatic functions such as altered sleep, feeding and even mobility. Most patients 
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consistently experience a subset rather than all symptoms, but each seems to be driven by 
similar pathophysiological mechanisms. Below we outline the likely neural basis for the 
headache quality, and some of the most well-known associated symptoms that accompany 
migraine. 
 
A. Premonitory symptoms 
 
Premonitory symptoms are part of the non-headache symptoms of migraine attacks. Per 
definition, they occur prior to the onset of headache and are different from migraine aura. In a 
prospective electronic diary study, Giffin and colleagues (300) assessed whether migraineurs 
were able to identify non-headache symptoms that could predict migraine attacks. From the 
symptoms entered by the patients, seventy-two percent were indeed able to do so. The most 
common premonitory symptoms were feeling tired and weary (72%), concentration problems 
(51%), and neck stiffness (50%). Less common, but importantly associated with a higher 
predictability of migraine attacks were yawning, blurred vision, noise sensitivity, difficulties of 
higher cortical function (such as reading, writing, speech, thinking), and feeling emotional and 
irritable. In addition, homeostatic regulation seems to be disturbed during the premonitory 
phase manifesting with thirst, nausea, hunger, frequent urination, or constipation (300). This 
complex pattern of symptoms has led to the hypothesis that the symptoms might be 
hypothalamic in nature and/or diffuse cerebral (106). Due to the difficulties of predicting 
migraine attacks, only a few basic science studies have addressed the pathomechanism of these 
symptoms despite the enormous implications for our understanding of migraine.  
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As mentioned in detail in section III, Stankewitz and colleagues (749) used fMRI after trigeminal 
nociceptive stimulation and found interictal reduced activation of the spinal trigeminal nuclei. 
This normalized prior to the next attack with even increased activation during the attack (Figure 
1), although strictly not a study of the premonitory phase since the clinical phenomenology 
were not documented to make that distinction. Maniyar and colleagues (559) triggered acute 
migraine attacks with nitroglycerin and assessed rCBF in eight migraineurs using H215O-PET. 
Similar to the clinical description (106, 300), they found a complex pattern of rCBF increase 
during the premonitory phase including subcortical (posterior hypothalamus, ventral tegmental 
area, PAG, dorsal pons, putamen, caudate nucleus, and the pulvinar nucleus of the thalamus) as 
well as cortical areas (occipital cortex, frontal, prefrontal, temporal, parietal cortex, anterior 
cingulate, and posterior cingulate) (Figure 2). The premonitory symptoms of the study 
participants were tiredness, neck stiffness, thirst, frequent urination, photophobia, nausea, 
yawning, and mood changes. By combining the clinical picture with the functional imaging 
results we can map various premonitory symptoms to specific brain areas with putative novel 
treatment options of migraine. A key structure seems to be the hypothalamus, which could 
account for yawning, frequent urination, thirst, mood changes, through connections with the 
limbic system; food intake, craving and changes in sleep-wake cycle. Possible neurotransmitter 
systems involved in these processes are the dopaminergic system (56), vasopressin (482) and 
the orexins, which have in part been implicated in migraine therapy (78, 284, 829, 830). 
Interestingly, the late premonitory phase does not show the hypothalamic activation whereas, 
particularly, the cortical activity does persists, and even into the headache phase (559). One 
speculative interpretation is that the hypothalamic involvement might ignite the migrainous 
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process that finally results in the dis-inhibition of the top-down modulation of the trigeminal 
activity resulting in head pain and thus the migraine attack (21). 
 
B. Headache characteristics  
 
According to the ICHD the headache in migraine has to have at least two properties that include 
unilateral, pulsating quality, moderate or severe intensity and aggravation by or causing 
avoidance of routine physical activity (Table 1). As discussed in section I activation of 
trigeminovascular pain pathways that innervate the dural vasculature is thought to be 
responsible for this headache quality. Studies in the 1940s on conscious patients undergoing 
cranial surgery confirm this (658, 679). They found that manipulation of the dura mater with 
mechanical distension or electrical stimulation produced pain referred to the head that was 
localized to different regions depending on the sites of stimulation. While this stimulation did 
not trigger migraine in these patients, it did cause pain referred to specific regions of the head 
as well as some of its common associated symptoms (658, 679). Stimulation of the superior 
sagittal sinus produced pain in the peri-orbital region; stimulation of the middle meningeal 
artery produced pain in the parietal or temporal region; and stimulation at the floor of the 
posterior fossa, sigmoid, transverse and occipital sinuses produced pain in the occipital region. 
Interestingly stimulation away from the dural vessels was much less pain-producing. 
 
Clearly activation of axons that innervate the dural vasculature and originate in the trigeminal 
ganglion is painful, and produces head pain. It seems likely that activation, or the perception of 
activation under normal conditions, of these nociceptive nerve fibers, sometimes termed 
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meningeal nociceptors, which innervate the dural blood vessels is likely responsible for the 
severe and throbbing nature of pain in migraine. It remains unclear where that percept is 
processed. In preclinical studies, stimulation of the nociceptive specific dura mater (347, 
497)causes much greater increases in cerebral blood flow and release of CGRP and VIP, 
neuropeptides known to be released in severe migraine, than after stimulation of the 
trigeminal ganglion (324). While no animal model can claim to be inducing migraine, preclinical 
animal models that use mechanical or electrical stimulation of these dural blood vessels are 
likely activating the nociceptive pathways involved in generating the severe and pulsatile nature 
of the pain in migraine, as well as neurotransmitter release coincident in migraine. 
 
In preclinical studies mechanical or electrical stimulation of the dura mater only produces a 
short burst of neuronal activity in the TCC, whereas migraine pain and trigeminovascular 
activation is sustained for many hours These short bursts of neuronal firing are likely to 
represent the severe and throbbing/pulsatile quality of head pain experienced during migraine, 
although experimentally for only a short time. However, it is believed that peripheral and 
central sensitization of trigeminovascular neurons may contribute to migraine duration. In 
preclinical studies an inflammatory soup placed upon the dura mater is able to activate and 
sensitize peripheral and central trigeminovascular neurons for several hours (135, 766). This 
sensitization causes hypersensitivity to mechanical stimulation of the dural vasculature, 
including the sagittal and transverse sinuses, as well as expansion of the intracranial dural 
receptive field. More recent studies have shown that chemical migraine triggers, such the nitric 
oxide donor, nityroglycerin, also causes sensitization of central trigeminovascular neurons, 
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which produces hypersensitive responses to dural electrical stimulation (20). These studies 
demonstrate that peripheral and central sensitization of the trigeminovascular projection to the 
dural vasculature can exacerbate neuronal responses to innocuous mechanical and noxious 
intracranial dural inputs. This neural mechanism may provide an explanation for why normally 
innocuous physical activities such as exercise, or even unavoidable actions such as coughing, 
bending and taking the stairs, can exacerbate the headache in migraine, and are frequently 
avoided where possible. It may also add to the throbbing nature of pain in migraine as well as 
explaining why migraineurs tend to try to stay still as much as they can, and more often stay in 
bed during an attack.  
 
C. Photophobia and phonophobia  
 
How migraineurs commonly deal with their migraine is a clear indication of their 
hypersensitivity to sensory stimulation. Many patients will certainly report that during an attack 
they will go to bed, turn off the lights, and avoid any type of sensory stimulation from light, 
sound, touch or smells. As if they are shutting themselves away from all possible sensory 
inputs. Indeed included in the classification of migraine by the ICHD is that accompanying their 
migraine must be at least one of photophobia, phonophobia, nausea and vomiting (386). 
Photophobia in migraine may take the form of migraine pain being worsened by light, photic 
allodynia; where the light is itself unpleasant without pain, photic hypersensitivity. In recent 
years studies have begun to disseminate the likely neural mechanisms involved in their 
pathophysiology, specifically related to migraine (631). Findings determined that exacerbation 
of migraine headache requires an intact optic nerve, irrespective of visual ability. Damage to 
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the optic nerve prevents the exacerbation of migraine headache to light, yet blind migraineurs 
with an intact optic nerve can experience worsening pain as a consequence of light (632). 
Studies in rats were also able to demonstrate that light is able to activate specifically dural-
nociceptive posterior thalamic neurons, and this activation increases with increasing light 
intensity (632). A subgroup of these posterior thalamic neurons receives inputs from retinal 
ganglion cells, and these posterior thalamic neurons project to the somatosensory, visual and 
associative cortices (Figure 8A). Similar findings have been made with respect to the TCC, where 
light can also activate nociceptive trigeminal neurons (635). The neural substrate for the 
exacerbation of migraine headache by light would seem to be a consequence of convergence of 
photic signals from the retina, via an intact optic nerve, onto dural nociceptive 
trigeminothalamic neurons, which subsequently project onto cortical areas (S1 and S2) involved 
in nociceptive processing.  
 
As described in section III migraineurs also report a hypersensitivity or abnormal sensitivity to 
light, something which is likely to be the consequence of cortical hyper-responsiveness. 
Interictally in migraineurs luminous stimulation (600-1800 Cd/m2) activates the visual cortex 
bilaterally, but there is no such activation in controls. Furthermore, when visual luminescent 
stimulation was combined with trigeminal pain stimulation; using heat applied to the 
ophthalmic region of the face, cortical activation was determined in the visual cortex in controls 
and it potentiated activation in migraineurs (116) (Figure 8B). During spontaneous migraine low 
luminescence (median 240 Cd/m2) that does not provoke visual cortical activation outside of 
migraine, does cause activation during migraine, and also after pain relief with sumatriptan 
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treatment (208) (Figure 8C), although this activation was statistically lower than during 
migraine. These studies demonstrate that interictally and ictally there is cortical 
hyperexcitability to light in migraineurs, and convergence of trigeminovascular nociceptive 
inputs with photic signals, potentially in the posterior thalamic region described above (632), 
from where axons project to the visual cortex, may explain the neural mechanism for 
hypersensitivity to light in migraineurs. Given that there is cortical hyperexcitability even after 
pain relief, it implies that cortical hyperexcitability, and heightened sensitivity to light is not 
dependent on nociceptive trigeminovacular activation. Therefore modulation of cortical 
excitability may also be under the control of other regions of the brain relevant to migraine 
pathophysiology, potentially brainstem nuclei.  
 
1. CGRP and photophobia 
 
Biochemically it seems that CGRP may also have a role in photophobia. Genetically engineered 
mice with elevated expression in nervous tissue of the human receptor activity-modifying 
protein 1 (RAMP1), which is an important and required subunit of the CGRP receptor (694), 
spend less time in light environments than control littermates. In addition 
intracerebroventricular administration of CGRP causes a significant increase in light aversion, 
compared to those that received vehicle; a response that is prevented with simultaneous 
treatment with the human CGRP receptor antagonist, olcegepant (696). CGRP injection in 
control mice also caused the development of an aversion to strong light, a response that is 
attenuated by a triptan, 5-HT1B/1D receptor agonist (453), indicating that activation of 
endogenous CGRP receptor can drive this hypersensitive response. One possible mechanism 
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would be promotion of a trigeminal nociceptive pathway (635). These studies combined 
demonstrate the likely neural pathways involved in the development of symptoms of 
photophobia, and that CGRP, which is released in migraine (289, 325), contribute to these 
symptoms, although it is not clear at which loci the effect is driven.  The neural mechanism for 
phonophobia has not been directly dissected. However one could readily speculate that cortical 
hyperexcitability in areas of the auditory cortex that are involved in the processing of sound 
may be involved, which receive projections from nociceptive neurons that relay via the 
trigeminovascular system and thalamic nuclei.  
 
 
D. Nausea and vomiting  
 
Nausea and vomiting are common features of migraine, and disturbance of food intake is 
frequently reported, whether this is reduced food intake from nausea, or food craving, which is 
often reported in the premonitory phase. 
 
1. Hypothalamic mechanisms 
 
The hypothalamus is regarded as the regulator of homeostatic function, and regions such as the 
paraventricular and ventromedial hypothalamic nuclei are known to have altered neuronal 
activation as a consequence of hunger or satiety as described below (See- Migraine Triggers). 
Furthermore, dopamine is known to have a role in nausea and vomiting, with dopamine D2 
receptor antagonists known as the classic anti-emetics, while agonists, apomorphine and 
piribedil both provoke increased emesis in migraineurs (92). Migraineurs also present with 
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increased yawning, nausea, vomiting and dizziness as a result of apomorphine treatment (109, 
149). These data suggest a hypersensitivity to dopamine and its effects, and a response that is 
centrally mediated, as peripheral dopamine antagonists cannot reverse yawning symptoms in 
rats (725, 726). These studies do not suggest a locus of action, but hypothalamic regions are 
known to be affected by dopamine. Levels of dopamine in the ventromedial hypothalamus are 
known to go down as a result of feeding, and eating does not begin again until dopamine levels 
are re-established (596).  
 
Alteration to homeostatic functions, which includes feeding and sleep, are also common in 
migraine. In a rodent model of migraine, dural inflammatory soup causes neuronal activation in 
the parabrachial nucleus and ventromedial hypothalamus, believed to be via sensitization of 
central trigeminovascular neurons (557). In half of the rats there was also activation in the 
paraventricular and dorsomedial hypothalamus. These animals exhibited reduced feeding 0-4 
hours after the inflammatory soup placement, followed by increased feeding for the following 8 
hours, as a likely compensation mechanism. Furthermore there were also increased levels of 
mRNA for the anorectic peptide cholecystokinin (CCK) in activated parabrachial neurons and 
higher mRNA for CCKB receptor in activated ventromedial hypothalamic neurons. These data 
suggest that central sensitization of trigeminovascular neurons activate ascending food 
suppressing neuronal projections, which alter feeding in these animals. It is crucial to note 
rodents cannot vomit, and therefore it is not a symptom that can be measured in these 
animals. These studies suggest that only headache mechanisms driven by peripheral inputs lead 
to nausea and loss of appetite, but premonitory symptoms in migraineurs, which include 
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nausea, suggest that these hypothalamic mechanisms may be activated without 
trigeminovascular activation that may lead to headache. More likely is that a single 
pathophysiology leads to both nausea and trigeminovascular activation.  
 
2. Brainstem mechanisms 
 
Brainstem mechanisms involving the PAG-RVM pathway and the role these structures have in 
controlling homeostatic function may also contribute to associated symptoms in migraine, such 
as disruption to feeding, and even sleep. These mechanisms may offer a single explanation for 
the contribution to symptoms of the trigeminovascular system and homeostatic function. We 
describe below in Section IX how continued wakefulness and skipping meals will activate ‘ON’ 
cells (65, 278, 279), which may alter the descending control of nociceptive responses to central 
trigeminovascular neurons, as well as connections to the hypothalamus. Through these same 
mechanisms associated symptoms may be generated. Certainly excessive urination, hunger, 
eating and food craving (or altered feeding in general), the need for sleep, and avoidance of 
moving around are all associated with ‘OFF’ cell discharge, and perhaps during migraine these 
responses are prolonged or exacerbated. Without doubt symptoms of altered feeding, nausea 
and vomiting, as well as other homeostatic processes, through the duration of migraine likely 
involve the hypothalamus, as well as altered dopamine levels, and are exacerbated by 
trigeminovascular activation and sensitization. It is also likely that connections to the brainstem 
PAG-RVM pathway contribute. The nature of their exact mechanisms in migraine and their 
contribution to symptoms is not clear but it certainly seems likely that a single pathophysiology 
through the brainstem PAG-RVM pathway can result in altered perception of noxious 
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somatosensory stimuli, as well as changes to homeostatic processes that contribute to 
symptoms of altered feeding and sleep through the hypothalamus.   
 
2. Allodynia 
Another aspect of pain, similar to the hypersensitivity to light and sound that patient’s 
experience is hypersensitivity to touch, described as (cutaneous) allodynia and hyperalgesia. 
Allodynia: the perception of pain in response to a normally innocuous stimulus to the skin or 
scalp, and hyperalgesia; hypersensitivity to noxious stimuli, occurs in up to two-thirds of 
migraine patients (535, 723). It has been recognized at least since the 19th century (357). In 
migraineurs it is predominantly evident in the cephalic/facial region and pain can be provoked 
by simply brushing or drying one’s hair, shaving or showering.  It can also extend to 
extracephalic regions, and become an allover body allodynia, such as during dressing (127, 
128). Interestingly, the frequency and severity of cutaneous allodynia is more marked in more 
frequent and severe migraine, and may be considered a marker for the chronification to more 
severe and chronic forms of migraine (95, 100). Whether it marks a process that is starting or 
simply reflects what has happened is unclear. Preclinical studies have helped describe the 
neural basis for allodynia in migraine (135, 136). Studies which used dural inflammatory soup 
have demonstrated that sensitization of central trigeminovascular neurons causes expansion of 
the cutaneous facial receptive field, as well as hypersensitive responses to brush, pressure and 
pinch of this receptive field (135). These responses are indicative of cutaneous facial allodynia 
and hyperalgesia. The development of similar hypersensitivity to innocuous and noxious inputs 
to the facial cutaneous peri-orbital region has been demonstrated using the experimental 
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migraine trigger nitroglycerin, in rodents (20).  Indeed allodynia can be seen in patients 
triggered with nitroglycerin to have a migraine, when they report it as part of their normal 
spontaneous attack (Karsan, Bose & Goadsby, unpublished observations). It seems that 
sensitization of central trigeminovascular neurons is likely to cause referred extracranial pain as 
well as the hypersensitive response to cutaneous facial stimulation, and as a consequence 
symptoms of cephalic facial cutaneous allodynia and hyperalgesia. 
 
i. Thalamic involvement 
 
While peripheral and central sensitization of trigeminovascular neurons is thought to account 
for the facial cutaneous hypersensitivity in the referred pain region experienced by many 
migraineurs it cannot explain the extracephalic hypersensitivity; cutaneous allodynia and 
hyperalgesia which extends beyond the head and face to other regions of the body during 
migraine (128, 136). Central sensitization of trigeminothalamic neurons may likely to contribute 
to this mechanism. Preclinical studies using the dural inflammatory soup demonstrate that 50 % 
of thalamic neurons located in the posterior, VPM and lateral regions become hyper-responsive 
to noxious and innocuous inputs from contralateral cephalic and extracephalic regions (132). In 
patients that suffer extracephalic allodynia during migraine, BOLD imaging signals in the 
thalamus that are induced by brushing or innocuous heat to the hand were significantly larger 
when the patients were suffering with a migraine attack than before or after (132). The spread 
of cutaneous allodynia and hyperalgesia beyond the site of pain to contralateral cephalic and 
extracephalic regions is likely the result of sensitization of thalamic neurons. While the 
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pathophysiology of chronic migraine is not well understand (217) the frequency and severity of 
cutaneous allodynia may indicate that central sensitization of trigeminal and thalamic neurons 
becomes more common, and is perhaps less transient with little recovery between attacks. This 
is likely to be an avenue of research in both clinical and preclinical settings in the coming years.   
 
IX. Aura, CSD and the Trigeminovascular System  
As highlighted previously 25-30% of migraine patients suffer focal neurological symptoms (678) 
that commonly present as visual scintillations/scotoma, paresthesia and loss of sensation that 
often precede the headache by 30-60 minutes (386). Given that approximately 75% of all 
migraine patients do not suffer from aura, the level of attention it has received on the face of it 
seems disproportionate to its relative importance to migraine pathophysiology. Airy (15) drew 
beautifully his aura, while Lashley (506) described a slowly propagating wave of scotoma with 
scintillating border that drifted across his visual field at a rate of approximately 3 mm/min. 
Refining this further one patient recorded meticulously more than 1000 attacks that map well 
onto visual cortex (369).  This major focus on aura, probably because of its neurological 
correlate, and its now believed experimental correlate, cortical spreading depression (CSD), 
driven by two alternative theories. (1) Aura is the initial event which triggers migraine (110) and 
(2) Aura is simply a parallel factor of migraine which occurs in a minority of cases (308). While 
the headache field continues to debate the importance of aura for migraine and its 
symptomology, experimental studies have been extremely important in unraveling the possible 
role of CSD. 
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A. CSD and brain injury 
 
For some time CSD like events had not been clearly demonstrated in migraine with aura 
patients, despite the evidence available from cases of brain injury (259, 589, 768). In a number 
of patients who had undergone craniotomies for subarachnoid hemorrhage, stroke and 
traumatic brain injury direct cortical electrocorticography recording demonstrated repetitive 
CSDs, which were negatively associated with outcome. It is clear from the available clinical data 
that the occurrence of CSDs may have a severe detrimental outcome and this has recently been 
supported using experimental stroke models in familial hemiplegic migraine (FHM) mice (249). 
FHM mice exposed to transient occlusion of the middle cerebral artery experienced increased 
numbers of CSD, greater brain damage and poorer outcome than controls. Originally the 
association between CSD and aura was postulated based on a number of similar features 
including rate of propagation. More recently advances in brain imaging have enabled 
characteristic blood flow changes to be observed in humans, where an initial brief hyperemia 
(or hyperperfusion) is followed by a more prolonged oligemia (or hypoperfusion) spreading 
across the cortex, starting at the occipital lobe (192, 366, 636, 702). The hypoperfusion 
correlates with the scotoma experienced by some patients during aura (369); and it is thought 
the hyperperfusion correlates with the negative symptoms. 
 
B. CSD and migraine genetics 
 
The genetics of migraine are clearly complex and are addressed in the Section X. It is however 
clear from a number of studies that alterations in CSD properties are a common phenotype. 
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Initial studies characterizing the transgenic FHM mice which represent rare monogenic forms of 
migraine with aura highlighted an increased susceptibility to CSD, likely via increased cortical 
excitability. This increased propensity for cortical spreading depression was initially highlighted 
in FHM 1 (CACNA1A) mice (813) and later in FHM 2 (ATP1A2) mice (524). Despite early 
suggestions(586, 787), the lack of a clear link with more common forms of migraine (795), the 
above models of genetic susceptibility for migraine with aura have advanced our understanding 
of possible links between the two related conditions (795). Recently a mutation in the casein 
kinase 1δ (CK1) enzyme was found to be associated with increased prevalence of migraine 
with aura; interestingly a common phenotype of the newly developed transgenic mouse is also 
an increased susceptibility to CSD (119).  
 
The question of the role CSD has in migraine remains, that is, does CSD predispose individuals 
to migraine without aura or is it simply an additive phenotype which transforms migraine 
without aura, to that with aura? Regardless of the ongoing debate which will only be answered 
by detailed translational research the impact of CSD on the trigeminovascular system is giving 
up its secrets. 
 
C. CSD physiology 
 
Cortical spreading depression (CSD) was originally described in 1944 by Leao (518, 519) as a 
spreading suppression of spontaneous EEG activity evoked by electrical stimulation of the 
rabbit cortex, and he later demonstrated that an initial depolarizing wave preceded the 
prolonged depression. It is now clear through a number of excellent studies that CSD results 
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from the depolarization, followed by a sustained hyperpolarization (or quiescence (512, 513)] of 
neurons and glial cells with almost a complete reversal of membrane potential resulting in 
breakdown of normal ionic gradients (743). Although the exact role of glial cells is unclear as 
blockade of astrocytic calcium waves (661) fails to block the spread of CSD indicating two 
parallel phenomenon. As a result of CSD the cortical microenvironment is dramatically altered 
with large increases in extracellular potassium and hydrogen ions along with the release of 
arachidonic acid, glutamate, serotonin and nitric oxide and concurrent decreases in intracellular 
sodium (743). Changes in perfusion that accompany the metabolic/electrocortical changes 
during CSD result in cortical blood flow changes: hyperemia (increased blood flow) followed by 
sustained oligemia (reduced blood flow) (120, 519). These changes are thought to be a 
consequence of neurovascular coupling where perfusion increases to meet the demand of 
depolarization, and decreases following the hyperpolarization or quiescence (732). However, 
recent data has indicated that this neurovascular coupling is impaired during the oligemic phase 
(665) or there may even be an uncoupling of the vasomotor and neuronal changes (120, 153), 
especially under conditions of brain injury (259, 589, 768). Interestingly from a clinical 
perspective brainstem changes may be seen with CSD in rat (616), although many antimigraine 
drugs do not alter it when used acutely (460). Moreover, the phenomenon is more easily 
triggered in female mice (121), implicating sex steroids. In additional it has been shown female 
mice with mutations known to produce familial hemiplegic migraine (see Section X), S218L and 
R192Q, are more susceptible than CSD then males (248), 
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It has been demonstrated, using experimental animal models, that CSD induced by mechanical 
stimulation; pin-prick to the cortical surface, causes blood flow changes (23, 407) that travel 
across the cortex, vasodilation of the middle meningeal artery and increased neuronal activity 
of the TCC (110). This arterial vasodilation occurs coincident with the spread of blood flow 
changes, but also independently, after the initial increase in blood flow. More recently 
electrophysiological studies have demonstrated that CSD induced with chemical, mechanical or 
electrical stimulation can produce prolonged activation in approximately 50% of meningeal 
nociceptors (879, 880), which could last for nearly two hours in some cases. If one looks at this 
data set as whole it would appear than CSD, approximately half the time, is able to activate 
neurons of the trigeminovascular system, specifically at the C1-C2 level of the spinal cord, and 
activation of meningeal nociceptors may contribute to the delayed dural vasculature changes 
that appear to be independent of CSD wave. However, this activation of trigeminovascular 
structures is not always observed (235, 499, 500), which may be explained by experimental and 
species differences, and has been observed independent of a peripheral input (500).  
 
D. CSD and trigeminovascular activation 
 
The exact mechanism leading to increased CSD evoked trigeminovascular throughput is like so 
many other aspects, still debated (62, 134, 157, 313). Interestingly, medicines used in migraine 
prevention can block CSD (19, 63), as does vagal nerve stimulation (163). Recent evidence 
suggests that localized release of molecules activates meningeal nociceptors that can drive 
peripheral inputs to the TCC. In one study CSD was shown to activate neuronal Panx1 
megachannels, which can result in local sensitization of trigeminovascular afferents (457). 
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However, CSD can also evoke brainstem and trigeminovascular mechanisms without activation 
of meningeal nociceptors, indeed painless aura is a well-recognized concept (825). It is known 
to disrupt normal pain modulatory centers including the NRM (498), altering the processing of 
nociceptive inputs to the TCC. Direct corticotrigeminal projections have been demonstrated 
using a combination of electrophysiology and tract tracing. Two distinct functional networks 
exist (630), the first of which arises in the insula, projects to lamina I and II neurons in the TCC 
and facilitates trigeminovascular nociceptive tone. The second originates in the primary sensory 
cortex, and project to deeper TCC lamina (III and IV) and is inhibitory. The exact impact of CSD 
on two distinct populations of cells each with opposing effects is difficult to ascertain in the rat 
due to spatial localization and rapid spread of CSD. However, in gyrencephalic brains where 
spatial distribution is greater and CSD is thought to be more localized it is possible that 
individual CSDs could result in both a clear suppression and facilitation of trigeminal pain, based 
upon their anatomical localization.  
 
Thus it is likely that a combination of CSD peripheral trigeminovascular activation and central 
pain modulatory dysregulation underlie the association of CSD/aura and migraine. Perhaps the 
field of migraine research has been too focused on if CSD/aura is a trigger for migraine 
(discussed in the theories of migraine section) with or without aura, as many triggers are known 
to exist and should look at the disease as a whole. As presented above, migraine occurs in three 
stages with a premonitory phase starting 24-48 hours before the attack long before CSD is 
known to occur. It is thus conceivable that a central disruption predisposes individuals to 
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specific triggers, of which CSD/aura is one of many which may potentiate an already perturbed 
system. 
 
X. Genetics of Migraine  
 
The existence of a strong genetic component in migraine seems obvious from clinical practice 
(504) and is supported by population-based family studies (695, 758). These studies show 
immediate family members of migraineurs have a substantially increased risk of suffering from 
migraine compared to relatives of matched controls (758). Interestingly, the relative risk 
differed depending on the presence of aura and the degree of disability. First-degree relatives 
of patients suffering from migraine with aura had a 4-fold increase of relative risk of migraine 
while relatives of patients with migraine without aura showed only a 1.9-fold risk increase 
(695). Further hints are provided by twin-studies that reveal a significantly higher pairwise 
concordance rate of migraine in monozygotic compared to dizygotic twins (295-297, 810, 811). 
While specific genetic changes in common forms of migraine are yet to be reported, some 
specific biology has been identified that does inform our understanding of migraine aura. 
 
 
A. Familial hemiplegic migraine (FHM) 
 
FHM represents a monogenic subtype of migraine with aura that involves at least one limb 
weakness. It does not, in spite of the name, usually involve plegia, rather weakness; the term 
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hemiplegic is retained for historical consistency rather than neurological accuracy. The three 
responsible genes currently recognized were identified by classical linkage analysis in which 
genetic markers are compared to a specific disease trait. All three known FHM mutations 
encode mechanisms that impact ion transporters, the CACNA1A (FHM1) (645), ATP1A2 (FHM2) 
(203) and SCN1A (FHM3) (215) genes; their dysfunction ultimately leads to an increase in 
neuronal excitability (63).  
1. CACNA1A 
The CACNA1A gene was the first gene to be identified as causal for FHM1 (645). It is located on 
chromosome 19p13 and encodes the α1 subunit of neuronal CaV2.1 (P/Q-type) voltage-gated 
calcium channels (845). All known FHM1 mutations induce gain-of-function effects as they 
enhance channel open probability thereby increasing neurotransmission (368, 664, 798). Two 
mouse models; R192Q (813) and S218L (797) transgenic mice, have been developed to gain 
insight into the functional consequences of these mutations through a large amount of 
preclinical in vivo studies. Findings from these animal studies have substantially enhanced the 
understanding of migraine aura. 
 
2. ATP1A2 
The second FHM gene, ATP1A2, is located on chromosome 1q23 and encodes the α2 subunit of 
sodium-potassium pumps (203, 784). Until now over 30 mutations within the ATP1A2 gene 
have been associated with FHM2. All of them induce a loss-of function on sodium-potassium 
ATPases increasing the potassium ion levels within the synaptic cleft.  
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3. SCN1A 
Mutations within the SCN1A gene located on chromosome 2q24 represent the underlying cause 
for FHM3 (215). The gene encodes the α1 subunit of neuronal NaV1.1 voltage-gated sodium 
channels. Genetic mutations within the SCN1A gene that have been associated with FHM 
mostly exert a loss-of-function effect that mainly affects inhibitory neurons although gain-of-
function effects have been described. 
 
Finally, in many patients suffering from hemiplegic migraine none of the three known FHM 
mutations can be identified, especially in cases without familial clustering (268). These cases of 
so-called sporadic hemiplegic migraine (SHM) (791) indicate that other genetic abnormalities 
may exist in the pathogenesis of SHM (786). If these involve other unknown FHM genes or a 
specific combination of other multiple low-risk genetic variations is not known (657).  
 
4. Pathophysiology of FHM 
All known FHM mutations encode proteins involved in ion transport and lead to higher 
concentrations of glutamate and potassium in the synaptic cleft increasing neuronal excitability 
which may increase the susceptibility for the induction of CSD and thereby migraine aura, which 
is believed to be the underlying cause of the transient motor deficit occurring in hemiplegic 
migraine (63). However, it is still likely that other factors such as increased incoming neuronal 
signals from the periphery or hormonal changes, that may affect neuronal activity, may play a 
role or even be required for inducing CSD even if an increased susceptibility resulting from the 
FHM mutations exists. Whether functional consequences go beyond the increased propensity 
of CSD, for instance if in affected migraineurs CSD induces activation of nociceptive pathways 
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involved in the pathogenesis of migraine, has not been entirely clarified. Certainly FHM1 mice 
have reduced calcitonin gene-related peptide expression in the trigeminal ganglion (578). 
Consistent these data, Fos protein expression in FHM1 mice, when subject to dural stimulation, 
is not increased or altered by a triptan, as it is in wild-type mice. In contrast, FHM1 mice display 
enhanced transmission in thalamus (654). Moreover, it can be shown in rat that transcranial 
magnetic stimulation, which is effective for acute migraine with aura (537) and probably as a 
preventive when used regularly (94), can block CSD effects on trigeminothalamic neurons after 
a single pulse (45). These data suggest the burden of FHM1 pathobiology may be thalamic. 
 
5. Triggering and FHM 
 
One important, and as yet unexplained feature of FHM, is its lack of sensitivity to otherwise 
typical migraine triggers, such as nitric oxide donors (374, 376) or CGRP (375). This is not simply 
a matter of the aura phenotype, since both nitric oxide donors (441) and CGRP (372) trigger 
migraine without aura attacks, predominantly, in patients with simple migraine with aura. 
Rarely, aura can be seen triggered by NO-donors (12); this is the exception. It has also been 
shown that evoked potential habituation in FHM differs from other forms of migraine (370), 
although interestingly FHM patients identify similar trigger factors for their attacks as migraine 
with aura patients (371). 
 
B. Casein Kinase 1δ (CK1δ) 
 
In clinical practice migraineurs commonly report that abnormal sleep may trigger migraine 
attacks and that migraine leads to an abnormal sleep pattern (859, 860). Attacks frequently 
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start in the early morning (399), a time in which affected individuals usually are in their REM 
sleep phase or shortly after waking up. In addition, changes in wakefulness may be part of the 
premonitory symptoms of a migraine attack. These observations and the fact that migraineurs 
show a higher incidence of narcolepsy (194, 195) suggest that migraine may be linked to 
circadian mechanisms.  
 
A missense mutation in the gene encoding casein kinase 1δ (CK1δ) has been linked to migraine 
(119, 863). The CK1δ gene is a ubiquitous serine-threonine kinase involved in the regulation of 
sleep patterns. A missense mutation in the DNA-sequence of the CK1δ gene results in a 
threonine-to-alanine alteration at amino acid 44 (T44A) of the protein leading to reduced 
enzyme activity. This genetic alteration and its functional consequences lead in humans, and 
transgenic mice with the human mutation inserted, to the clinical phenotype of the Familial 
Advanced Sleep Phase Syndrome (FASPS), which is characterized by an abnormal sleep pattern 
consisting of early sleep times and early-morning awakening (794, 864). In six individuals of one 
family the genetic alteration has not only been associated to familial advanced sleep phase 
syndrome (FASPS) but also to migraine with and without aura (119). This observation suggests 
that beyond being a central element in the regulation of sleep, CK1δ may be functionally 
relevant in migraine pathophysiology. A second missense mutation with a histidine-to-arginine 
change at amino acid 46 of the CK1δ gene has been identified to cause reduced enzyme activity 
and co-segregate with FASPS and migraine highlighting its potential functional relevance in 
both disorders (119). 
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To assess their functional relevance in migraine, a series of in vivo studies have been conducted 
on transgenic in vivo models with mice carrying the T44A mutation (119). These studies 
revealed that compared to their wild-type littermates, mice carrying the T44A mutation show 
increased hyperalgesia after intraperitoneal injection of nitroglycerin, a substance known to 
induce neuronal activation in the dorsal horn in mice and migraine attacks in migraineurs. Mice 
carrying the CK1δ-T44A gene also show a reduced threshold for the induction of CSD as well as 
an enhanced vasodilation of meningeal and cortical arteries following CSD. The latter is 
interesting in the context of CK1δ playing a role in glutamatergic transmission (164). Moreover, 
mice with the T44A mutation display a similar reduced trigeminocervical complex activation 
profile (400), as that cited above for FHM1 mice (654), linking in some respects the migraine-
related biology of these two very different mutations. These observations suggest a 
pathophysiological influence on migraine aura and its functional consequences. Taken together, 
these preclinical and clinical findings suggest that mutations in the CK1δ gene may contribute to 
the pathogenesis of migraine and migraine aura.  
 
C. TWIK-related spinal cord potassium channel (TRESK) 
 
A candidate gene approach led to the identification of the frameshift mutation F139WfsX24, 
encoded within the KCNK18 gene, which prematurely truncates the TRESK protein to 162 
residues inducing a complete loss-of-function, in a large multigenerational family affected by 
migraine with aura (493). The influence of TRESK on neuronal resting membrane potential, its 
wide distribution throughout the CNS, its functional implication in pain pathways and the 
segregation with migraine with aura led to the conclusion that the KCNK18 gene may be 
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functionally involved in the pathogenesis of migraine, and the TRESK channel even represents a 
potential therapeutic target. This hypothesis has been supported by the fact that two-pore 
domain (K2P) potassium channels, such as the TRESK channel, are targeted by several volatile 
anesthetics leading to its activation. Investigation of mutant TRESK function points towards 
altered hyperexcitability in trigeminal ganglion neurons (540) and further that TRESK channel 
openers can reverse this hyperexcitability and may hold potential as therapeutic targets (365). 
However, further studies have revealed that other genetic mutations that also cause a 
complete loss-of-function of the TRESK channel do not specifically segregate with migraine (48) 
have raised doubt on the functional consequence of mutations within the KCNK18 gene that 
lead to a dysfunctional TRESK channel, in regard to the pathogenesis of migraine. Nevertheless, 
the influence of K2P-channels on neuronal excitability and on pain pathways may warrant 
further studies to investigate their potential as a therapeutic target.  
 
D. Genome wide association studies (GWAS) 
 
In recent years GWAS have identified a series of single nucleotide polymorphisms (SNP) that 
may be relevant for the pathogenesis of migraine (53, 54, 159, 160, 283). GWAS are based on 
the hypothesis-free analysis of a large amount of SNPs in relation to specific disease traits. The 
advantage of this technique lies in the fact that compared to other genetic approaches a large 
number of genes can be analyzed with respect to a specific disease. However, due to the large 
amount of tests, GWAS are associated with several caveats inherent to the technique. Results 
have to be cautiously corrected for multiple testing and only associations with p-values below 5 
x 10-8 can be considered significant (250). Furthermore, the identified genetic variants are 
87 
 
 
 
characterized by a very low relative risk questioning their clinical significance. In contrast, if 
high-risk genetic variants exist which show only marginal allele frequency, a GWAS approach 
will likely miss this genetic association. Finally, GWAS do not capture interactions between 
allele variants that may be functionally relevant. As a result of these difficulties, conclusions 
regarding the relevance of GWAS findings for the pathophysiological mechanisms of migraine 
and their clinical significance, especially conclusions on an individual genetic risk, have to be 
interpreted with caution. Therefore an identified association should always be confirmed in 
independent case-control studies before any conclusions are drawn.  
 
Regardless of these technical considerations, three GWAS have been published with respect to 
migraine (53, 54, 159, 160, 283). These studies identified a series of potentially migraine-
relevant susceptibility genes that are involved in glutamatergic neurotransmission (MTDH, LRP1 
and MEF2D) and are functionally involved in pain-sensing pathways (TRPM8), neuronal 
development (MEF2D, ASTN2, PRDM16, PHACTR1 and TGFBR2) and brain vasculature function 
(PHACTR1 and TGFBR2). Among these genetic variants the most consistent results have been 
observed for LRP1 and TRPM8. While LRP1 encodes a lipoprotein involved in nociceptive 
glutamatergic signaling (147), TRPM8 encodes a cold-sensitive calcium channel that may induce 
burning pain (84, 592, 656). The TRPM8-channel is expressed on unmyelinated C-fibers and 
myelinated Aδ-fibers (477) and may co-express with TRPV1-channels and CGRP (212). Beyond 
peripheral sensory neurons (477), the TRPM8-channel has been identified on the trigeminal (2) 
and dorsal root ganglia (431) indicating a functional relevance in migraine. However, despite 
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these anatomical observations further in vivo studies are required to elucidate the functional 
consequences of mutations within the TRPM8 gene.  
 
A challenging and exciting observation for the future is an initial finding of the SNP, rs2651899 
in PRDM16 has an odds ratio of 2.6 in predicting triptan efficacy in acute migraine treatment 
(168). Such a result suggests the eventual possibility of personalized medicine for the treatment 
of migraine. 
 
Taken together, recent data suggests that in contrast to FHM, which appears to be a monogenic 
disease, common forms of migraine are likely to be the result of several genetic factors which 
interact with each other and with environmental influences which finally lead to an increase in 
the susceptibility of migraine.  
 
XI. Neural basis of migraine triggers  
Migraine attacks are generally considered spontaneous in nature and sometimes thought of as 
occurring without any tangible trigger or precipitating factors, yet many patients will frequently 
report known exogenous or endogenous factors they believe to reliably trigger their migraine 
attacks, or at least increase their likelihood of occurring (504). Perhaps this confusion and the 
distinct lack of clarity about if and what factors can be involved in precipitating migraine attacks 
is a consequence of two major observations. First, it is likely that the entire phenotype and 
duration of the migraine syndrome is misunderstood by patients, but sometimes also by 
clinicians. The migraine attack does not begin at the perception of head pain, or in the case of 
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aura, during the first neurological aura deficits, but most likely 24-48 hours prior to these 
symptoms, during the premonitory phase (300). As described in the earlier sections, many 
patients will report having a feeling that a migraine is coming even though they are not in pain 
several days before the headache, and this is often characterized by specific symptoms, such as 
tiredness, lack of attention, and food craving (300). Indeed, imaging studies have demonstrated 
that there are significant changes in brain activation while these symptoms are perceived (559, 
749). It is possible that a blurring of the lines between premonitory symptoms and migraine 
triggers has led patients and clinicians alike to believe that certain environmental factors 
believed to precipitate their migraine attack actually represent a symptom of their syndrome, 
such as craving certain foods, including chocolate and cheese, as well as tiredness. The other 
factor which complicates this issue is that there are very few controlled studies that have 
actually dissected internal or external events triggering attacks. One recent interesting study, 
which controlled both bright light and/or strenuous exercise as a triggering mechanism for 
migraine with aura, only produced modest predictability, in patients who self-reported these 
factors as triggering their attacks (427). This is not to say that certain factors do not trigger 
migraine attacks, or at least increase the likelihood of an attack occurring, and the volume of 
patients that describe, for example, skipping meals, sleep disturbance and stress as 
precipitating factors cannot be ignored. Perhaps the truth is closer to what we cannot see, or 
easily measure on a day to day basis, and down to the natural fluctuations in neuronal 
excitability in the brain that have been observed (750). The brain may be naturally protected at 
times of lower excitability, but much more susceptible to triggers at the peak of excitability 
fluctuations. Despite this lack of clarity there are still certain environmental and endogenous 
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factors known to increase the likelihood of precipitating an attack that warrant discussion of 
their neural basis.  
 
A. Chemical triggers and inflammation 
 
Environmental or experimental chemical triggers of migraine have proven, over the last 25 
years, to be the most reliable approach for experimentally triggering migraine in the clinical 
setting (441). A number of molecules are accepted to trigger migraine (386).  These are largely 
vasoactive and many are present at the nerve endings of perivascular nerve fibers innervating 
the cranial vasculature from the sensory, parasympathetic and sympathetic nervous systems 
(Table 2), and be released as a consequence of activation, although not all appear to be 
released during migraine.  
 
1. Triggering and vasodilation are uncoupled 
 
Nitric oxide (NO) donors, such as nitroglycerin (NTG), are highly volatile vasodilator agents 
(606), and have been recognized to trigger migraine for some years (515, 673). NTG-triggered 
migraine has been well described for many years as a model system (441) and has been the 
most studied preclinically. It produces an immediate headache in almost all subjects, but also a 
delayed migraine, after two-six hours, in migraineurs. Similar responses have been 
demonstrated with CGRP, PACAP and prostaglandin E2 (PGE2) and I2 (PGI2) (52, 58, 508, 720, 
849). The mechanism for triggering these migraine attacks is still speculated upon. A common 
denominator is that they all cause immediate vasodilation of extracerebral blood vessels (52, 
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58, 639, 641, 642, 720, 849), and the reversal of vasodilation with sumatriptan aborts migraine 
(59, 440). Similar findings have been demonstrated preclinically in rats, with NO donors, CGRP, 
PACAP, PGE2 and PGI2 (29, 111, 622, 623, 767, 852) all causing meningeal vasodilation. 
 
However, evidence of vasodilation as a cause of pain in migraine has now been effectively 
excluded. Human studies show no meaningful change in external carotid branches (40, 58, 713), 
and never demonstrated a temporal relationship between headache resolution and vascular 
changes with sumatriptan (531). Furthermore, both vasoactive intestinal polypeptide (VIP, 674) 
and prostaglandin D (848) are clear examples of vasoactive mediators causing immediate 
vasodilation and mild headache in healthy controls and migraineurs, but no occurrence of 
delayed migraine. In contrast pituitary adenylate-cyclase activating peptide (PACAP), which 
shares VIP receptor targets (83), is equi-efficacious in terms of vascular effects (39), and does 
trigger migraine (720) in patients. These data conclusively demonstrate that vasodilation is not 
an obligate component of migraine pathophysiology, and that the mechanism by which these 
substances trigger is not vascular. 
 
2. Inflammatory mechanisms do not explain migraine therapies 
 
There is some evidence that migraine triggers may stimulate inflammatory processes, which are 
responsible for activating a cascade of events involving sensitization of meningeal nociceptors, 
resulting in migraine headache. NTG administration causes delayed release of inflammatory 
mediators from the meninges (682) in rats, which are involved in activating and sensitizing 
meningeal nociceptors, which has been hypothesized to promote pain in a migraine attack (91). 
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PGE2 is used in the inflammatory soup that is placed on the dura mater, which induces 
peripheral and central sensitization (135, 766) and dural PGI2 produces peripheral sensitization 
of meningeal nociceptors (881). These data potentially point to a mechanism of dural 
inflammation and activation of meningeal nociceptors to trigger the migraine attack. NTG also 
produces an up-regulation of dural mRNA for inducible nitric oxide synthase (iNOS) followed by 
protein expression 4-10 hours after NTG, as well as plasma protein leakage that are suppressed 
by iNOS inhibition (682).  
 
In contrast, iNOS inhibitors are ineffective in clinic either as an acute or preventive treatment 
strategies  (403, 649), and likewise plasma extravasation inhibitors have also failed in the acute 
treatment of migraine (233, 691). Other evidence further indicates that dural inflammatory 
mechanisms are unlikely to be the triggers for the migraine attack. CGRP and PGE2 are well-
known inflammatory mediators, but at supramaximal doses known to cause vasodilation, 
neither was able to induce dural plasma protein extravasation in rats (566). Furthermore, an 
iNOS inhibitor was unable to inhibit either neurogenic or CGRP-induced vasodilation of 
meningeal vessels (31), a model that has proven predictive of therapeutic efficacy (88). Finally, 
PACAP is known to be released upon inflammation to protect neurons and is thought of as anti-
inflammatory (835). These data imply that dural inflammatory mechanisms are unlikely to be 
involved in triggering migraine with these vasodilator agents, although as yet only neural 
mechanisms have been identified in the laboratory in terms of trigeminocervical inhibition (17). 
 
3. Brain mechanisms and triggering 
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If neither dural vasodilation nor inflammatory mechanisms are responsible for triggering the 
migraine attack after administration of vasoactive agents, other neural structures along the 
trigeminovascular pathway must play role. Perhaps inside the brain is where the answers lie. 
Premonitory symptoms, accompanied by activation of dorsolateral pons, midbrain and 
hypothalamic regions, have been demonstrated in NTG-triggered migraine (13, 559), prior to 
any description of headache, suggesting that brainstem and diencephalic nuclei may be 
involved in the migraine triggering process. One would anticipate that if peripheral vascular or 
neurovascular mechanisms through inflammation and activation of meningeal nociceptors, are 
involved in triggering migraine with chemical triggers, pain should be the first symptom 
reported as a consequence of central trigeminovascular activation, rather than occurring after 
other neurological deficits. This gap in trigeminovascular activation is also demonstrated in 
rodents, where NTG causes activation in the mid brain vlPAG, locus coeruleus and parabrachial 
nucleus, as well hypothalamic nuclei, before any activation in the TNC is detected (782, 783). 
Furthermore changes to levels of PGE2 and cyclo-oxygenase-2 in the rat brain after NTG occur 
in the hypothalamus prior to changes in the lower brainstem (821).  
 
So are these migraine triggers activating nuclei in the brain involved in triggering an attack? 
Locally applied NO donors, including NTG, excite central trigeminovascular neurons (495, 496), 
demonstrating a direct effect of these molecules in the TCC and VPM thalamus. These data 
point towards a more neuronal basis to the triggering mechanism of these vasoactive 
mediators. Perhaps electrophysiological studies provide the clearest example of the systemic 
effects of migraine triggers on central trigeminovascular neurons. Messlinger and colleagues 
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have demonstrated that the NO donor, sodium nitroprusside produces a biphasic response on 
meningeal nociceptive central trigeminovascular neurons, with an initial increase in basal firing 
that accompanies sodium nitroprusside administration, but a delayed and prolonged facilitation 
for up to two hours (480). These effects are reversed by systemic administration of the CGRP 
receptor antagonist, olcegepant (481). This effect is most likely to be on second order central 
trigeminovascular neurons, as local cranial dural inhibition of CGRP receptors does not inhibit 
spinal trigeminal neurons (276), particularly as there is no evidence of CGRP receptors on 
peripheral axons, although they are present of central projecting axons (523). More recently we 
have also demonstrated with NTG that the delayed facilitation of basal trigeminal tone is 
prolonged beyond three hours, and there is also sensitization of noxious and innocuous 
responses to dural and cutaneous facial stimulation (20). 
 
Locally applied CGRP also causes excitation of both central trigeminovascular (760) and VPM 
thalamic nociceptive neurons (769), and olcegepant inhibits glutamate-evoked firing in these 
areas. Furthermore, locally applied CGRP or olcegepant in the vlPAG, activates or inhibits, 
respectively, dural nociceptive trigeminovascular responses (668). However, given systemically 
CGRP does not activate or sensitize peripheral meningeal nociceptors, for up to one hour (526), 
which implies a peripheral neural mechanism of action is unlikely, although observations have 
not been made beyond this time frame. However, central trigeminovascular responses do seem 
to be transiently sensitized to facial vibrissal innocuous inputs after CGRP, although these 
responses were largely low threshold mechanoreceptors outside of the ophthalmic dermatome 
(188). However, the longer term effects of CGRP, beyond one hour, on central 
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trigeminovascular neurons, which would mirror its delayed effects in migraineurs is not known. 
In general it seems that vascular, and also likely, peripheral neurovascular mechanisms do not 
play a role in triggering migraine as a result of vasoactive agents. Indeed the vascular effects 
may be better described as a ‘red herring’, which distracts attention from their likely 
mechanism of action inside the brain. These data point to a neuronal mechanism of activation 
involved in triggering a migraine attack. One last and important factor that needs to be 
considered is that, other than NTG, which is highly volatile and readily diffuses into tissue, 
including the brain, CGRP, in particular, is a large peptide unlikely to cross the blood-brain 
barrier and therefore it is thought they cannot get into the brain to have an effect. PACAP on 
the other hand has a specific pump mechanism to facilitate its transport (69). It is interesting 
that triggers of all sorts are only effective in migraneurs, whose brain biology certainly appears 
to be different to healthy controls; whether this alters their ability to enter the brain can only 
be speculated upon.  
 
B. ‘Skipping meals’  
 
It is generally accepted that metabolic disturbances, such as fluctuations in water balance, food 
intake, mood and sleep contribute to migraine in some patients (228, 300). According to some 
studies, lifetime migraineurs experience headache attacks preceded by triggering factors such 
as food deprivation and/or fasting (skipping meals) (196). Although it is debated whether 
fasting is actually a headache trigger or rather that food craving is a symptom in the 
premonitory phase of migraine. Blau and Cumings (108) attempted to identify a correlation 
between blood glucose and migraine, rather than fasting itself, and reported that fasting 
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caused headache in 50% of migraineurs. The authors proposed “some patients have some of 
their attacks of migraine fired off by missing a meal, and that this is related to a low blood 
sugar, which must persist in that individual for a certain length of time to cause headache”. 
Although there are many observations of food cravings during the premonitory phase of 
migraine, with researchers reporting that some patients would crave for sweet foods (228), and 
one study, using individual electronic diaries, reported that 18% of the patients reported 
hunger or food craving as triggers of their headache (300). These studies clearly demonstrate a 
blurring of the lines between altered feeding as either a cause or a symptom in migraine. 
 
Some authors have tried to reconcile these two migrainous attributes, with Martin and 
Seneviratne (568) offering an explanation for their finding that food deprivation caused 
headache in 58% of patients with frequent migraine or tension-type headache. The authors 
write that “hunger arising from low blood sugar levels, for example, may lead to cravings for 
particular foods such as chocolate, on the one hand, and lead to headaches, on the other hand, 
but the headaches may be erroneously attributed to the food consumption rather than the low 
blood sugar levels”. Perhaps what these studies demonstrate most is the importance of 
alteration of the feeding schedule, either skipping or delaying meals, in migraineurs, as it clearly 
has an impact on the phenotype of patient suffering.  
 
What is understood about the neural mechanisms that regulate feeding is that they are 
controlled within the hypothalamus (742, 869), a brain structure that we know to be active and 
involved in migraine pathophysiology (21, 559), and this structure is likely to impact our 
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understanding of the role of altered feeding in migraine. The hypothalamus is a major center of 
convergence and integration of several nutrient-related signals and, thus, hypothalamic 
neurons are thought to promote the homeostasis of physiological systems involved in 
synchronization of circadian rhythms, salt balance, appetite and energy expenditure, thirst and 
water balance, among other functions (690). A summary of the hypothalamic pathways and 
neuropeptides involved can be found in figure 9 and the subject is extensively reviewed 
elsewhere (220, 742, 869) 
 
1. Anatomy of feeding and fasting 
 
i. Hypothalamic-based mechanisms 
 
Two populations of neurons located in the hypothalamic arcuate nucleus, one expressing the 
orexigenic neuropeptide Y (NPY) and agouti-related peptide (AGRP), which promote feeding, 
and the other expressing the anorexigenic peptides proopiomelanocortin (POMC) and cocaine-
and amphetamine-regulated transcript (CART), which cause a loss in appetite, are the primary 
integrators of nutritional information, being sensitive to signals of energy availability (reviewed 
in 55, 220, 742, 869). Leptin is also one of the most important regulators of energy balance 
since arcuate POMC and AgRP/NPY neurons are targets of leptin with opposing signaling 
effects: AgRP/NPY neurons are inhibited by leptin (81, 717), in contrast to POMC neurons which 
are excited (718). Likewise, orexins A and B are also involved in feeding regulation in the 
arcuate nucleus, where orexin A activates NPY-containing neurons to promote feeding (866). As 
well as the interaction between NPY/AgRP and POMC/CART neurons, arcuate neurons also 
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project to other key hypothalamic nuclei, such as the paraventricular nucleus (PVN), 
dorsomedial nucleus (DMH), lateral (LH) and ventromedial (VMH) hypothalamic nuclei, 
orchestrating adaptive responses to energy homeostasis imbalance (reviewed in 73). These are 
all regions known to be relevant to migraine pathophysiology. A summary of orexigenic and 
anorexigenic neuropeptides and their roles in homeostatic function can be found in Table 3. 
 
ii. Brainstem mechanisms 
Outside the hypothalamus, the nucleus tractus solitarius (NTS) and the VTA are also known to 
be involved in feeding control and pain modulation. Leptin receptor ObRb mRNA is present in 
the NTS (599) and leptin causes neuronal activation (251). NTS neurons project to the VTA, PAG 
and LC (293), and the NTS, along with the arcuate nucleus, is the only source of anorexigenic 
POMC neurons (442). Injection of anorexigenic neuropeptides into the NTS reduces food intake, 
and antagonists increase food intake (362, 850), with 75% of NTS neurons firing in response to 
blood glucose fluctuations (870). The VTA is implicated in modulating food craving behaviors 
(600), as well as the drive to access highly palatable foods (3, 4) and increased leptin signaling in 
the VTA decreases food intake and firing rates of DA neurons (287, 414).  
 
2. Neuropeptides during feeding and fasting 
 
i. Orexins 
 
Orexins are made solely in the hypothalamus (356), but particularly in the lateral, posterior and 
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paraventricular nuclei of the hypothalamus (356, 700). Intracerebroventricular (ICV) or direct 
micro-injection into the arcuate nucleus stimulates food intake (383, 619, 701) and this 
response appears to be predominantly mediated by OX1 receptors (741). During fasting and 
hypoglycaemia there is increased orexin release in the hypothalamus (141, 142, 458, 701), 
accompanied by an increase in OX1R receptor mRNA expression in the VMH and increase in 
OX2R mRNA expression in the arcuate nucleus (551). Orexins have a close relationship with 
glucose metabolism, with orexin cells stimulated by low glucose levels and elevation in glucose 
levels suppresses both spontaneous and evoked firing in orexin neurons (125). ICV (871) or 
systemic injection (633) of OxA causes an increase in plasma glucose levels, and peripherally 
administered OxA increases insulin secretion (633).  
 
In the context of migraine, OxA and B levels are lower in the periphery during episodic 
migraine, whereas OxA levels are increased in chronic migraine (706). Therefore there is 
evidence of a potential perturbation of the orexinergic system in different migraine states. 
Preclinical studies demonstrate that systemic OxA inhibits dural-evoked trigeminovascular 
nociceptive neurons, predominantly via Ox1 receptors, whereas OxB has no effect (408, 409). A 
dual orexin receptor antagonist (DORA-12), which has equal affinity to both Ox1 and Ox2 
receptors is also able to inhibit dural-evoked trigeminovascular nociceptive responses (402). 
However, a DORA was ineffective as a migraine preventive when dosed daily, although sedation 
was more commonly seen as a side effect in the active then the placebo arm (150). 
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ii.  Neuropeptide Y (NPY) 
 
The other main orexigenic neuropeptide is NPY, which is known to be involved in regulation of 
the cardiovascular system, pain modulation, appetite control and circadian rhythm 
synchronization, and is abundantly expressed in the basal ganglia, limbic system and 
hypothalamus (7). It is synthesized in the arcuate nucleus (67) and released into the PVN and LH 
(123, 753), where it exerts its appetite stimulating properties. ICV injection or direct micro-
injection into the PVN causes stimulation of food intake (751). This response is regulated by 
OxA activating (866) and leptin inhibiting (756, 832) NPY-containing arcuate neurons. These 
NPY neurons also project to many pain modulating nuclei in the brainstem, including the PAG, 
DRN, NRM, LC and NTS (737), and NPY Y1 knock-out mice show increased nociception (485) and 
intra-arcuate administration of NPY exerts an antinociceptive effect in intact rats and in rats 
with inflammation through NPY Y1 receptor activation (530). During fasting or food restriction 
there is increased NPY release in the hypothalamus (846), including the PVN (455), where NPY 
Y1 expression is also increased (862).  
 
In the context of migraine, evidence of altered NPY levels is conflicting. One study shows 
lowered peripheral levels in episodic migraineurs (146), whereas a study that measured plasma 
from the extracerebral circulation found no changes during the headache phase (325). 
However, it is a common theme in migraine that interictally brain activation is lower, yet ictally 
activation appears to be normalized, and it is perhaps this relative change between states that 
is important rather than direct comparisons to healthy subjects. NPY Y1 and Y2 receptors are 
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present in human trigeminal ganglia (807) and NPY Y1, Y2, Y4 and Y5 are present in the rodent 
TCC (655). In preclinical studies intravenous NPY inhibits dural-evoked neuronal firing in rats, a 
response that is mediated by the NPY Y1 receptor (570). These data indicate that NPY can alter 
trigeminovascular nociceptive transmission.  
 
iii. Leptin 
 
The main anorexigenic peptide is leptin, which is secreted by the adipose tissue and 
transported to the brain where it crosses the blood-brain barrier (285, 841). In the brain it acts 
on ObRb, the long form of the leptin receptor (175, 252, 621, 721, 781). Circulating leptin is 
thought to be an indicator to the CNS of total body energy stores (282). When injected either iv, 
or icv, leptin activates neurons in the PVN, ARC, VMH and DMH (252, 255, 256, 815), and 
suppresses feeding (733). During fasting, serum levels of leptin decrease, normalizing after 
refeeding (478, 608). Leptin activates the food suppressing POMC pathway, and actively inhibits 
the orexigenic AgRP/NPY pathway, and during fasting this effect is reversed.  
 
There is also evidence of perturbations in leptin levels in migraineurs, with increased leptin and 
insulin levels in one study (90), but lower serum levels interictally in another (364). There is 
evidence of leptin receptor (ObRb) mRNA in neuronal cell bodies of trigeminal motor nuclei as 
well as the LC, dorsal vagal complex and parabrachial nucleus (363). Preclinically, leptin causes 
a moderate but significant reduction in firing of dural-evoked trigeminovascular nociceptive 
neurons (569).  
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3. Implications for migraine 
i. Brain mechanisms, migraine and feeding 
 
The relevance of these structures to migraine pathophysiology, and specifically the ascending 
projections to the trigeminovascular system and descending control of trigeminovascular 
nociceptive transmission has been described in detail (Section V). Briefly, it has been shown 
that nuclei in the region of the hypothalamus are active before (559) and during migraine 
headache (210). There is activation of VMH, DMH, PVN (557), posterior (PH) and supra-optic 
hypothalamic nuclei (85) in response to trigeminovascular stimulation, and descending 
projections exist from the PVN, PH, perifornical, A11 and retrochiasmatic area (1, 688), to the 
TCC. Projections from the PH (78) and PVN (688) are known to modulate basal and nociceptive 
meningeal-evoked activity of trigeminal neurons. These connections are thought to contribute 
to migraine symptoms such as loss of appetite and pain modulation. The VMH also sends 
topographically organized projections to areas involved in nociceptive modulation such as the 
PAG, LC, parabrachial nucleus and NTS (145) and the PVN sends descending projections to the 
superior salivatory nucleus (688). It is clear that various hypothalamic nuclei are ideally 
positioned to mediate the integration of the trigeminovascular system with dietary fluctuations 
including disrupted feeding patterns.  
 
The NTS is known to be involved in pain modulation, and is activated in response to dural 
nociceptive trigeminovascular activation, a response inhibited by triptans (421). A region seen 
activated on human brain imaging in the premonitory phase of migraine would be consistent 
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with NTS activation (560). Given that descending mechanisms from midbrain structures have 
been hypothesized to contribute to the triggering of migraine, altered feeding, such as fasting 
or hypoglycemia, which affects neuronal firing in the NTS could alter the descending 
modulation of trigeminovascular neurons, as well as alter appetite during migraine. 
Furthermore, the NTS is intrinsically involved in the ‘emetic reflex arc’ (602). Consistent with 
that involvement, medial-caudal NTS neurons are activated in cat (463) and monkey (330, 422) 
when dural afferents are stimulated. Remarkably, vomiting is a common symptom of migraine 
that can often ameliorate, or even stop an attack (152). It is possible to speculate that NTS 
activation might be part of the adaptive processes that take place in the brain before and 
during an attack, as a consequence of the migraine.  
 
The VTA is also involved in nociceptive processing (34, 64, 230, 698), food reward, drug 
addiction (479, 600), and mood disorders (697). Food cravings and alterations of mood are 
considered by some patients to be present in the premonitory phase of the migraine attack 
(228, 300) and, importantly, the VTA was shown to be active during the premonitory phase 
(559).  
 
In order to control body fuels during and after periods of fasting, several adaptive mechanisms 
take place, including reduction of resting metabolic rate and blood glucose, the priority of 
gluconeogenesis over glycogenolysis, and the production of ketones. These adaptations are 
caused or followed by several hormonal changes, including the decline in insulin and leptin 
serum levels and the rise in glucagon, catecholamines and cortisol (140, 214, 263, 478, 707). 
104 
 
 
 
Anatomically, there is increased activation of the perifornical region, DMH, VMH and arcuate 
hypothalamic neurons, which include activation of orexin-containing neurons (214), and 
elevation of mRNA levels of orexin and melanin-concentrating hormone (MCH) (672, 701). 
Furthermore NPY levels in the arcuate nucleus and PVN increase in response to food 
deprivation or food restriction and normalize after refeeding (118, 144, 647, 699), and NPY 
release in the PVN increases before a programmed meal and decreases during the course of the 
meal (455). Also, hypoglycemia induced by insulin causes significant activation in the PVN, as 
well as the LC, dorsal motor nucleus of the vagus and NTS (873). 
 
ii. Feeding peptides and migraine 
 
Considered altogether the data are consistent with a view that blood glucose fluctuations, as a 
consequence of changes to orexigenic and anorexigenic neuropeptides in specific hypothalamic 
nuclei, may increase the predisposition to triggering migraine through altered feeding, or 
reflect a change in that predisposition. Two studies demonstrate consistently higher insulin 
levels in migraineurs compared to controls (148, 676) suggesting that insulin resistance may be 
present in migraineurs. A significant prevalence of insulin resistance was also observed in 
chronic migraine patients (261). A significant association between a polymorphism of five single 
nucleotides of the gene encoding for insulin receptors in migraineurs has been found (590), 
which may affect insulin resistance during fasting in migraineurs. Thus, migraine might be more 
likely in susceptible persons when there is low insulin receptor activation (590), through fasting. 
It is interesting that mild hyperinsulaemia is reported in NPY Y1 receptor deficient mice (489), 
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which might imply that low NPY Y1 receptor activation impairs glucose and insulin metabolism 
that is reported in migraineurs. Furthermore, while obesity is not considered a risk factor for 
migraine, it is associated with an increase in frequency and intensity of attacks (99, 102, 858). 
Plasma OxA levels correlate negatively and plasma leptin levels correlate positively with body 
mass index (BMI) (5), therefore, obese individuals should present lower plasma OxA levels and 
higher plasma leptin levels when compared to normal individuals. This is in accordance with the 
lower peripheral OxA levels seen in episodic migraineurs (146) and, also, with higher blood 
leptin levels shown in non-obese female migraineurs (90), compared to healthy controls. In 
some respects disentangling cause and effect remains the major challenge in terms of meal 
skipping. 
 
Looking at the wider impact of hunger, it is a strong and basic physiological drive. It involves 
activation of several pathways, including the hypothalamic orexinergic system, and is the 
product of multiple perceptions (taste, smell, sight, thoughts, visceral) and motivations. While 
migraine clearly includes pain, it has also been described as an altered activation (or perception 
of activation) of the senses, senses that are affected by hunger, including the trigeminovascular 
system. We can look at this in two ways in susceptible migraineurs; first, hunger triggers 
changes in activation in feeding centers in the brain, aimed at promoting feeding, which affect 
our sensory system, altering our perception of sensory inputs, which includes noxious 
craniovascular somatosensory inputs, but also those of sound, vision and smell, amongst 
others. Secondly, it could be argued that alterations in the individual perception of hunger, 
might in itself also cause disturbances of somatosensory processing, especially nociceptive 
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processing that result in migraine head pain. Thirdly, and perhaps more likely, there is a global 
alteration in the perception of our motivations and senses, including hunger and nociception, 
which become symptoms of the same cause and trigger, and thus all these symptoms of 
migraine are essentially a consequence of a brain state, rather than a single trigger.   
 
B. ‘Sleep disruption’ 
 
The relationship between migraine and sleep has been debated for a number of years (625): 
sleep is considered an effective means of alleviating pain associated with migraine; migraine 
can emerge during nocturnal sleep or following a brief period of daytime sleep; attacks can be 
preceded by a lack of sleep. Furthermore, sleepiness might also emerge during various phases 
of a migraine attack (71). Sleep deprivation, or consistent interrupted or reduced sleep is also 
described by many patients as a possible trigger of migraine (107). The regulation of sleep, 
particularly within the hypothalamus, is strongly linked to the regulation of feeding processes, 
and the interaction of both of these homeostatic mechanisms is likely involved in the triggering 
of migraine.  
 
1. Anatomy of sleep  
 
Both sleep and feeding rhythms are synchronized to the environmental 24-h cycle mainly by 
light–dark information perceived by the eyes, and regulated within the hypothalamus. 
Generation of these rhythms occurs in the master circadian clock, the suprachiasmatic nucleus 
(SCN) of the anterior hypothalamus (201, 867). The SCN output is crucial for synchronization of 
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many metabolic and endocrine factors, such as glucose (143, 491, 693)and leptin (456). Zurak 
(883) reviewed the role of SCN in migraine and suggested that dysfunction of the SCN could be 
related to the prodromal phase of a migraine attack, suggesting SCN as the initial site of 
migraine attacks.  
 
Feeding behavior and metabolite availability can in turn regulate the circadian clock. The DMH, 
a suggested food entrainable oscillator (354), receives neural input from feeding control areas 
(790) and is a major target of the SCN (838). DMH also projects to brain regions critical for the 
regulation of sleep and wakefulness (167). Specifically, DMH sends GABAergic projections to 
the sleep-promoting ventrolateral preoptic nucleus (VLPO) (548), and glutamate-thyrotropin-
releasing hormone projections to the wake-promoting LH area (167). Therefore, increased 
neuronal activity in the DMH might promote wakefulness by simultaneously inhibiting sleep-
promoting neurons in the VLPO and activating wake-promoting neurons in the lateral 
hypothalamus. The DMH also sends a dense projection to the PVN (255, 789). The activation of 
these pathways might explain why lack of sleep or wakefulness might trigger a migraine 
headache attack as Fos protein expression has been demonstrated in the DMH and PVN in an 
experimental model of migraine in animals (557); and PVN neurons directly control both 
spontaneous and evoked activities of spinal TCC neurons (688).  
 
Midbrain nuclei, already described with respect to mechanisms that control pain, may also be 
involved in the triggering of migraine, as well as contributing to the associated symptoms via 
projections to hypothalamic and other brainstem and diencephalic nuclei. As well as controlling 
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pain modulation, ‘ON’ and ‘OFF’ cells in the RVM and NRM are also involved in controlling 
responses to external innocuous stimuli, motor activity and homeostatic processes (571, 573). 
‘ON’ cells are state-dependently active during waking hours, but not during feeding and 
micturition, or during sleeping (65, 278, 279, 525). Whereas ‘OFF’ cells are active during sleep, 
and active during waking only prior to micturition as well as during feeding. Therefore ‘OFF’ cell 
firing in these midbrain structures, during important homeostatic functions such as sleep, 
feeding and urination prevents responding to innocuous and even acute noxious stimuli, 
whereas during waking ‘ON’ cell firing facilitates alertness to sensory stimuli. Furthermore, the 
vlPAG participates in mechanisms of arousal, through the activation of dopaminergic neurons 
during wakefulness and inactivation of these neurons during sleep (549); and vlPAG is also 
involved in the switch between non-REM and REM sleep (286, 550). These important 
mechanisms probably represent important evolutionary developments to control sensory, 
autonomic and motor processes during different levels of alertness to provide the greatest 
protection to the animal from nociceptive inputs. Certainly in the context of potential migraine 
triggers, sleep deprivation is a homeostatic process that results in specific neuronal responses 
in the PAG-RVM pathway, particularly ‘ON’ cell activation and inhibition of ‘OFF’ cell firing. In 
migraineurs, it is possible that altered responses of ‘ON’ and ‘OFF’ cells to nociceptive and 
homeostatic changes, such as sleep disruption, and the neuronal projections of the PAG-RVM 
systems to hypothalamic nuclei and spinal and trigeminal nociceptive neurons, described 
above, contributes to triggering the sensory and physiological symptoms of migraine.    
 
2. Neurochemicals in sleep regulation 
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Interestingly, sleep is affected by feeding, specifically endogenous energy reserves, which may 
impact its influence as a migraine trigger. Indeed sleep is thought to be dependent on the 
availability of utilizable metabolites at the cellular level (198). Sleep debt has been shown to 
have a harmful impact on carbohydrate metabolism and endocrine function (747). Indeed, 
sleep deprivation, induces an increase in glucose and insulin plasmatic levels (684) and lower 
glucose tolerance (747) in humans. Furthermore, melanin-concentrating hormone (MCH) is 
known to promote sleep (6, 824) and integrates energy homeostasis responses (722). Increased 
extracellular glucose levels are known to enhance the electrical excitability of these neurons 
(125), and thus, the excitatory actions of glucose on MCH neurons may promote rest and, 
conversely, a fall in glucose levels would decrease the excitability of MCH neurons, hence 
suppressing sleepiness (125). Collectively, these data might support the view of an impairment 
of glucose metabolism that has already been proposed in migraine patients (148, 676). 
 
i. Hypoglycemia and arousal 
 
Recent evidence indicates that hypoglycemia produces arousal from sleep in normal adult 
humans (68, 288). Several neuropeptides involved in food regulation are known to also 
influence sleep regulation and consciousness. Hypothalamic orexin levels are highest during 
wakefulness and lowest during sleep (258, 469), with almost total cessation during REM 
periods, in vivo (521). It is known hypoglycemia in rats strongly activates wake-promoting 
orexin neurons (141, 611, 651). Furthermore, insulin-induced hypoglycemia activates 
orexinergic and cholinergic neurons, increasing arousal in adult male rats, similar to the effect 
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of nocturnal hypoglycemia in adult humans (793). Thus, orexins appear to stimulate feeding 
and increase metabolism (774) during active, awake periods. It has been reported that 
deficiency in orexin neurotransmission results in the sleep disorder narcolepsy in mice, dogs, 
and humans (161, 532, 628, 778) and one aspect of orexin activity is the direct excitation of 
noradrenergic neurons in the LC to promote wakefulness (117, 416). These observations are 
important as clinical studies demonstrate that patients with narcolepsy show a higher 
prevalence of migraine (195) and that migraine attacks initiate mostly in the early morning 
hours (33, 399). 
 
ii. Orexins, feeding and sleep 
 
Another feature that connects orexins with feeding and sleep is the hunger-induced 
wakefulness, a well-established phenomenon in animals (112, 443), wherein food deprivation 
induces expression of Fos protein in orexin neurons and increases mRNA orexin levels (214), 
but food deprivation does not induce wakefulness in orexin-deficient mice (865). This is 
consistent with electrophysiological findings showing that food deprivation induces synaptic 
changes in orexin neurons, where the number of asymmetric (putative excitatory), but not 
symmetric (putative inhibitory), synapses on orexin-containing cell bodies are elevated 
significantly in mice after just  one episode of food deprivation, compared with fed controls 
(415). From an adaptive evolutionary perspective, synaptic plasticity in orexin neurons may be a 
critical mechanism contributing to the determination of behavioral status by energy status in 
animals.  
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iii. Sleep and NPY 
 
Arcuate POMC neurons and NPY/AgRP neurons are also involved in sleep regulation (432, 476, 
522). Bilateral destruction of NPY receptor-expressing neurons in the arcuate nucleus (847) are 
required for integration of sleep-wake rhythms. In humans, NPY enhances sleep by prolonging 
the sleep period and reducing sleep latency and wakefulness (51, 390). However, studies in rats 
show that NPY has opposing effects on sleep patterns depending on the site of administration 
(752, 776, 796). 
 
iv. Sleep, leptin and body mass 
 
While sleep can be affected by changes in energy homeostasis, changes in sleep patterns can 
likewise disturb endocrine regulation of energy homeostasis (475). Leptin plasma levels show a 
diurnal variation, with levels increasing during nocturnal sleep in humans (738, 841). Leptin also 
influences sleep stages, as systemic leptin significantly decreased the duration of REM sleep 
and increased the duration of slow wave sleep in rats (739). Furthermore, studies in humans 
show lower leptin levels during short habitual sleep time (154, 618, 746, 777), suggesting that 
sleep restriction causes increases of appetite and higher BMI. Recent epidemiological studies 
have pointed to a distinct relationship between sleep duration and body weight, suggesting a 
U-shaped association in that both shortened and extended sleep durations coincide with 
increases in body weight (290, 380, 777, 826). These effects might be important in the context 
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of migraine, as metabolic syndrome has been suggested to explain obesity as a risk factor for 
migraine frequency and severity, as well as to progression from episodic to chronic migraine 
(99, 101). 
 
v. Sleep disturbance- trigger or consequence 
 
While it is still not clear whether disruption to homeostatic regulation is actually a trigger of 
migraine, a symptom, or contributes to both, changes of appetite (loss of appetite or hunger), 
sleepiness and irritability reported during migraine may be mediated by reciprocal projections 
between nociceptive trigeminovascular neurons and the lateral hypothalamus. In this area 
neurons expressing MCH or orexin regulate food and water intake, sleep and arousal, through 
widespread projections to the cerebral cortex, brainstem and spinal cord (104, 701, 814). It 
could be argued that there is a hyperactivity of the brain mechanisms responsible for the 
hunger behavior in the premonitory phase of migraine, leading to arousal and lack of sleep. 
Hence, in some cases it would not be the voluntary bedtime sleep deprivation that would 
trigger the headache attack but, instead, an endogenous wakefulness mechanism that would 
be active, or a perception of wakefulness state, that could trigger the activation of the 
trigeminovascular system. Sleep deprivation is also known to activate hypothalamic feeding 
mechanisms and, thus, not only trigeminovascular neuronal pathways would be activated 
through reciprocal projections between the TCC and the hypothalamus, but also changes of 
appetite would be likely to happen. Therefore, in some respects, it may be difficult to dissect a 
difference between the mechanisms triggered by food or sleep deprivation, but it is clear each 
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can affect the other, and may increase the likelihood of a migraine attack. 
 
C.  ‘Stress’ 
 
Stress and negative emotions are commonly listed as triggers by migraineurs (227, 300). 
Although stress-sensitive patients may perceive more stress in the days before an impending 
migraine attack, there is very little experimental evidence showing a biological stress response 
in migraineurs. Migraine patients were reported to have large variations in plasma cortisol 
levels, a stress response indicator, when compared to the control group, and a subgroup of 
migraine patients exhibited abnormal circadian levels of cortisol (882). A study also showed 
statistically significant associations between the cortisol response and both headache severity 
and duration (355). While stress as a trigger may also be related to other potential triggers that 
are a response to disrupted homeostasis, such as sleep and food deprivation reviewed above, 
we will describe the mechanisms through which ‘stress’ may contribute to these processes.  
 
The hypothalamo-pituitary-adrenocortical (HPA) axis is recruited by the organism in response 
to real or perceived threats to homeostasis or ‘stress’. Corticotropin-releasing hormone (CRH) 
and vasopressin (AVP) are produced in the parvocellular neurons of the hypothalamic PVN. 
These neurons secrete peptides into the portal vessel system to activate the synthesis of pro-
opiomelanocortin (POMC) in the anterior pituitary, which is processed to corticotropin (ACTH), 
opioid and melanocortin peptides, among others. Then, ACTH stimulates the adrenal cortex to 
secrete cortisol (humans) and corticosterone (humans, rats and mice) as a stress response 
(reviewed in 205). Signals of homeostatic imbalance in the brainstem also lead to activation of 
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the HPA axis:ascending brainstem and spinal pathways project to the parvocellular divisions of 
the PVN. For instance, noradrenergic and adrenergic projections to the hypophysiotrophic zone 
of the PVN originate in the NTS and C1-C3 (189, 190) and participate in the HPA axis. 
Furthermore, in a preclinical animal model of migraine using nociceptive activation of 
trigeminovascular neurons, a stress protocol in these animal reduced the ability of PVN neurons 
to provide descending control of trigeminovascular nociceptive neurons (688).  
 
1. Neuropeptides in stress 
 
Similar to feeding and sleep, stress is also influenced by the orexinergic system; orexin mRNA is 
increased in the LH due to stress (436). In patients with chronic headache and medication 
overuse headache (MOH), increased cerebrospinal fluid levels of corticotrophin-releasing factor 
and OxA have been demonstrated (706). These results are in agreement with a suggested 
hypothalamic–pituitary axis alteration in these patients (675). 
 
2. Orexins and corticosteroids 
 
In preclinical studies, ICV administration of orexins in the rat produces activation of 
parvocellular PVN neurons that are putative CRH-containing neurons (200, 244, 488). Central 
injection of orexins also caused significant secretion of ACTH (488) and elevation of plasma 
concentration of corticosterone (244, 436, 446, 488), and this response is completely 
eliminated by pre-administration of the CRH antagonist, α-helical CRH9-41 (446). The CRH-
producing neurons in the parvocellular PVN also show abundant expression of the OX2R gene, 
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as well as receiving axonal projections from orexin-producing neurons (200). Recent 
experimental data in this regard indicate that the CRH peptidergic system directly innervates 
and can depolarize orexin-expressing neurons, an effect which is blocked by a CRF-R1 
antagonist. In addition, activation of orexinergic neurons induced by high arousal states, 
including stress, is impaired in CRF-R1 knockout mice (257, 856, 857). These data suggest that 
the CRF-R1 receptor mediates stress-induced activation of the orexinergic system (706).
 
There 
are also experimental findings suggesting that orexins in the CNS may be involved in the 
activation of central CRH neurons induced by stress (436). Furthermore, it is suggested that CRH 
activates the orexin system, relaying orexin-A to brainstem nuclei such as the LC as well as the 
nucleus accumbens, VTA and amygdala (856), which are critical structures involved in 
determining the rewarding or aversive value of an environmental stimulus such as stress 
(reviewed in 697). 
 
3. Leptin and corticosteroids 
 
It is possible that orexins together with leptin may take part in counter-regulatory mechanisms, 
which, through the modulation of glucocorticoid secretion, are involved in the maintenance of 
physiological blood glucose levels and energy homeostasis. Indeed, as opposed to orexin-
induced glucocorticoid secretion, leptin has been shown to inhibit the stress-induced activation 
of the HPA axis (388) and to inhibit glucocorticoid secretion (113, 301, 302, 669). Individuals 
who have perceived psychological stress (self-reported) had higher leptin levels, compared to 
those patients who reported little stress in their daily life (646). Since the central orexin system 
is related to physiological stress responses and activation of both orexin receptors modulates 
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acute dural and facial nociceptive inputs, it is likely that there is a causal link between a stress 
response, the potential origin of the premonitory symptoms of migraine and the descending 
modulation of trigeminovascular nociceptive traffic.  
 
4. Neuropeptide Y (NPY) 
 
NPY is an established moderator of stress responses (reviewed in 387, 744, 792), by mediating 
activation of the HPA axis. It has been shown that NPY-containing neurons form a prominent 
afferent pathway between the arcuate nucleus and the PVN (529, 534). In addition, half of the 
glucocorticoid receptor (GR)-positive neurons in the arcuate nucleus are also immunoreactive 
for NPY (392). Inadequate nutritional intake, such as food deprivation/fasting also activates the 
HPA axis, demonstrated by increased cortisol release in humans (87, 818) and increased activity 
of NPY neurons in animals (229, 377). Intra-PVN administration of NPY stimulates food intake 
and this effect is suppressed by CRH (389). Furthermore, NPY release in the PVN modulates 
activity of parvocellular neurons and increases ACTH and corticosterone release (32, 437). This 
activation seems to be explained by the presence of NPY Y1 receptors on CRH neurons in the 
PVN (222), and NPY Y5 receptors may also be involved in regulating HPA axis function in rats 
(454). Functional NPY gene variation has been proven to influence the behavioral adaptation to 
stress (533) and as described above, NPY is able to modulate acute dural nociceptive inputs in 
the TCC by inhibiting neuronal firing through the activation of the NPY Y1 receptor (570). Thus it 
is possible that impaired central NPY signaling might be involved in stress-induced migraine.  
 
5.  Stress and migraine 
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It is assumed that, in general, acute stress should not result in detrimental effects. Instead, 
through physiological adaptation, the organism should become capable of functioning in the 
midst of this altered environment. However, we have detailed above how migraineurs seem to 
be particularly susceptible to environmental changes. They might therefore have enhanced 
neuroendocrine responses, as a manifestation of enhanced sensitivity of brainstem and 
diencephalic pathways, leading to inappropriate processing or interpretation of stressful 
information. The parvocellular division of the PVN seems most likely to play a central role in the 
homeostatic stress response and these neurons are known to project to the brainstem and 
spinal cord (775) and more specifically to regions of the TCC (688). In addition, afferent 
pathways such as limbic pathways that are activated by psychological stressors (444), and 
ascending brainstem pathways that convey visceral and sensory stimuli may also activate CRH 
neurons in the PVN (687). Therefore, activation of parvocellular neurons in the PVN might be 
key to the cascade of events leading to the activation of the trigeminovascular system and, 
ultimately, could explain the low stress resilience in susceptible individuals or the stress-
induced migraine.  
 
XI. Pharmacology of Migraine – Treatments 
 
Activation of the trigeminovascular system results in the release of a number of neuropeptides 
based upon the sympathetic, parasympathetic and sensory innervations of the cranial 
vasculature, summarized in Table 2. The sympathetic innervation is characterized by NPY and 
noradrenaline (239-241), both of which are vasoconstrictors while the parasympathetic fibers 
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are characterized by VIP and PACAP, which are amongst the most potent vasodilators (240). 
The sensory innervations are characterized by substance P, CGRP and PACAP (247). 
Experimental activation of the trigeminal ganglia in animals and humans (324) results in the 
release of SP and CGRP which can be inhibited by different triptans. Given the release of SP and 
at the time, an emerging theory of a role for neurogenic inflammation in the pathophysiology 
of migraine, an unsuccessful program targeting the neurokinin 1 receptor ensued (583). The 
failure of substance P directed interventions was highlighted in follow up studies exploring 
neuropeptide changes in migraine and targeted cerebrovascular stimulation in animals. In these 
studies CGRP, VIP and PACAP are most commonly upregulated with no change in substance P 
levels (325, 874). A summary of approaches in, or near development, for the treatment of 
migraine is found in Table 4. 
 
 
A. Serotonin (5-HT) 
 
The initial involvement of serotonin (5-HT) in migraine was postulated more than 50 years ago 
with seminal observations of increased 5-hydroxyindoleacetic acid (metabolite of 5-HT) 
associated with migraine attacks (191, 734). Further evidence was gained from two key studies 
identifying reductions in platelet 5-HT during attack onset (50) and that infusion of 5-HT could 
abort both reserpine-induced (468) and spontaneous headache (503). In response to these 
seminal studies the 5-HT receptor system gained much attention culminating in the discovery of 
the triptans, serotonin, 5-HT1B/1D receptor agonists (434).  
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1. Triptans- Serotonin, 5-HT1B/1D receptor agonists 
 
Of the fourteen 5-HT receptors identified all except 5-HT3 (ligand-gated ion channel) are G 
protein-coupled receptors (430). While the triptans are classed as 5-HT1B/1D receptor agonists, 
most also activate to a lesser extent the 5-HT1A, 5-HT1E or 5-HT1F receptors (310, 434). Originally 
the triptans were developed to act on the craniovasculature, an idea supported by their clear 
vasoconstrictive actions (174, 177, 264, 265) and the preferential expression of the 5-HT1B 
receptor on cranial rather than peripheral vessels (809). In conjunction with progress in 
theories of migraine (section XI), understanding of the mechanism of action of the triptans has 
evolved, largely due to the discovery that triptans are not selective cerebral vasoconstrictors 
and the presence of central effects. Both sumatriptan and dihydroergotamine, a less specific 5-
HT1B/1D receptor agonist (86), were demonstrated to inhibit trigeminal afferents by an 
exclusively neural mechanism, without effect of vessels, that is also acting on central trigeminal 
neurons (419, 420, 462). A neural mechanism of triptans on peripheral trigeminal nerve endings 
could inhibit proinflammatory neuropeptide release and neurogenic dural vasodilation (853, 
854), which was consistent with the developing theme of migraine as a neurovascular disease.  
 
It is now clear that the triptans may be acting within the TCC to modulate trigeminovascular 
nociceptive neurons which express 5-HT1D and 5-HT1F receptors (170, 426, 552). It has been 
demonstrated that TCC neuronal activity can be inhibited by more centrally active triptans (314, 
322, 331, 333, 334) and this effect is mediated predominantly by 5-HT1B/1D receptors (332). The 
growing interest in possible CNS sites of action for the triptans led to more focused approaches 
relying upon direct delivery to discrete areas combined with detailed electrophysiological 
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approaches. Microiontophoresis of 5-HT1B/1D agonists on trigeminovascular neurons in the TCC 
results in a clear reversible inhibition of trigeminal activity (763), highlighting this key relay 
center as a major site of action. However, as discussed earlier, multiple CNS sites of action have 
now been established including the PAG (77), PVN (688) and thalamus (730). The diversity of 
the target sites raises an intriguing scenario where modulation of 5-HT1B/1D receptors could 
influence ascending trigeminothalamic projections in tandem with actions on descending pain 
modulatory structures. 
 
2. Ditans- Serotonin, 5-HT1F receptor agonists 
 
Despite the clear pharmacology of the triptans in the treatment of migraine their use is limited 
in patients with cardiac risk factors (223), resulting in the need to target receptors lacking 
vasoconstrictive actions. One such target is the 5-HT1F receptor which is activated to a degree 
by some triptans, such as naratriptan, and not by others, such as rizatriptan (310). 5-HT1F 
receptors are found in the TCC and trigeminal ganglion (42, 115, 124, 170), and their activation 
inhibits trigeminal activity in the rat and cat (728, 762). Indeed it can be shown that after 
blockade of 5-HT1B and 5-HT1D receptors with SB224289 (724) and BRL-15572 (670), 
respectively, naratriptan retains an inhibitory effect on trigeminocervical responses evoked 
from superior sagittal sinus (316), while a 5-HT1F receptor agonist LY344864 (663) has inhibitory 
TCC effects and no effect on the cat carotid circulation (316). Moreover, the inhibitory effect of 
alniditan, a 5-HT1B/1D receptor agonist with no 5-HT1F effects (528) and proven anti-migraine 
effects (352), is completely blocked by the combination of SB224289 and BRL-15572 (316). 
Evidence for a neural mechanism which may be devoid of vascular effects (114) is further 
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supported by selective 5-HT1F inhibition of dural extravasation and inhibition of TCC neuronal 
activation following trigeminovascular activation (449, 604, 605, 624, 663). While the 
development of specific 5-HT1F receptor agonists has not been without complication (350), 
successful phase II randomized clinical trials with lasmiditan (624) highlight the potential of 
targeting specific neuronal targets (260, 267).  
 
 
B. Calcitonin gene-related peptide (CGRP) 
 
CGRP is a 37 amino acid neuropeptide with potent vasodilator effects (486, 852) that is 
produced by alternative splicing of the calcitonin gene (35, 692). Other members of the gene 
family are amylin, adrenomedullin and adrenomedullin 2 (intermedin) (694). With respect to 
the nervous system αCGRP is predominantly expressed, while βCGRP is associated with the 
enteric sensory system (617). CGRP acts at two receptors, one the so-called canonical CGRP-
receptor complex is made up of a G-protein-coupled receptor consisting of a seven 
transmembrane spanning protein (calcitonin receptor-like receptor; CLR) and a single 
transmembrane receptor modifying protein (RAMP) 1 (16, 593). RAMP 1 is critical for the 
transport and cell surface expression of the CGRP receptor complex (593) and its 
overexpression results in migraine like phenotypes including light aversion and CGRP induced 
allodynia (453, 680, 681, 696). The second CGRP receptor has been called the amylin receptor 
(AMY1) and consists of the calcitonin receptor (CTR) and RAMP 1 (382). It has now been clearly 
shown that CGRP activates this receptor (831). Amylin is a glucoregulatory hormone and has 
additional bone metabolism effects. 
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CGRP is widely distributed including in the striatum, amygdale, hypothalamus, thalamus, 
brainstem and TCC (404, 816, 868). Within the primary afferent trigeminovascular pathways 
CGRP expression is highest in the sensory trigeminal ganglion and its Aδ and C-fiber projections 
to cerebral and dural blood vessels as well as centrally to the spinal cord (242, 246, 780), where 
it can impact second order ascending projections. Functional CGRP receptors and binding sites 
have been identified on dural artery smooth muscle cells and in the trigeminal ganglia, 
thalamus, hypothalamus, amygdale, cortex and brainstem (238, 246, 523, 643, 769). 
Interestingly in the TCC CGRP receptors are thought to co-localise with CGRP in terminals of 
primary afferents and not ascending fibers (523). 
 
CGRP is a potent vasodilator which when given to migraine sufferers is known to trigger attacks 
(508); however, the exact triggering mechanism is not clear since VIP another potent 
vasodilator fails to initiate attacks (674) suggesting a non-vascular mechanism. As discussed 
earlier CGRP is released during spontaneous (325) or triggered attacks (289), which can be 
inhibited by triptan treatment (323). Experimental activation of trigeminal ganglion cells is 
known to result in the release of CGRP, which is dose dependently inhibited by 5-HT1B1D 
agonists (231), highlighting the trigeminal ganglion as a key site that may be a target of CGRP 
receptor antagonism and triptan response (245, 247). In addition to its vascular effects, CGRP 
has emerged as a key modulator of neuronal function which has important effects on 
neurotransmitter systems such as the glutamatergic system (760). Local administration of CGRP 
facilitates dorsal horn and TCC nociceptive neurons, while CGRP antagonism points towards a 
123 
 
 
 
tonic facilitatory role as blockade with the truncated CGRP8-37 reduced neuronal responses 
below baseline levels (760). Similarly targeted administration of CGRP to the ventrolateral PAG 
facilitates trigeminovascular processing via descending modulatory mechanisms (668), while 
thalamic modulation identified a clear inhibitory action of CGRP antagonism, both on 
nociceptive signaling and spontaneous background activity (769). 
 
1. Gepants- CGRP receptor antagonists 
 
Based on the available bench and clinical data (395), an effort was commenced to develop 
CGRP receptor antagonists (226). Olcegepant (BIBN4096BS) demonstrated excellent efficacy in 
animal models of CGRP-induced vasodilation (610), and interestingly reversed spinal morphine 
tolerance (667). In a proof-of-principle phase II study using an Up/Down design rule, it was 
effective at a dose of 2mg intravenously (638). It was never commercialized due to formulation 
issues. Subsequently telgecepant (MK-0974) also demonstrated efficacy in better than placebo 
and comparable to triptans (179, 393, 396), as the first oral CGRP receptor antagonist. It had 
excellent long term tolerability (178), and was also well tolerated in patients being investigated 
for coronary artery disease (397). However, the development of telcagepant and its follow-on 
MK-3207 (391) was halted when liver enzyme problems emerged in a preventive study, which 
was interestingly enough positive (394). It has been generally considered as an off-target effect 
of a metabolite of the compounds, which has not been reported with rimagepant (562) or 
BI44370 TA (216). Most recently a further compound ubrogepant has been identified, again it 
was effective in a placebo-controlled trial as an acute migraine treatment (828), and along with 
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AGN-241689, which will be developed as a preventive (Table 4), this class of therapies has much 
promise. 
 
2. CGRP peptide and receptor monoclonal antibodies (-numab & -nezumabs) 
 
In order to capitalize on the proven anti-migraine effects of blocking CGRP mechanisms in 
migraine, monoclonal antibodies have been developed as novel preventive treatments.Three 
antibodies to the CGRP peptide, ALD-403 (224), galcanezumab (LY2951742, 225) and TEV-48125 
(96), have each published a positive randomized, placebo-controlled trial in episodic migraine 
prevention that has been positive. One CGRP ligand monoclonal antibody has published 
positive data for chronic migraine (97), and the CGRP receptor (CLR/RAMP1 complex) antibody, 
erenumab, has also presented positive placebo-controlled trial data in episodic migraine (770). 
These antibodies seem well tolerated with no significant adverse events across the studies, and 
no issues emerging from phase I studies (98, 103, 204). These compounds represent a truly 
innovative, immunopharmacological approach to blocking CGRP mechanisms that is now in 
phase III development. 
 
C. Nitric Oxide Synthase 
 
Nitric oxide (NO) is an abundant gaseous signaling molecule which like the previously 
mentioned neuropeptides is involved in a variety of functions including endothelial dependent 
vasodilation (441). Nitric oxide donors, such as glyceryltrinitrate/nitroglycerin, like CGRP (508) 
and PACAP (720), are used for the experimental induction of migraines (439, 441) and 
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premonitory symptoms (11). Given the clear role of NO donors in triggering attacks it is 
unsurprising that they have received similar attention in preclinical models where they produce 
vasodilation (30, 767) and trigeminovascular activation (480, 495, 783). Perhaps the most 
interesting feature of experimental NO use is the biphasic nature of the TCC activation with an 
initial acute activation and a delayed general activation (20, 480) which appears to mirror the 
acute throbbing and delayed migraine seen in patients. NO donors clearly facilitate 
trigeminovascular activation resulting in activation of the TCC with resultant increases in CGRP 
and neuronal nitric oxide synthase (nNOS)(652, 653) and NOS  inhibitors have also proven 
preclinical efficacy. Nitric oxide synthases are a family of enzymes which catalyze the 
production of NO consisting of endothelial (eNOS), neuronal (nNOS) and inducible (iNOS). Non-
specific blockade of NOS prevents neurogenic dural vasodilation (31) and TCC neuronal 
activation (417, 634). Interestingly and in support of the current theme of migraine as a 
neurovascular disorder specific nNOS inhibitors mimic the effects of non-specific blockers (31, 
93).  
 
The available clinical and preclinical data highlighted NOS inhibitors as a reasonable target for 
anti-migraine therapy and while early studies showed beneficial outcomes (507) they were not 
without issue. Given the unwanted side effects of eNOS actions current research has focused 
towards other specific NOS inhibitors, with the initial study of a specific iNOS inhibitor failing to 
reach its clinical end point in both an acute (649) and preventive study (403). A mixed triptan 
and nNOS inhibitor NXN-188 was also found to be ineffective in both migraine without aura 
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(595) and specifically in the aura phase (428). The issue of a possible effect of a specific nNOS 
inhibitor is unresolved. 
 
D. Pituitary adenylate cyclase-activating peptide (PACAP) 
 
PACAP like CGRP is released during migraine (803, 874, 875) and can trigger attacks (720) in 
patients leading to its exploration as a possible anti-migraine target. It is a member of the VIP-
glucagon growth hormone releasing factor-secretin superfamily which comes in two forms; 
PACAP-38 accounts for approximately 90%, whereas PACAP-27 is relatively poorly expressed 
(57). Like the majority of neuropeptides targets PACAP is widespread throughout the CNS and 
peripheral tissue (574, 806, 808) where it has potent vasodilator effects. PACAP is known to 
have a specific uptake mechanism into the brain (70). The pharmacology of PACAP is slightly 
more complex due to its binding affinities to three G-protein coupled receptors which also bind 
VIP. It should be highlighted again that VIP does not induce migraine unlike PACAP and CGRP, 
highlighting the importance of non-vascular targets. VPAC1 and 2 bind VIP, PACAP-38 and 
PACAP-27 in order of descending affinity while PAC1 is relatively specific for PACAP (492). It is 
expressed in the TCC, spinal cord, trigeminal ganglia, sphenopalatine ganglia and CNS structures 
including the thalamus, hypothalamus and brainstem (186, 450, 574, 779, 808). It is likely the 
central expression pattern underlies the proposed role in migraine, and like CGRP, PACAP has 
been linked to sensitization and light aversion (564). This facilitatory role has recently been 
demonstrated in the hypothalamus where PACAP administration facilitated trigeminovascular 
nociception via a PAC1 mechanism (688).  
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Recently, in a rodent model of nociceptive trigeminovascular activation it has been shown that 
VIP and PACAP-38 caused short-lived meningeal vasodilation mediated by VPAC2 receptors, 
without activation of central trigeminovascular neurons (17). PACAP-38 and not VIP caused a 
delayed activation and sensitization of central trigeminovascular neurons. In this context 
behaving as it does in triggering migraine (720). Intravenous delivery of a PAC1 receptor 
antagonist inhibited the peripheral meningeal vasodilatory effects of dural trigeminovascular 
nociception, whereas only central (intracerebroventricular) administration of the PAC1 receptor 
antagonist inhibited dural nociceptive trigeminovascular activation (17), suggesting a central 
PAC1 receptor as an important target. While not as advanced as CGRP targeting, it is clear that 
PACAP has a role to play in the pathogenesis of migraine and as such will continue to progress 
as a therapeutic target. 
 
 
XII. Theories of migraine  
Theories of migraine have changed greatly over the years, often turning full circle and returning 
to the original theories from 250 years ago. However the last 60-70 years has seen the largest 
development of theories as a consequence of medical research and advancing scientific 
technologies. Certainly since the observations of Harold Wolff and colleagues in the 1940s, 
where mechanical stimulation and distension of cranial blood vessels resulting in headache-
type pain in patients undergoing cranial surgery, a ‘vascular theory of migraine’ took on 
momentum. The theory is driven by the idea that vasodilation of extracranial arteries and also 
intracranial blood vessels produce mechanical activation of perivascular nerve fibers that 
128 
 
 
 
innervate the vessels, resulting in headache pain (861). This concept was supported by the 
observation that migraine headache commonly has a pulsating quality, as well as by more 
recent studies showing that nitric oxide and CGRP are able to trigger migraine attacks and the 
vasoconstrictive and therapeutic effect of triptans support this. However, recent preclinical and 
clinical data in these same areas demonstrate that this concept was based on 
misinterpretations. In contrast to the common assumption, the experienced pulsations during a 
migraine attack are not synchronized with cardiac contractions as the painful pulsations have a 
lower frequency (14, 603). Furthermore, arterial vasodilation produced by VIP does not trigger 
migraine headache in patients (674) and arterial vasodilation that has been reported during 
CGRP-evoked migraine (58) is modest and unlikely to be sufficient to activate perivascular 
nociceptive afferents. In addition, Amin and colleagues (40) demonstrated in a study using 
state-of-the-art MR-angiography techniques that meningeal vessels do not dilate during 
spontaneous migraine attacks (40), something which has been previously demonstrated during 
experimentally triggered migraine (713). The results further indicate that intracranial vessels 
show only a slight dilation that is not affected by sumatriptan, making the vascular theory 
obsolete (40).   
 
The importance of the intracranial vasculature, or its nerve fiber innervation, still remains 
significant. The studies of Ray and Wolff demonstrated that headache-like pain and nausea can 
be generated by stimulation of the dura mater, particularly surrounding the dural and cerebral 
blood vessels, whereas stimulation away from the vessels was not effective at inducing pain 
(679). As described above the dural blood vessels are richly innervated by nociceptive 
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unmyelinated (C-fiber) and myelinated (A-fiber) axons that originate in the trigeminal 
ganglion, and contain vasoactive neuropeptides (Table 2). These data consolidate the theory 
that headache in migraine may be mediated by activation of nociceptive nerve fibers that 
innervate the meningeal blood vessels. The key question is what causes these fibers to become 
activated during migraine. One proposal in the 1980s was that a ‘sterile neurogenic 
inflammation’ of the dural meninges may result in activating the perivascular innervation to 
trigger migraine (612). Activation is driven by local dural release of endogenous inflammatory 
mediators such as CGRP, substance P, neurokinin A and prostaglandins, which increase local 
blood flow (predominately driven by CGRP), leakage of plasma proteins from blood vessels, 
mast cell degranulation and platelet aggregation. It is induced experimentally in rats by 
trigeminal ganglion stimulation, a process that also induces similar responses in the retina (565, 
566). The success of acute migraine treatments including ergot alkaloids, sumatriptan and non-
steroidal anti-inflammatory drugs in blocking these effects (138, 139, 567) has added support to 
this theory. 
 
However, over the last two decades an overwhelming volume of data has been generated 
which make this theory seem implausible, and in some respects impossible. Firstly, only CGRP 
has been shown to be released during migraine, with no evidence of substance P or neurokinin 
A release (289, 325). Furthermore, of all the inflammatory molecules shown to induce dural and 
retinal plasma protein extravasation, only CGRP, a marker of a migraine attack, failed to 
produce a response (566). It has proven very difficult to induce plasma protein extravasation in 
human skin, a process that is readily induced in guinea pigs, implying there may be a clear 
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species difference that negates these preclinical studies (660). Also retinal plasma protein 
extravasation is not present during migraine (587) and there is little evidence of inflammatory 
pathology in migraineurs. Further, a plethora of molecules developed to block extravasation 
without the vasoconstrictive effects of triptans, including neurokinin 1 receptor antagonists 
(349, 351) and extravasation inhibitors (233, 691) failed as both acute and preventive 
treatments of migraine. These data indicate that it is unlikely that neurogenic dural 
inflammation plays a significant role in the pathophysiology of migraine, and the fact migraine 
can be so frequent and debilitating, and occur over many years, such an inflammatory insult 
would likely leave a pathology that is picked up on imaging, but nothing has been found (648). 
 
Today migraine is more commonly described as a ‘neurovascular disorder’, and specifically a 
disorder of the brain. One theory that has grown in significance over the last 15 years extolling 
this view, and has served to explain many features of migraine previously unexplored or simply 
not clear is ‘peripheral and central sensitization’. Sensitization is a common feature of many 
chronic pain disorders and is hypothesized to also be present during migraine. It is long-lasting 
activation and sensitization of peripheral nociceptors and central nociceptive neurons, and it 
may explain the longevity of the migraine attack, and the transition to chronic migraine, as well 
as specific related symptoms. This theory was borne out of experimental studies on rodents 
using an inflammatory soup placed upon the dura mater to induce peripheral and central 
sensitization of trigeminovascular neurons (766). Within the inflammatory soup are chemical 
mediators; histamine, serotonin and cytokines, that are believed to be released as a 
consequence of the dural inflammation and plasma protein extravasation, which complicates 
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the efficacy of this theory given the data regarding neurogenic dural inflammation. Certainly, 
peripheral sensitization of trigeminal nociceptive afferents that innervate the dural meninges 
has gone some way to explain the likely exacerbation of intracranial headache pain due to 
physical activity and movement, as well as the throbbing nature of pain during migraine (766). 
Central sensitization of trigeminovascular neurons has aided our understanding of the neural 
basis for extracranial hypersensitivity in migraine; the referral of pain and allodynia to peri-
orbital and cutaneous facial areas (91, 135). Sensitisation of trigeminothalamic neurons is likely 
to account for the widespread cutaneous allodynia to extracephalic regions (128, 132).  
 
A major tenet of this theory is that the primary trigger of migraine comes from the periphery, in 
the dural blood vessels, with activation of the trigeminovascular system coming from firing of 
first-order peripheral trigeminal neurons in response to nociceptive injury or signals coming 
from the meninges that release neuro-inflammatory mediators. Sustained activation of dural 
meningeal nociceptive neurons causes sequential activation and sensitization of first 
(peripheral nociceptors), second (at the level of the TCC) and third-order (trigeminothalamic) 
trigeminovascular neurons, as well as ascending activation of brainstem and other diencephalic 
structures (91). This sequential activation is thought to explain the throbbing nature of pain in 
migraine, the noxious sensory hypersensitivity, associated neurological symptoms including 
nausea, vomiting, altered feeding and sleep, as well as cognitive disruption. In principle the 
theory seems to address every symptom of migraine with the initial symptom or trigger being 
head pain, and everything else following as a consequence. Clinically however, there are many 
gaps. Premonitory symptoms in migraine can be present 24-48 hours prior to headache, and 
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are represented by changes in activation in midbrain and hypothalamic brain regions (300, 
559). Migraine triggers such as sleep and food deprivation, and stress, are under homeostatic 
control, likely via the hypothalamus and midbrain structures, and they do not directly activate 
the meninges. They do however modulate nociceptive inputs to the TCC through descending 
mechanisms, and have ascending projections to the cortex, and with these as trigger it is likely 
headache would not be the first sign of the disease. As reported there is little evidence of 
vasodilation during migraine, which one would assume to be a consequence of release of 
inflammatory mediators and activation of nociceptive nerve fibers that innervate the meninges. 
Therefore while sensitization of trigeminovascular pathways is clearly important, the 
mechanism that drives this response is not clear. 
 
Despite these clinical anomalies as outlined above, there remains a strong belief that CSD the 
experimental correlate for aura is the primary triggering event for meningeal activation (the 
evidence for and against has been discussed above). As mentioned, aura is only present in 
approximately in one third of migraineurs, although a common hallmark in the rare genetically 
identified forms. It is unlikely that all the different forms of migraine, (migraine with (MA) and 
without aura (MoA), FHM  (645) and cerebral autosomal dominant arteriopathy 
with subcortical infarcts and leukoencephalopathy (CADASIL) (151, 451), are all a consequence 
of different pathophysiological mechanisms. Given that most MA patients also suffer MoA and 
FHM patients can present with MA and MoA, it would suggest that a common pathophysiology 
underlies the conditions with heterogeneity amongst the associated symptoms that is certainly 
influenced by genetic predisposition. 
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Stepping back from CSD, it is perhaps pertinent to explore the role of the cortex itself. There is 
contradictory evidence of cortical excitability in migraine, on one hand migraineurs are more 
susceptible to visual triggering and have heightened sensitivity to such stimuli. This may result 
from hyperexcitability, particularly in MA (169), with a decreased threshold to produce 
phosphenes (82, 122, 298). However, there are similar reports of hypoexcitability states and 
significantly higher phosphene thresholds (8, 182). An elegant review of the data concluded 
that these observed changes in cortical excitability may not actually be a predisposition factor 
to develop migraine, but rather that changes in neuronal excitability are a function of the 
chronicity process in the disease (750) and an example of when in the cycle patients were 
tested. It would appear more reasonable to assume that altered cortical switching between 
hypo and hyper-excitable states exists resulting in dysregulation of normal cortical function. 
Alternatively much of the evidence supporting the hyperexcitability may result from lower 
order trigeminovascular alterations via thalamocortical networks, such as the recently 
identified thalamic involvement in photophobia (reviewed earlier (632)). 
 
In the case of MoA, if CSD is the triggering factor of attacks then patients must demonstrate 
cortical changes similar to CSD without the physical symptoms (silent aura). There also needs to 
be explanations for the examples of aura without pain, or indeed treatments that improve aura, 
but not pain (340), but these are limited. We know that CSD has been very difficult to 
demonstrate in humans in situ and the only unequivocal evidence has been in injured human 
cortex (259, 589, 768). Recent studies supporting CSD in human brain during migraine aura 
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(366, 702) only use blood flow evidence rather than neuronal changes, which is what 
technically defines CSD, and merely provide more sophisticated technology to measure the 
response than the original study from the 1980s (640). But there is evidence from imaging 
studies of unilateral occipital hypoperfusion prolonged well into the headache phase of 
migraine with aura (640, 702), while the aura symptoms do not persist. This could be 
interpreted as a demonstration of aura pathophysiology without aura symptoms and similar 
mechanisms could hypothetically be involved in migraine without aura. However, in MoA there 
is much conflicting information regarding hypoperfusion, with several studies demonstrating no 
perfusion changes during MoA, particularly during the headache phase (192, 702) while a more 
recent study demonstrated prolonged bilateral posterior cerebral hypoperfusion, and this 
continued beyond pain relief with sumatripan (210). It is worth noting that global 
hypoperfusion has also been demonstrated simply in response to pain (173). Therefore it is 
unlikely that CSD can explain prolonged bilateral hypoperfusion in this case. CSD is described as 
a wave that requires dense populations of neurons to spread across the cortex, therefore 
hemispheric boundaries cannot be negotiated. Recently it has been hypothesised there may be 
a dissociation between the neuronal and vascular responses to CSD, with evidence that 
vasomotor changes spread at greater velocities to the metabolic/neuronal changes (120, 153). 
As such, it could be hypothesized that independent mechanisms, which do not involved CSD, 
but result in similar vasomotor physiology, may underlie the prolonged hypoperfusion that has 
been demonstrated in migraine with and without aura. 
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The final disparity between MA and MoA lies in the epidemiology of the conditions as risk 
factors for other disorders. It was recently demonstrated that FHM mice undergoing 
experimental stroke suffered greater brain damage and poorer outcomes than control mice. It 
seems migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations. 
Clinically, MA is a risk factor for stroke (483), especially in females although not for MoA (487, 
716) which is indicative of at the very least significantly fewer CSD events in MoA. There is 
therefore uncertainty and continuing debate about the role of aura in the cascade of events 
resulting in migraine pain and accompanying symptoms, which will likely continue due to the 
complex nature of the disease rendering it difficult to separate the component parts in a 
feasible manner. 
 
If the triggering of migraine does not come from the periphery or cortical spreading depression, 
how can the provocation of a migraine attack be explained? 
 
While migraine pain is undoubtedly a consequence of activation, or the perception of activation 
of neurovascular mechanisms, as a disorder it is now being thought of by some as a purely 
neuronal disorder. Much evidence indicates that the brains of migraineurs may be different in 
how they respond to sensory stimulation, even interictally (116, 158, 182, 749). An alternative 
and all-encompassing hypothesis is that the brain is at the heart of triggering migraine. Rather 
than a sequential activation of different brain regions, migraine is a disorder of the brain and 
therefore considered a ‘brain state’, and is a consequence of changes, or dysfunction, in 
brainstem and hypothalamic regions, which contribute to changes in cellular and vascular 
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function in many regions of the brain. This hypothesis states that migraine may be best 
described as a consequence of dysfunction in the brainstem and hypothalamic nuclei that 
normally modulate or gate sensory inputs, including touch, light, sounds, and smells. These 
brainstem and hypothalamic nuclei can be considered ‘migraine mediators’ and their 
dysfunction can lead to the failure of brain integration and filtering mechanisms, resulting in 
the perception of activation of sensory systems under normal conditions. The complex network 
of connections between regions of the brainstem, which include the PAG, RVM, locus coeruleus 
and SuS, and diencephalic nuclei including hypothalamus, thalamus and cortex can lead to the 
generation of symptoms through the same core dysfunction. Dysfunction in these regions, 
through descending control of trigeminovascular nociceptive traffic, can lead to the perception 
of head pain through normal vessels throbbing, and continued dysfunction can lead to central 
sensitization of trigeminovascular neurons and the exacerbation of pain to normal physical 
activity, cutaneous cephalic and extracephalic allodynia. Convergence of sensory inputs in the 
thalamus that project to the cortex can explain the hypersensitivity to light, sounds, and smells. 
The same dysfunction can lead to homeostatic changes, controlled by the hypothalamus, 
related to sleep, feeding, and activity. The general alteration of cortical and subcortical function 
can trigger events such as migraine aura, and extend to a general inability to function properly. 
Inherited genetic factors clearly play a role in pre-disposing migraine susceptibility, as do the 
role of potential migraine triggers, whose common link seems to play at the heart of brain 
homeostasis in the hypothalamus and brainstem. 
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Certainly much is still unclear about how we understand migraine. It is most likely that many of 
the ideas surrounding its pathophysiology are relevant, from a genetic predisposition, to brain 
hyperexcitability, to peripheral and central sensitization, and brainstem and hypothalamic 
dysfunction. They all contribute to the phenotype of the migraineur and are avenues that need 
to be explored further to understand the pathophysiology of migraine, and the development of 
novel safer and effective migraine therapeutics.  
 
 
Conclusion 
Migraine is a complex, basically inherited variable disorder of brain function. Its afferent 
pathway arises in the nociceptive durovascular afferents that seemed design to warn not 
localize. Their projection to the thalamus and cortex, and the regulation of this pathway, 
importantly at each level, and by multiple systems offers the possibility to understand the 
complex symptoms and target therapies. Migraine is a trait, well demonstrated by 
neurophysiological data that waxes and wanes to attacks. The attacks start as premonitory 
symptoms, such as concentration impairment, yawning, mood change, homeostatic changes- 
eating and fluid balance, and can include more generalized sensitivities, such as photophobia 
and phonophobia. The premonitory phase gives way to the pain phase with its attendant 
suffering and terminates in a postdromal phase of feeling washed out by the experience. 
Migraine aura, at least in its classical sense has some relationship to cortical spreading 
depression, although this is neither necessary nor sufficient for the attack, more likely acting as 
a parallel actor on an arguably smaller stage. A crucial advance in understanding has been the 
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re-appreciation of migraine as a predominantly neural disorder with the development of non-
vasoactive acute and preventive strategies for treatment. Understanding migraine both offers 
the tangible benefit of reducing the burden of the sixth most disabling medical problem on the 
planet and the real opportunity to gain insights in basic aspects of human neurobiology. 
Migraine pathophysiology has come a long way in the last two millennia and seems poised to 
accelerate the pace and deliver even more benefits the in the coming decades.  
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Table 1: International classification for headache disorders (ICHD)-3β (386) 
 
Criteria for migraine without aura 
A.  At least five attacks fulfilling criteria B-D 
B.  Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated) 
C.  Headache has at least two of the following four characteristics: 
 1. unilateral location 
 2. pulsating quality 
 3. moderate or severe pain intensity 
4. aggravation by or causing avoidance of routine physical activity (e.g. walking or 
climbing stairs) 
D.  During headache at least one of the following:  
 1. nausea and/or vomiting 
 2. photophobia and phonophobia  
E.  Not better accounted for by another ICHD-3 diagnosis 
 
Criteria for migraine with aura 
A.  At least two attacks fulfilling criteria B and C 
B.  One or more of the following fully reversible aura symptoms: 
 1. visual 
 2. sensory 
 3. speech and/or language 
 4. motor 
 5. brainstem 
 6. retinal 
C.  At least two of the following four characteristics: 
1. at least one aura symptom spreads gradually over ≥ 5 minutes, and/or two or more 
symptoms occur in succession 
 2. each individual aura symptom lasts 5-60 minutes  
 3. at least one aura symptom is unilateral  
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 4. the aura is accompanied, or followed within 60 minutes, by headache 
D.  Not better accounted for by another ICHD-3 diagnosis, and transient ischaemic attack has 
been excluded.  
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Table 2: Summary of craniovascular nerve fibers and their vasoactive neuropeptides involved in 
migraine   
 
Craniovascular nerve fiber localization Vasoactive neuropeptide/Neurotransmitter 
Trigeminal Sensory Nerve Fibers 
 Calcitonin gene-related peptide (CGRP) 
 Substance P (SP) 
 Neurokinin A (NKA) 
 Pituitary adenylate cyclase-activating 
peptide (PACAP) 
 Nitric oxide synthase (NOS) 
 
Parasympathetic Nerve Fibers 
 Vasoactive intestinal peptide (VIP) 
 PACAP 
 Neuropeptide Y (NPY), 
 Acetylcholine 
 NOS 
Sympathetic Nerve Fibers 
 Noradrenaline, 
 NPY 
 Adenosine triphosphate (ATP) 
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Table 3: Summary of neuropeptides and their role in homeostatic function 
 
Neuropeptide Effect on 
appetite 
Receptors Food 
restriction 
Refeeding Sleep 
deprivation 
Normal 
sleep 
Physiological 
stress 
Migraineurs 
Leptin Anorexigenic 
(reduces 
appetite) 
ObR(a-f) 
leptin 
signaling 
through ObRb 
↓ leptin 
plasma levels 
 
↑ leptin 
binding in 
ARC 
↑ leptin 
secretion  
↓ leptin 
plasma levels 
↑ leptin 
plasma 
levels  
Leptin ↓  
glucocorticoid 
secretion 
Lower 
serum 
leptin 
interictally 
 
Neuropeptide 
Y (NPY) 
Orexigenic 
(increases 
appetite) 
NPY Y(1-6) 
Only Y1, Y2, 
Y4 and Y5 
physiologically 
relevant  
↑ NPY mRNA 
in ARC 
 
↑ secretion 
of NPY into 
PVN 
Normalizes 
NPY levels 
in ARC 
 
↑ NPY in 
PVN 
 
↑ NPY 
hypothalamic 
mRNA levels  
NPY 
promotes 
sleep  
↑ NPY in the 
PVN  
 
↑ACTH and 
corticosterone 
release 
ND 
Orexin (OX) A 
and B 
Orexigenic OX1R and 
OX2R 
↑ Ox release  
hypothalamus  
↑ OX1R VMH 
mRNA  
↑ OX2R ARC 
mRNA  
↑ prepro-
orexin 
mRNA in 
LH 
↑ mRNA Ox 
levels in 
hypothalamic   
Ox 
neurons 
stop 
firing 
during 
sleep  
Orexin ↑ 
glucocorticoid 
secretion 
Higher CSF 
OxA levels 
in CM/MOH 
 
↑, increase; ↓ decrease; ARC, hypothalamic arcuate nucleus; PVN, paraventricular hypothalamic nucleus; VMH, ventromedial 
hypothalamic nucleus; CM, chronic migraine; MOH, medication overuse headache; ND, no data 
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Table 4: Current developmental pipeline in migraine (modified after306) 
 
Mechanism/Indication Treatment Current 
Stage 
 
Calcitonin gene-related peptide (CGRP) mechanism antagonist 
 
 
 CGRP receptor antagonist (gepant) 
 
 
 
Olcegepant (638) 
Telcagepant- acute (396) 
Telcagepant- preventive (394) 
Rimagepant (561) 
BI44370TA (216) 
MK-3207 (391) 
Ubrogepant (828) 
AGN-241689 (preventive)¶ 
 
 
Phase II 
Phase II* 
Phase II 
Phase II 
Phase II* 
Phase II 
Phase II 
Phase I 
 CGRP antibody (-nezumab) 
 
 
 
 CGRP receptor antibody (-numab) 
ALD-403 (224) 
galcanezumab (225) 
TEV-48125 (96, 97) 
 
erenumab (770) 
Phase III 
Phase III 
Phase III 
 
Phase III 
 
Serotonin-related 
 
 
Serotonin 5-HT1F receptor agonist- 
(ditan) 
 
 
Lasmiditan (260, 267) 
 
 
Phase III 
 
Nitric oxide synthase (NOS) inhibition 
 
 
 Pan NOS 
 
 Inducible NOS 
 
 
 
 Neuronal NOS plus triptan 
 
546C88 (507) 
 
 
GW274150 acute (649) 
GW274150 preventive (403) 
 
NXN-188 (428, 595) 
 
Phase II 
 
 
Phase II (F) 
Phase II (F) 
 
Phase II (F) 
 
Glutamatergic targets 
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 NMDA receptor migraine with 
prolonged aura 
 
 Prevention of aura not headache  
 
 AMPA/kainate 
 
 iGluR5 (kainate) receptor 
 
 mGluR5 (glurants) 
 
 AMPA receptor antagonist 
Ketamine (10) 
 
 
Tonabersat (326, 381) 
 
Tezampanel/LY293558 (704) 
 
LY466195 (448) 
 
ADX10059 (839) 
 
BGG492 (353) 
Phase II 
 
 
Phase II 
 
Phase II 
 
Phase II 
 
Phase II 
 
Phase II (F) 
 
 
 
Neuroinflammatory targets 
 
 
 TRPV1 
 
 
 Substance P/neurokinin-1 
 
 
 
 
 
 Neurogenic plasma protein 
extravasation (PPE) 
 
SB-705498(165) 
 
 
Dapitant (218) 
Lanepitant (351) 
GR205171 (176) 
L-758,298 (629) 
Lanepitant (349) Prevention 
 
CP-122,288 (691) 
4991W93 (233) 
 
Phase II (F) 
Phase II (F) 
 
Phase II (F) 
Phase II (F) 
Phase II (F) 
Phase II (F) 
Phase II (F) 
 
Phase II (F) 
Phase II (F) 
 
Other targets 
 
 
 Orexin 1 and 2 receptors (rexants) 
 
 Angiotensin Receptor (?) 
 
Fliorexant (150) 
 
Candesartan (765, 800) 
Telmisartan (219) 
 
Phase II (F) 
 
Off-License 
(F) 
 
Emerging targets 
  
 
 Acid Sensing Ion Channel (ASICs) 
 
 Pituitary adenylate cyclase 
activating peptide (PACAP) 
 
 
Amiloride (406) 
 
PACAP receptor antagonists (17, 
41, 874) 
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 Neuronal NOS 
 
 Phosphodiesterase inhibition 
Neuronal NOS inhibition (310) 
 
Ibudilast (514) 
 
Neuromodulation strategies 
 
 
Transcranial magnetic stimulation 
(TMS) 
 
Occipital nerve stimulation (ONS) 
 
Transcutaneous vagal nerve 
stimulation 
 
Supraorbital nerve stimulation 
 
Sphenopalatine ganglion stimulation 
 
Single Pulse TMS (94, 537) 
 
 
Chronic migraine (538, 705, 735) 
 
Gammacore device (327, 736) 
 
 
Cefaly (711) 
 
ATI device (NCT01540799) 
 
Marketed 
 
 
Phase II (F) 
 
Phase II (F) 
 
 
Marketed 
 
Phase II 
 
 
(F)- Study failed; *Liver toxicity led to termination of development; ¶Reported to exist in 
November 2015 at Allergan R&D Day 
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Figure 1 The migrainous brain interictally 
Imaging studies in the migraineurs’ brain interictally demonstrates there is reduced activation 
of the spinal trigeminal nuclei in response to trigeminal nociceptive stimulation, which 
normalizes prior to the next migraine attack. This change might reflect an increased 
susceptibility of the brain to generate the subsequent attack in the sense of a defective top-
down modulation of trigeminal input (taken with permission from 749). 
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Figure 2 The migrainous migraine during the premonitory phase 
In nitroglycerin-induced migraine attacks H215O-PET demonstrated increased rCBF in the 
posterior hypothalamic region (A and B), the periaqueductal grey region (C and D), and in dorsal 
pons (E and F) are highlighted by circles. The color bar indicates the color coding of the Z scores.  
(559). From a clinical perspective, the hypothalamus might be involved in the premonitory 
symptoms prior to the experience of head pain. Such symptoms involve tiredness, 
concentration problems, yawning, appetite alterations, and frequent urination. Activation in 
the midbrain and PAG likely reflects a mechanism through which nociceptive head pain 
symptoms may be generated (Taken with permission from 559).  
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Figure 3 The migrainous brain during migraine head pain 
Many studies have demonstrated that migraine attacks are associated with an increase of rCBF 
in mesencephalon and pons, which cannot be found in experimental head pain, indicating 
specificity for migraine attacks (842). After termination of the migraine attack with sumatriptan 
these changes persisted, suggesting involvement in migraine generation or sustentation, rather 
than specifically trigeminally-mediated pain. 
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Figure 4 Anatomy of the trigeminovascular system – ascending projections  
The trigeminal ganglion (TG) gives rise to pseudo-unipolar trigeminal primary afferents which 
synapse on intra and extra-cranial structures (blood vessels) as well as the spinal cord 
trigeminocervical complex (TCC). Second order neurons from the TCC ascend in the 
quintothalamic (trigeminothalamic) tract synapsing on third order thalamocortical neurons. 
Direct and indirect ascending projections also exist to the locus coeruleus (LC), periaqueductal 
grey (PAG) and hypothalamus. The third order thalamocortical neurons in turn synapse on a 
diffuse network of cortical regions including the primary and secondary motor (M1/M2), 
somatosensory (S1/S2) and visual (V1/V2) cortices. A reflex connection from the TCC to the 
superior salivatory nucleus (SuS) exists, which projects via the sphenopalantine ganglion (SPG) 
providing parasympathetic innervation to the extra and intra-cranial structures. Insula; Ins, 
Parietal Association; PtA, Retrosplenial; RS, Auditory; Au, Ectorhinal; Ect, Rostral ventromedial 
medulla; RVM. 
 
  
150 
 
 
 
Figure 5 Modulation of trigeminovascular nociceptive transmission – descending 
projections 
The trigeminocervical complex (TCC) is subject to direct and indirect descending pain 
modulatory pathways arising in the cortex. Direct projections exist from primary 
somatosensory (S1) and Insular (Ins) cortices while indirect projections arising in S1 that 
project via the hypothalamus. A local corticothalamic circuit also exists which can modulate 
trigeminothalamic processing. Hypothalamic projections again form direct TCC modulatory 
projections as well as indirect projections via the locus coeruleus (LC) and periaqueductal 
gray (PAG) which can further pass via the rostral ventromedial medulla (RVM). This 
complex network of direct and indirect pathways provides potent anti- and pro-nociceptive 
modulation of incoming trigeminal nociceptive signaling, the dysfunction of which is 
thought to contribute to triggering migraine attacks. Sphenopalantine ganglion; SPG, 
superior salivatory nucleus; SuS, trigeminal ganglion; TG. 
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Figure 6 Anatomy of the trigemino-autonomic pathway believed to contribute to head pain 
and cranial autonomic symptoms in migraine.  
A) Schematic representation of trigemino-autonomic pathway includes the peripheral and 
central projections of the trigeminovascular system (black neurons). There is also a trigemino-
autonomic reflex connection from the trigeminocervical complex (TCC; grey neuron), to the 
superior salivatory nucleus (green cell; SuS) and its parasympathetic projection to the cranial 
vasculature, predominantly via the greater petrosal nerve (green projection) and its synapse 
with the pterygopalatine ganglion (PG), as well as via the facial (VIIth cranial) nerve (purple 
neuron). B) Electrophysiological recording of neurons in the rat TCC is activated by SuS 
stimulation, firstly there is a shorter latency response (C) believed to be activated by antidromic 
activation of the trigemino-autonomic reflex, and a longer latency response (C and D) caused by 
activation of the parasympathetic outflow to the cranial vasculature; a signal which traverses 
the nociceptive meninges, which subsequently causes activation of the central 
trigeminovascular projection to the TCC. E) Lacrimal gland/duct (yellow cell in B) blood flow also 
increases concurrent with SuS stimulation, as a result of the parasympathetic projection to the 
lacrimal gland. TG; trigeminal ganglion. (Parts C-E are modified from 25, 26). 
 
  
152 
 
 
 
Figure 7 Proposed mechanism of descending modulation of trigeminovascular nociceptive 
transmission through brainstem nuclei, mediated by 5-HT and endocannabinoids 
A) The spontaneous firing of neurons in the TCC is modulated by micro-injection of CB1-
mediated endocannabinoids (ACPA) in the ventrolateral periaqueductal grey (vlPAG), with 
transient inhibition of firing. B) ACPA micro-injection in the vlPAG also inhibits dural-evoked 
nociceptive firing in the TCC, an effect that is replicated by naratriptan micro-injection. We 
propose that the mechanism of action of this inhibitory effect is by modulating descending 
GABAergic projections C and D). At the level of the vlPAG GABAergic projection (blue) neurons 
synapse with glutamatergic projections (purple) to ‘OFF’ and ‘ON’ cells in the rostral 
ventromedial medulla (RVM). Tonic release of GABA (blue circles) controls the level of 
descending inhibition to the TCC, via ‘OFF’ and ‘ON’ cell activity in the RVM. Cannabinoid (CB1, 
green) and triptan (5-HT1B/1D, orange) receptors are located pre-synaptically on these 
GABAergic projections. Orexin 1 (Ox1, red) receptors are also located post-synaptically on the 
glutamatergic projections. Endogenous release or exogenous administration of ECs (green 
circles) and 5-HT agonists (yellow circles) activate pre-synaptic receptors inhibiting the release 
of GABA, increasing the likelihood of activation of the descending glutamatergic projections to 
‘OFF’ cells in the rostral ventromedial medulla (RVM). Activation of post-synaptic Ox1 receptors 
are also thought to stimulate the production and release of ECs from the post-synaptic cell, 
activating pre-synaptic CB1 receptors and inhibiting GABA release, disinhibiting, and thus 
activating glutamatergic projections to ‘OFF’ cells in the RVM. This implies that orexin peptides 
may also be involved in this mechanism of descending control. D) At the same time a 
hypothesized projection (dashed lines) from the descending glutamatergic projection also 
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synapses with an inhibitory interneuron (light blue neuron-dashed lines) in RVM, which inhibits 
activity of ‘ON’ cells. Activation of RVM ‘OFF’ cells and inhibition of ‘ON’ cell results in switching 
off activity at the level of the trigeminocervical complex (TCC) second order neuron. 
 D) Additionally at the level of the RVM CB1 receptors situated pre-synaptically on GABAergic 
projections to ‘OFF’ cells, when activated by endogenous or exogenous ECs, inhibit the release 
of GABA, increasing ‘OFF’ cell activity by disinhibition, likewise we propose that pre-synaptic 
CB1 receptors on glutamatergic projections to ‘ON’ cells inhibit the release of glutamate 
blocking ‘ON’ cell activation, and thus reducing activity at the level of the TCC. ‘ON’ cell activity 
may also be inhibited by CB1 receptor-mediated inhibition of pre-synaptic release of GABA from 
neurons that synapse on inhibitory interneurons (light blue neuron-dashed lines). There is also 
thought to be a state-dependent and bidirectional control of pain modulation through 
serotonergic projections from the RVM to the TCC that is distinct to ‘ON’ and ‘OFF’ cell 
modulation. (Data in A and B adapted from24).  
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Figure 8 Proposed mechanisms for the neural basis of photophobia in migraine 
A) It is proposed that there is convergence of photic signals from the retina, via an intact optic 
nerve, onto posterior thalamic neurons that also receive nociceptive inputs from the dura 
mater, via the trigeminothalamic tract. These inputs subsequently project to nociceptive areas 
of the cortex (S1 and S2) resulting in the exacerbation of migraine headache by light, and areas 
of the visual cortex that cause hypersensitivity to light itself. B) PET imaging during the interictal 
phase of migraine demonstrates that 600-1800 Cd/m2 light causes activation in the visual 
cortex in migraineurs, whereas in controls there is no activation (lower panel). During pain in 
the trigeminal distribution light does causes activation in the visual cortex of control subjects, 
and a hypersensitive response in the visual cortex of migraineurs. C). During migraine low 
intensity light (240 Cd/m2) also causes activation in the visual cortex which is significantly 
greater compared to that after headache relief with sumatriptan and headache-free interval. 
Also activation of the visual cortex to the low level light after headache relief is still greater than 
that during headache-free interval. These data indicate that further physiological mechanism 
may contribute to the hypersensitivity to light as it appears to be not dependent on a 
trigeminovascular nociceptive input. (Parts B and C are taken and adapted from 116, 208). 
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Figure 9 Anatomy and pharmacology of the hypothalamic nuclei and brainstem nuclei 
involved in energy homeostasis and pain modulation in the context of migraine 
Projections to and from specific nuclei within the hypothalamus are involved in the complex 
neural circuitry of energy homeostasis, including the arcuate (ARC), paraventricular (PVN), 
ventromedial (VMH), dorsomedial (DMH) and lateral (LH) hypothalamic neurons. In the ARC 
energy homeostasis is controlled by orexigenic neuropeptides (stimulating (+) food intake and 
decrease energy expenditure) neuropeptide Y (NPY) and agouti-related peptide (AgRP) and 
anorexigenic peptides (inhibit (-) food intake and increase energy expenditure) 
proopiomelanocortin (POMC) and cocaine-and amphetamine-regulated transcript (CART). 
Peripheral circulating hormones insulin and leptin inhibit NPY/AgRP and stimulate POMC/CART 
neurons. Communication amongst these neural circuits is further controlled by the release of 
orexin A and B, corticotropin-releasing factor (CRF),  melanin-concentrating hormone (MCH), -
aminobutyric acid (GABA), glutamate (GLU) and brain-derived neurotrophic factor (BDNF), 
amongst others. The role these nuclei have in potentially triggering migraine, as a consequence 
of altered feeding and changes in energy homeostasis, is through their descending projections 
to brainstem nuclei known to be involved in the modulation of pain processing related to 
headache. These include direct PVN projections to the trigeminocervical complex (TCC), VMH 
projections the periaqueductal grey (PAG) and the locus coeruleus (LC), and indirect 
communication through the ventral tegmental area (VTA) and nucleus tractus solitarius (NTS). 
Hypothetically altered feeding will affect neuronal processing in the ARC, and subsequently in 
other hypothalamic nuclei through its connections to them, including the PVN, VMH and LH. 
Their control of transmission of nociceptive inputs to the trigeminovascular system may be 
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altered, which ultimately produces the perception of noxious input from the craniofacial region 
and activation of trigeminovascular system, with a specific injury or insult.  
NPY receptors, NPY1R and NPY5R; orexin receptors, OX1R and OX2R, long ‘signaling’ isoform of 
the leptin receptor, ObRb; insulin receptor, INSR and 3rd ventricle, 3V  
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